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General introduction
Chapter 1
Allogeneic stem cell transplantation, graft-versus-host disease andgraft-versus- 
leukemia
Allogeneic stem cell transplantation (allo-SCT) is at the present the most effective 
consolidation treatment for patients with acute leukemia in first or second complete 
remission or lymphoblastic lymphoma.1-6 In chronic myeloid leukemia, myelodysplastic 
syndrome, low grade non-Hodgkin’s lymphoma and chronic lymphoid leukemia allo-SCT
7 13is the only curative option. - The role of standard allogeneic SCT in multiple myeloma 
patients remains controversial due to the high transplant related morbidity and mortality 
(30-50%) in these patients. However, durable remissions have been described in 30 to 
50% of the patients who survive the first year after SCT, and a graft-versus-myeloma 
effect has been observed resulting in sustained molecular remissions.14-18 Major goals of 
allo-SCT are the eradication of the malignant clone by a high dose chemo-radiotherapy, 
eradication of all non-malignant patient-derived hematopoietic cells with a sustained 
hematological and immunological donor reconstitution resulting in complete donor 
chimerism and an immune mediated graft-versus-leukemia reactivity induced by donor-
19 22derived T lymphocytes directed against the malignant clone.19-22 Several studies have 
demonstrated decreased relapse rates after allo-SCT compared to autologous SCT and 
SCT with stem cells from genotypically identical monozygotic (syngeneic) twins 
indicating that the effectiveness of allo-SCT can not entirely be attributed to the pre­
transplant cytoreductive regimen. Generally, patients are transplanted with stem cells from 
a major histocompatibility complex (MHC)-identical donor. The recognition of minor 
histo-compatibility complex (mHag) antigens and/or tumor specific antigens by allo- 
reactive donor T lymphocytes is crucial in the setting of this MHC-identical 
transplantation and is held responsible for a graft-versus- leukemia effect (GVL) and the
19 21 24better outcome of allo-SCT. , - The mHag are known as peptides derived from 
polymorphic cellular proteins presented to e.g. cytotoxic donor T cells by MHC 
molecules.25-28
One of the major drawbacks in allo-SCT is the development of acute and chronic graft- 
versus-host disease (GVHD) associated with a high transplant related morbidity and 
mortality. Acute GVHD develops within the first 3 months of SCT and affects mainly the 
skin, gastro-intestinal tract, and liver. Chronic GVHD has a later onset than acute GVHD
10
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and is often clinically distinct. Patients can manifest sclerodermatous skin changes, 
keratoconjunctivitis, sicca syndrome, lichenoid oral mucosal lesions, esophagal and
19 29 32vaginal strictures, liver disease and pulmonary insufficiency. , - Differences in major 
(HLA-mismatched family donors or voluntary unrelated donors) and/or minor (HLA- 
matched family donors) histocompatibility antigens on other organs than the 
hematopoietic system may be recognized as foreign peptides by donor T cells. Organs like 
skin, gut, liver, lungs, and bone marrow stromal cells presenting these peptides may be 
attacked and destroyed by the allo-reactive T cells. The combination of inflammatory 
cytokines released by chemo-radiotherapy-damaged tissues and cytokines released by the 
activated donor immune system may strengthen the GVHD-effect.33-36 The relationship 
between acute and chronic GVHD and the GVL effect is strong and it results in lower 
probabilities of relapse after SCT. However, lower relapse rates in allograft recipients not 
developing GVHD compared to patients receiving syngeneic grafts suggest a GVL 
reaction of allografts independently of clinically manifest GVHD. The possible underlying 
mechanisms differentiating between the GVL effect and GVHD are still not completely
19 37 38understood. , , Since both acute and chronic GVHD result in significant morbidity and
35mortality, the GVL effect of GVHD does not always result in improved survival. 
However, improvement in overall survival is usually seen after SCT for advanced disease. 
There is increasing evidence that allo-reactive T cells that mediate GVHD are not the only 
effectors of GVL and that GVHD and GVL may be separable. It is possible that different 
subsets of blood cells mediate GVL and GVHD with e.g. distinct roles for CD4+ and 
CD8+ T lymphocytes in the stem cell graft.39-41
T cell depletion
Removal of T cells from the donor graft (T cell depletion) offers the possibility for 
prevention of GVHD and subsequently less transplant related morbidity and mortality. 
The probability of acute GVHD > grade 2 after HLA-identical SCT varied from 25-60% 
for patients transplanted with unmanipulated grafts and 0-35% after T-cell depleted SCT. 
Approximately 30-50% of patients develop chronic GVHD after HLA-identical sibling 
SCT. The incidence of chronic GVHD may be even higher after allogeneic transplantation 
using unmanipulated peripheral blood stem cells (PBSCT) due to the higher number of T
11
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cells in these grafts.42-44 Extensive chronic GVHD requires prolonged immunosuppressive 
treatment and is associated with a mortality of more than 50% mostly secondary to 
infections resulting from severe immune dysfunction.45
The removal of immunocompetent T lymphocytes did not result in improved overall 
survival because of increased graft failure (primary and secondary rejection), higher 
relapse rates and an increased probability of Epstein-Barr virus associated B cell 
lymphoproliferative disorders (EBV-LPDs).46-52 Graft failure occurred in 2-50% of HLA- 
identical T cell-depleted sibling transplants compared to 0-5% of recipients of HLA- 
identical unmanipulated stem cells. Because graft rejection is mediated by residual host T 
cells which survive the conditioning regimen, early preventive strategies were focused on 
intensification of the myeloablative regimen. High doses of cytarabine, thiothepa, and 
anthracyclines have been incorporated into standard ablative regimens and have reduced 
the rate of graft failure after T cell-depleted SCT. Another advantage of these agents may
53-57be an increased eradication of the tumour burden and consequently lower relapse rates. - 
However, these regimens may also induce an increased conditioning-related toxicity.
A major advantage for patients transplanted with T cell-depleted grafts consist of a better 
quality of life due to less morbidity caused by acute and chronic GVHD. The lower 
probability of transplant related morbidity and mortality offers to a larger number of 
patients the possibility to become eligible for various forms of additional immunotherapy 
like donor leukocyte infusion (DLI), infusions with disease specific cytotoxic T- 
lymphocytes, activated donor NK-cells and dendritic cell vaccination strategies.58-67 
Augmentation of the GVL effect without introducing significant GVHD may result in 
lower relapse rates and increased probabilities of leukemia-free and overall survival.
To improve transplant results in the T cell-depleted setting we and others introduced 
techniques to partially remove lymphocytes from stem cell grafts. A fixed number of T 
cells in the graft and additionally selective depletion of B-lymphocytes reduced the 
probability of graft failure, resulted in lower relapse rates and significantly decreased the 
induction of EBV-LPDs.56,68-72 However, the ideal number of T cells in the graft that 
induces optimal GVL effect without severe GVHD is still not known. An average 
recipient of unmanipulated stem cell graft receives a T cell dose in the order of 1-5 x 10 
cells/kg recipient body weight. Using counterflow centrifugation a reduction from 45% to
12
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22% in the incidence of acute GVHD was observed by decreasing the number of T 
lymphocytes in the graft from 1 x 106 cells/kg to 0.5 x 106/kg demonstrating a very narrow
73,74immunological therapeutic window. , These observations were confirmed by our own 
experience with counterflow centrifugal elutriation.56,75,76 The technique of T cell 
depletion that determines the characteristics of the T lymphocytes left in the graft and the 
variability between donor recipient pairs depending on minor antigen differences are also 
important factors influencing outcome of T cell-depleted SCT.
Depletion of lymphocytes from the stem cell grafts can be achieved by various selection 
techniques. These techniques can be divided in physical, immunological, and combined 
physical/immunological separation methods, respectively. Examples of physical 
separation techniques included differential agglutination with lectins followed by rosetting
77 73,75with sheep red blood cells,77 counterflow centrifugal elutriation73,75 and fractionation on
78 79 81density gradients. Immunological techniques use monoclonal antibodies - , antibodies
48,68,82-89in conjunction with homologous, heterologous or rabbit complements,48,68,82-89 directed
against T cells. The most frequent used monoclonals are the CAMPATH 1 antibodies that
88can be used in vitro or in vivo. Other antibody based methods that do not depend on 
complement include immunotoxins, e.g. anti-CD5-ricin90-92 and immunomagnetic beads.93 
From 1990 onwards, combined immunological/physical methods using CD34+, CD2+ and 
CD19+ monoclonal antibodies loaded with iron particles have been developed that can be 
used for positive stem cell selection or negative T and B cell depletion using magnetic 
columns.94-96 These methods offer several advantages compared to the immunological and 
physical methods. They are easy to perform in closed systems under good laboratory 
practice conditions. Selected cell populations are highly pure with very good yields of the 
target cells. The methods are less laborious compared to physical separation techniques 
like counterflow centrifugation. A fixed number of T cells can be used including the 
opportunity to manipulate the number of T lymphocytes in the graft which is e.g. not 
possible using methods like CAMPATH 1. Finally, effective B cell depletion can be 
accomplished preventing the risk for development of EBV-LPDs. Worldwide, the 
majority of transplant centers that perform T cell depletion gradually introduce these new 
combined physical/immunological positive and negative selection techniques in clinical 
practice.
13
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Therapeutic and pre-emptive donor leukocyte infusions
A major breakthrough in the treatment of leukemia, relapsed after transplantation, was 
infusion of lymphocytes from the original donor. Several authors have reported on this 
form of adoptive immunotherapy.60,97-103 Application of DLI to treat relapsed CML after 
SCT has a powerful antileukemic effect, resulting in durable remissions in 75-80% of 
patients.104,105 However, responses after DLI are limited in more advanced stages of CML, 
especially in blastic phase.60,106-108 In the more advanced stage, the number of leukemic 
cells is higher and residual donor hemopoiesis is lower, leading to fewer remissions and to 
frequent longlasting aplasias.60,107,109-111 DLI is also effective in relapsed low grade NHL, 
CLL, and MM.112-116 In these patients DLI has emerged as a potential approach to 
compensate for the higher rate of malignancy relapse after T cell-depleted SCT. Overall 
survival may exceed survival in patients transplanted with unmanipulated grafts due to the 
lower incidence and severity of GVHD and decreased transplant related mortality. In 
patients with AML, ALL or MDS who relapse less than 20% respond with a complete 
remission after adoptive immunotherapy with DLI. It is not clear which mechanisms cause 
this decreased sensitivity towards DLI. Explanations may be the large tumor burden 
already present at relapse, the growth rate of the malignant clone, the number of 
autologous lymphocytes present at time of relapse exerting allo-reactivity against freshly 
infused donor leukocytes leading to rejection of these leukocytes, and probably, 
differences in antigen presentation of the tumor cells that make them unrecognizable by 
allo-reactive T cells.105,107,117 Graft-versus-host disease and marrow aplasia with related 
infectious complications are the main causes of treatment related mortality associated with 
the use of DLI.60,106 Several treatment strategies currently under investigation may reduce 
toxicity from DLI and may result in improved outcomes. Stepwise cell-dose escalation 
starting with low dose DLI and the use of CD8-depleted DLI may be effective in reducing 
GVHD to a minimum.118,119 Another method under investigation is the use of the 
transfection of donor T cells with the herpes simplex virus thymidine kinase suicide gene
which enables the selective in vivo T cell depletion after DLI using the virostatic drug
120 121ganciclovir. , Early detection of residual disease and relapse e.g. by sensitive 
quantitative detection techniques like real-time PCR and early implementation of DLI is 
therefore likely to minimize the incidence and severity of marrow aplasia because
14
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122 124hematopoiesis is still predominantly donor-derived. - Administering DLI together with 
CD34+ selected stem cells may shorten the period of aplasia reducing the probability of 
life threatening infections.
One of the possibilities to overcome the complications of therapeutic DLI is the induction 
of GVL before relapse has occurred by pre-emptive donor leukocyte infusions. In patients 
with residual disease at the time of SCT, in patients after T cell-depleted SCT who do not 
develop significant GVHD, and patients with additional risk factors for relapse, delayed 
add-back of DLI may induce additional GVL without the risk of severe GVHD. Both 
animal and man experimental data support the hypothesis that GVL reactivity can be 
generated by post-transplant infusion of donor leukocytes while GVHD is controlled. The 
risk of acute GVHD after DLI depends on the number of infused lymphocytes and the 
interval between SCT and DLI.19,20,107,111,125-130 Additional add-back of donor lymphocytes
131shortly after transplantation resulted in severe GVHD. Delayed donor leukocyte
5 7infusions (DLI) with T-cell doses of 10 -10 /kg resulted in less severe GVHD with an 
incidence of 42-53%.49 Two prospective clinical studies show an effective GVL-effect 
without severe GVHD using a fixed low number of T cells administered more than 6 
months after SCT in patients who were free of all immunosuppressive drugs and who did 
not suffer from significant GVHD after transplantation.63,112 Larger randomized studies to 
evaluate the effectiveness of this approach in patients with acute and chronic leukemia and 
MDS are underway.
Chimerism in allogeneic stem cell transplantation
In Greek mythology Chimera was one of five progeny resulting from the mating of the 
monster Echidna, half woman and half serpent, with Typhon a monster so large that his 
head was said to brush the stars. Traditionally the chimera has been composed of the head 
of a lion, the body of a goat and the tail of a serpent. In medicine the term chimera is 
defined as an organism whose body contains cell populations derived from different 
individuals of the same or different species occurring spontaneously or produced
132artificially. In 1956 the term radiation chimera was introduced to designate mice where 
the hematopoietic system has been rescued following total body irradiation (TBI) by
133transplantation of hemopoietic stem cells from another mouse. In human SCT it was
15
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believed that eradication of all autologous malignant and benign hematopoietic cells by 
high dose chemo-radiotherapy resulting in complete donor chimerism was essential for 
sustained engraftment and cure of the patient. However, since the introduction of more 
sensitive techniques to investigate chimerism after SCT, the persistence or reappearance of 
autologous cells has been observed more frequently, especially in patients who received T 
cell-depleted SCT. The chimera in which one or more lymphoid-hematopoietic cell 
lineages in the blood and/or in the bone marrow are of recipient origin, and one or more 
other cell lineages are of donor origin, is defined a mixed chimera.
A number of methods has been used to evaluate chimerism post SCT. Techniques used to 
date include cytogenetics (banding techniques on metaphases), Y body detection and 
protein polymorphisms. These techniques have a sensitivity as low as 12-20%, and is in
134-137the case of cytogenetics dependent on the number of analyzed metaphases. - When
recipient and donor are of different sex, heterosome determination of 400 interphases
(fluorescent in situ hybridization; FISH) allows additional differentiation between donor
and host cells, resulting in a sensitivity of 1% for the demonstration of a minor cell
population. Red blood cell phenotyping (RCP) is a very sensitive technique based on
differences in blood group antigens between patient and donor. A set of 15 different
fluorescent antibodies can discriminate for patient and donor red cells in 70-75% of cases.
The sensitivity of this method is high with 0.01% for the fluorescent microscopic and 0.1­
1380.3% for the flow cytometric method, respectively. Limitations of this method are a 
laborious and expensive transfusion policy and chimerism is studied only in one cell
139 123type. , The introduction of DNA based methods including restriction fragment 
polymorphisms (RFLP) and minisatellites resulted in a sensitivity of 5-10% and allowed 
all nucleated cell types to be analyzed.140-142 The application of polymerase chain reaction 
(PCR) based techniques for assessing chimerism, initially in sex mismatched donor- 
recipient pairs using an Y specific PCR, but subsequently using PCR of RFLP or variable 
number of tandem repeats (VNTR) has further increased sensitivity to 0.1-1%.143-146 A 
newer technique is based on PCR amplification of microsatellites (short tandem repeats; 
STR) which are highly polymorphic simple repeat sequences randomly dispersed at 
different loci in the human genome. This technique is sensitive (0.01-1%) although precise
147quantification of the PCR products is not possible. The most recently developed
16
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technique is a real-time quantitative PCR for the detection of recipient/donor-specific 
single nucleotide polymorphic alleles and/or the male specific SMCY gene. This is a 
reliable, easy to perform and sensitive technique (0.01-0-1% sensitivity, depending on the
148amount of input DNA) allowing accurate quantification of donor and recipient cells.
The significance of mixed chimerism after allogeneic SCT in still a matter of debate. Early 
after SCT, especially after T cell-depleted SCT, low numbers of autologous cells, 
predominantly lymphocytes, are replaced by donor cells. Chimerism during this interval is 
usually defined as transient mixed chimerism. Within a short period post SCT all cells 
become donor derived and complete donor chimerism is achieved. Persistent autologous 
hemopoiesis may represent residual normal cells belonging to one or more specific subsets 
which have survived the conditioning regimen and which are tolerated by the transplanted 
donor immune system. However, these cells may also originate from the malignant clone 
and may represent residual disease more or less controlled by the donor derived immune 
system. The term mixed chimerism need to de defined carefully and most authors agree 
that recipients of transplants should only be referred to as mixed chimeras if they are 
transfusion independent and a mixture of donor and recipient cells is present in the bone 
marrow and/or blood without evidence of relapse from the original disease and without 
any sign of graft rejection.149,150 The long term clinical significance of mixed chimerism 
after SCT remains controversial. Some studies observed high relapse rates in patients with 
mixed chimerism after T cell-depleted SCT151-155 while other studies could not 
demonstrate this correlation.156-158 Sequential quantitative monitoring of chimerism in 
different subsets of white blood cells using sensitive techniques with simultaneously 
quantitative determination of minimal residual disease in prospective studies is the only 
way to increase our knowledge about the significance of mixed chimerism post
SCT 132,150,159
Aims and outline of this thesis
Allogeneic stem cell transplantation with lymphocyte depleted grafts is associated with 
increased incidence of graft rejection and higher relapse rates compared with patients 
transplanted with unmanipulated grafts. However, compared with unmanipulated SCT, the 
lower incidence and severity of GVHD resulting in less transplant related morbidity and
17
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mortality after T cell-depleted SCT offers to a higher number of patients the opportunity to 
be treated with pre-emptive and/or adoptive immunotherapeutical strategies in order to 
reduce the probability of relapse. These strategies, aiming at a decrease of graft rejection 
and an increase of the GVL effect, may improve the outcome of T cell-depleted SCT and 
probably exceed the results of transplantation with unmanipulated grafts. Sequential 
evaluation of chimerism after SCT, during relapse, and after DLI, using sensitive and 
reliable techniques may further improve our knowledge and insight in the GVL-effect and 
may be a valuable tool for the timing of pre-emptive or adoptive immunotherapy. In this 
thesis we evaluated different immunotherapeutical strategies to improve outcome after 
partially T cell-depleted SCT. Existing methods to evaluate chimerism were used and new 
sensitive techniques were developed to demonstrate the dynamics of patient and donor 
blood cells after SCT.
In chapter 2 the impact of an intensified conditioning regimen on the outcome of partially 
T cell-depleted SCT was evaluated in 181 standard-risk leukemia patients. In order to 
reduce relapse rate, anthracyclines were added to the conditioning regimen of 116 patients 
before SCT with grafts partially T lymphocyte depleted by density gradient and 
counterflow centrifugation. Multivariate analysis showed the positive impact of the 
intensified conditioning regimen on acute and chronic GVHD, transplant related mortality, 
relapse, leukemia-free survival, overall survival and chimerism. Additionally, this study 
demonstrated the influence of the number of T lymphocytes left in the graft on acute and 
chronic GVHD.
Sequential monitoring of chimerism after partially T cell-depleted SCT resulted in a 
remarkable number of patients with persisting mixed chimerism. Purpose of the study 
described in chapter 3 was the long term follow-up of these mixed chimeras and definition 
of patterns of chimerism in the various subsets of peripheral blood mononuclear cells 
(PBMCs), granulocytes and red blood cells using a PCR-STR technique and RCP. We 
evaluated long-term mixed chimerism and its relationship towards relapse, the correlation 
between the conditioning regimens and mixed chimerism, and the inter- and intra­
individual differences in the subsets of patient/donor blood cells.
Long before a reliable and sensitive quantitative PCR for the detection of the Bcr/Abl 
fusion protein became available to detect minimal residual disease or insidious relapse
18
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from CML, we were able to detect early relapse from CML in a very sensitive way using 
RCP. The CML clone also produces red cells and increasing numbers of patient red cells 
was always a sign of relapse of CML. This strategy offered the opportunity to treat 
patients in an early phase during relapse with adoptive immunotherapy (DLI) which has 
contributed to the success of DLI in our hands. In Chapter 4 we described fifteen patients 
who relapsed from CML and who were subsequently treated with DLI to obtain a second 
or even third complete remission from the leukemia. In this study we analyzed chimerism 
using RCP and these results were compared with cytogenetic data and outcome of 
qualitative and quantitative PCR for Bcr/Abl breakpoint molecules.
Not all patients who relapse from hematological malignancies respond to DLI. In chapter
5 we analyzed the factors that determined the success of DLI after relapse. Multivariate 
analysis demonstrated that the indication for SCT (CML versus AML/ALL and RAEB-t) 
and the percentage T lymphocytes from donor origin in the blood at time of DLI were 
significantly correlated with remission.
It is still not clear which factors are responsible for the success of DLI in CML, CLL, 
MM, and low grade NHL, and for the more disappointing results of DLI in acute 
leukemias and MDS. Antigen presentation by the malignant cells, recognition of these 
antigens by donor allo-reactive T cells, the number of malignant cells in the patient, the 
doubling time of the malignant cells, and the balance between donor and patient T cells 
may all be involved in a complex of mechanisms involved in the GVL effect.
To improve outcome in patients who usually do not respond to DLI after relapse, we 
developed a prospective non randomized trial of pre-emptive DLI for patients who did not 
develop significant GVHD after SCT (chapter 6). After withdrawal of all 
immunosuppressive drugs these patients received a fixed dose of fresh donor lymphocytes
6 months after transplantation. Outcome of transplantation was compared with a control 
group of patients who did develop GVHD after SCT and were not eligible for DLI. This 
study was a pilot for a larger national randomized study in the Netherlands evaluating the 
effect of pre-emptive DLI on outcome after T cell-depleted SCT.
Chimerism studies using conventional techniques like cytogenetics, FISH, RCP, RFLP, 
VNTR and STR all have their limitations. The techniques are not sensitive enough, or they 
can only be applied if donor and patient are of different sex, or they supply only
19
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information about one cell type, or quantification is difficult. We developed a completely 
new technique to investigate chimerism after SCT by a real-time PCR method using single 
nucleotide polymorphisms (SNP) as discriminating markers. Using this technique 97% of 
all patient/donor couples can be discriminated, the sensitivity is high, and accurate 
quantification is possible. This technique has been described in chapter 7.
Using the real-time PCR SNP technique in purified subsets of granulocytes and PBMCs 
we were able to investigate the dynamics of chimerism in patients treated with a standard 
regimen and with an anthracycline intensified conditioning regimen. In chapter 8 we 
evaluated outcome and chimerism of CML patients conditioned with and without 
anthracyclines and we confirmed our earlier observations described in chapter 2. In 10 
patients randomized to be conditioned either with or without idarubicine we demonstrated 
the immunosuppressive effect of anthracyclines that may have contributed to the increased 
GVL effect and the favorable outcome in the patients conditioned with the addition of 
anthracyclines.
20
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Abstract
One hundred and eighty-one consecutive patients with standard-risk leukemia were 
transplanted with HLA-identical sibling grafts depleted of lymphocytes using counterflow 
centrifugation. In 116 patients, standard conditioning was intensified by the addition of 
anthracyclines. Multivariate analysis revealed significantly more acute GVHD > grade 2 
and a trend towards more chronic GVHD in patients conditioned with the addition of 
anthracyclines. For all patients the risk for chronic GVHD, but not for acute GVHD, 
increased with a higher number of T cells in the graft. The projected 5-year probability of 
relapse was significantly lower in the group of patients conditioned with anthracyclines; 
26% versus 52%, (P  = 0.015). In multivariate analysis the addition of anthracyclines to 
the conditioning regimen was the only significant factor contributing to a lower 
probability of relapse. The projected 5-year probability of leukemia-free survival (LFS) in 
the patients conditioned with and without the addition of anthracyclines was 56% and 
36%, respectively (P  = 0.004). In multivariate analysis the addition of anthracyclines to 
the conditioning regimen correlated significantly with a lower number of mixed chimeras 
in patients at 6 and 12 months after SCT. Mixed chimerism at 6 months after 
transplantation did not significantly correlate with a higher incidence of relapse in further 
follow-up. In contrast, mixed chimerism at 12 months after SCT was significantly 
associated with higher relapse rate.
We conclude that the addition of anthracyclines to the conditioning regimen improves 
outcome of allogeneic SCT using T cell-depleted grafts.
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Introduction
Allogeneic stem cell transplantation (SCT) is an effective consolidation treatment for 
patients in complete remission from acute leukemia or lymphoblastic lymphoma.1-6 In 
chronic myeloid leukemia, myelodysplastic syndrome and low grade non-Hodgkin's
7 12lymphoma, SCT is the only curative treatment. - Allogeneic SCT appears to be the most 
promising treatment for multiple myeloma.13,14 Major complications after SCT are acute 
and chronic graft-versus-host disease (GVHD). Moderate to severe GVHD occurs in 
about 45% of recipients of HLA-identical marrow grafts and contributes to death in 20%- 
70% of those affected.10,15-20 Reduction of GVHD can be accomplished by T cell 
depletion of the graft. However, the removal of immunocompetent T lymphocytes is
10 15 16 21 22associated with increased graft rejection and increased relapse rate. , , , , We have 
previously reported on the outcome of 80 consecutive patients transplanted for acute and 
chronic leukemia with HLA-identical sibling grafts depleted of lymphocytes by
counterflow centrifugation. We concluded that the probability of survival and leukemia
20free survival (LFS) was comparable with the data of recipients of unmanipulated grafts.
In the present analysis we extended our observations to 181 consecutive patients 
transplanted for standard risk acute and chronic leukemia between 1981 and 1995. This is 
one of the largest groups of patients described in the literature transplanted with T cell- 
depleted marrow grafts from one single center. The median follow-up was 5.5 years 
(range, 3 months-14 years). The longer median follow-up and the higher number of 
patients enabled us to address the issues of sustained engraftment, acute and chronic 
GVHD, the impact of intensification of the conditioning regimen by the addition of 
anthracyclines, the influence of the number of T lymphocytes infused within the graft, 
chimerism, transplantation-related mortality, leukemic relapse, long-term survival and 
LFS.
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Materials and methods
Patients and donors
Between May 1981 and September 1995, 181 consecutive patients (105 males and 76 
females) received a transplant for acute myeloid leukemia in first complete remission 
(AML-CR1: n = 70), acute lymphoid leukemia in first and second complete remission 
(ALL-CR1,CR2: n = 57) and chronic myeloid leukemia in first chronic phase (CML-CP1: 
n = 54). Donors were HLA-identical and MLC-negative siblings. Median age of recipients 
and the donors was 34 (range, 13-59) and 35 (range, 11-71) years, respectively. Informed 
consent was obtained from all recipients and donors or their guardians. Donor marrow 
was depleted of lymphocytes by density gradient centrifugation followed by counterflow
centrifugation as previously described.17,19 The median number of T cells infused was 0.8
6
(range, 0.1-3.2) x 10 /kg body weight. All patients were managed in single rooms with 
filtered air under positive pressure during their hospital stay. All patients received oral 
selective gut decontamination, as well as co-trimoxazole for Pneumocystis carinii 
prophylaxis and oral acyclovir for prophylaxis of herpes virus infections. The patient's 
characteristics are summarized in Table 1.
Chemotherapy before allografting
All patients with CML had been treated with hydroxyurea or busulfan. In three patients 
interferon-alpha was added. Patients with AML were in CR1 and patients with ALL were 
in CR1 or CR2 after chemotherapy according to current EORTC (European Organization 
for Research and Treatment of Cancer) protocols.
Conditioning regimen
All patients were treated with cyclophosphamide (Cy) (60/mg/kg body weight) 
intravenously (i.v.) on each of days -6 and -5. Fractionated total body irradiation (TBI) 
was given to 174 patients in two equal fractions on days -2 and -1 to a total dose of either 
9 Gy (n = 143) or 12 Gy (n = 31). Midline average dose rate was 4.1 ± 0.5 cGy/min in 33 
patients and 12.3 ± 2.0 cGy/min in 141 patients. TBI was delivered by a 16 or 18 MV 
photon beam linear accelerator. Lungs and eyes were shielded to 7 or 8 Gy and 6 Gy, 
respectively, using individually adapted lead blocks. If the total dose was 12 Gy, the
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kidneys were shielded to 9 Gy. In an attempt to reduce relapse rate, the conditioning
regimen was intensified in 116 patients by the addition of daunorubicine to a total dose of
2
156 mg/m body surface (n = 10) or demethoxy-daunorubicine (idarubicine) to a total
2 23 24dose of 42 mg/m body surface (n = 106). , Anthracyclines were given by continuous
i.v. infusion for 2-7 days. However, the first cohort patients treated with anthracyclines
25showed significantly more severe oral mucositis and delayed bone marrow recovery. In 
the next cohort TBI was increased to 2 x 6 Gy and no anthracyclines were given. This 
resulted in a high 5-year probability of relapse which was 57% (95% CI, 37%-77%). 
Since oral mucositis and delayed engraftment were schedule dependent, anthracyclines 
were reintroduced from February 1991 onwards and given on day -11 and -12 instead of 
day -7 to -2 in combination with 2 x 4.5 Gy TBI. In 7 recipients TBI was replaced by 
busulphan (4mg/kg/day on each of 4 consecutive days). The donor marrow was infused 
24 hours after completion of TBI or 72 hours after the last dose of busulphan.
Immunoprophylaxis after transplantation
20Details of immuno-prophylaxis post-transplant have been described before. Two 
patients did not receive any GVHD-prophylaxis and both developed grade 3 acute GVHD. 
Eight patients received methotrexate (MTX). As soon as Cyclosporine A (CsA) became 
available, 22 consecutive recipients received MTX in combination with CsA. From May 
1986 onwards all patients (n = 149) were treated with CsA only; 3 mg/kg/d by continuous
i.v. infusion from days -1 to +14, followed by 2 mg/kg/d as a continuous i.v. infusion until 
day 21. Beyond day 21, CsA was administered orally at a dose of 6 mg/kg/d until 12 
weeks after SCT. CsA was gradually tapered off and discontinued 16 weeks post-grafting. 
Acute and chronic GVHD were classified grade 1-4 and limited or extensive, respectively, 
according to the criteria described by Glucksberg18 and Shulman.26
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Table 1 Disease-, Patient-, Donor-, and treatment-related variables o f 181 patients 
transplanted fo r acute and chronic leukemia w ith and w ithout the addition o f 
anthracyclines in the conditioning regimen
Conditioned with 
anthracyclines
Conditioned without 
anthracyclines
Diagnosis, no. (%) of patients
AML, CR1 41 (23) 29(16)
CML, CP1 40 (22) 14 (8)
ALL, CR1 30 (16) 18(10)
ALL, CR2 5 (3) 4 (2)
No. (%) of male / female patients 71 (39) / 45 (25) 34 (19) / 31 (17)
No. (%) of male / female donors 64 (35) / 52 (29) 44 (24) / 21 (12)
Donor-recipient sex match, no and (%) of patients
Male to male 37 (20) 30 (17)
Male to female 27 (15) 11 (6)
Female to male 33 (18) 9 (5)
Female to female 19 (11) 15 (8)
Age patients, median (range) in years 36 (13-59) 32 (16-55)
Age donors, median (range) in years 37 (11-71) 32 (16-59)
Conditioning regimen, no and (%) of patients
Cyclophosphamide, TBI 110 (61) 64 (35)
Cyclophosphamide, busulphan 6 (3) 1 (1)
Graft versus Host prophylaxis, no and (%) of patients
Cyclosporine A 116 (64) 33 (18)
Cyclosporine A plus methotrexate 0 (0) 22 (12)
Methotrexate 0 (0) 8 (5)
None 0 (0) 2 (1)
No. of T cells in graft, median (range) x 106/kg 0.9 (0.1-3.2) 0.7 (0.2-2.7)
Follow-up, median (range) in years 3.8 (0.3-9.5) 5.6 (4.0-14)
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid 
leukemia; CR1, first complete remission; CR2, second complete remission; CP1, first chronic phase; TBI, 
total body irradiation.
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Definitions
Engraftment: the first day of engraftment was defined as the first of 3 consecutive days 
with peripheral white blood cell (WBC) counts of > 1.0 x 109/l. Graft failure was defined
9
as primary failure if WBC never reached 1.0 x 10 /l or as secondary failure if the WBC
9
reached 1.0 x 10 /l on 3 or more consecutive days and disappeared during further follow- 
up. Transplant-related mortality was defined as mortality not due to relapse. Relapse was 
defined as hematological relapse, i.e. the reappearance of clinical features and laboratory 
findings compatible with the underlying leukemia. LFS was defined as survival in 
hematological or hematological and cytogenetic remission.
Statistical analysis
Probability of relapse, survival, LFS, GVHD and influence of chimerism on subsequent 
relapse were evaluated using the Kaplan-Meier product-limit method. The differences 
between curves were tested for statistical significance with the two-tailed log-rank test. To 
determine whether diagnosis, recipient age, recipient sex, donor age, donor sex, 
chemotherapy before allografting, conditioning regimen, T cell dose and GVHD- 
prophylaxis were independent predictors of relapse, survival, LFS, acute GVHD, chronic 
GVHD and chimerism, multivariate stepwise regression analysis was performed using 
Cox's proportional hazard model and logistic regression. P values < 0.05 were considered 
significant. Follow-up ended on 1 January 1996. Survival and relapse were followed to 
the time of last contact with the patient.
Results
Engraftment
Six patients died within 22 days after SCT and were not evaluable for engraftment. Take 
failure occurred in 4/114 evaluable patients (3%) after conditioning with anthracyclines 
and in 4/61 evaluable patients (7%) conditioned with the standard regimen. In both groups 
one patient never showed any sign of engraftment (primary graft failure). Another 6 
patients rejected their graft (secondary take failure) at 28-172 (median, 106) days. 173
9
patients engrafted with leukocytes > 1.0 x 10 /l at a median of 17 (range, 10-58) days after 
SCT. The speed of engraftment did not differ between the patients who were conditioned
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with anthracyclines at day -12 and -11 and the patients conditioned without 
anthracyclines. They engrafted at a median of 17 (range, 9-35) days and a median of 16 
(range, 5-58) days after SCT, respectively. However, in patients conditioned with 
anthracyclines from day -7 to day -2 engraftment was considerably delayed to median 20 
(range, 8-37) days.
Acute GVHD
The characteristics of GVHD are summarized in Table 2. 34/175 (19%) patients at risk 
developed acute GVHD > grade 2. GVHD grade 3 and 4 occurred in only 8 of 175 
patients (5%), and included the two patients who did not receive GVHD prophylaxis after 
SCT. The probability of acute GVHD > grade 2 at day 100 after SCT was 19% (95% 
confidence interval (CI) 11-27%). Using multivariate analysis acute GVHD > grade 2 was 
significantly higher in the patients conditioned with anthracyclines (Odds 2.56; P = 
0.024). Patients transplanted for AML had more acute GVHD > grade 2 than ALL (Odds 
2.27; P = 0.039) or CML (Odds 2.63; P = 0.028) cases. We did not observe any 
significant relation between T cell dose in the marrow graft and acute GVHD.
Chronic GVHD
Sixty out of 152 patients (39%) with a follow-up of > 3 months developed chronic 
GVHD. The 5-year probability of extensive chronic GVHD was 11% (95% CI, 5%-17%). 
Surprisingly, in multivariate analysis, patients with a female donor developed less chronic 
GVHD than patients with a male donor (Odds 0.30; P = 0.0004). In contrast to acute 
GVHD, the risk for chronic GVHD increased with a relatively higher T cell dose in the 
marrow graft (Odds 1.85; P = 0.039). No significant relationship was observed between 
intensification of the conditioning regimen by the addition of anthracyclines and chronic 
GVHD, although the group treated with anthracyclines showed a trend to develop more 
chronic GVHD.
Mortality.
Seventy-nine of 181 patients (44%) died after SCT. Principal causes of death were: 
relapse (n = 36), GVHD-related (n = 24), infection (n = 8), acute respiratory distress 
syndrome/capillary leakage (n = 5), secondary graft failure (n = 3), primary graft failure
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(n = 1), veno-occlusive disease (n = 1) and bleeding (n = 1). Transplant-related mortality 
censored by relapse was 22% in the patients conditioned with anthracyclines and was 26% 
in the patients conditioned without anthracyclines. 51/181 patients (30%) died within one 
year after SCT. Mortality was transplant-related in 39 patients and 15 patients died from 
relapse.
Table 2 Incidence o f GVHD in patients conditioned w ith or w ithout the addition o f anthracyclines
No. (%) of patients
Conditioned with 
anthracyclines
Conditioned without 
anthracyclines
Acute GVHD (n = 175)
Grade 0 48 (42) 36 (59)
Grade 1 39 (34) 18 (29)
Grade 2 22 (19) 4 (7)
Grade 3 2 (2) 3 (5)
Grade 4 3 (3) 0 (0)
All patients 114 (100) 61 (100)
Chronic GVHD (n = 152)
None 56 (55) (7163
Limited 31 (31) 3)(22
Extensive 14 (14) 3 (6)
All patients 101 (100) 51 (100)
Relapse.
Fourty-eight patients (27%) relapsed after SCT. The projected 5-year probability of 
relapse was 39% (95% CI, 25-53%) for AML-CR1, 32% (95% CI, 14-50%) for ALL- 
CR1,2 and 39% (95% CI, 13-65%) for CML-CP1. The projected 5-year probability of 
relapse in all patients treated with anthracyclines was 26% (95% CI, 16-36%). This was 
significantly lower than the probability of relapse of 52% (95% CI, 38-66%) in all patients 
conditioned without the addition of anthracyclines (P  = 0.015). These relapse curves are
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shown in Figure 1a. Probabilities of relapse for patients treated with and without 
anthracyclines are summarized in table 3. In multivariate analysis relapse rates were 
significantly lower in patients conditioned with the addition of anthracyclines (Odds 0.50; 
P = 0.044).
Two patients with relapse from CML were retransplanted after conditioning with 16 
mg/kg busulphan alone without an attempt to induce CR with donor lymphocyte 
transfusions. One patient died from subsequent relapse 17 months after retransplantation 
and one patient died from sepsis two years after second SCT. Twenty-five patients (AML: 
n = 9, CML: n = 11 ALL: n = 5) who relapsed from their original disease were treated
18 27 28with lymphocyte-infusions from the original marrow donor. , , Eleven patients (44%) 
responded (AML: n = 1, ALL: n = 1, CML: n = 9) and reached a second hematological 
and cytogenetic remission. They are without any sign of relapse until end of follow up. 
Two patients with a relapse from CML who did not respond to lymphocyte infusions were 
retransplanted with unmanipulated donor marrow and both are alive without leukemia at 
33 and 23 months after retransplantation.
Survival.
One hundred and one of 181 patients (56%) were alive at 3-166 (median, 63) months after 
SCT. The projected 5-year probability of survival was 45% (95% CI, 32-58%) for AML- 
CR1, 54% (95% CI, 42-66%) for ALL-CR1,2 and 70% (95% CI, 62-78%) for CML-CP1. 
The projected 5-year probability of survival in all patients conditioned with anthracyclines 
was 62% (95% CI, 52-72%). This was significantly better than the 44% (95% CI, 33­
55%) obtained in all patients conditioned without anthracyclines (P  = 0.01), (Figure 1b). 
Using multivariate analysis, survival was significantly better in those patients conditioned 
with anthracyclines compared to patients treated with cyclophosphamide and TBI only 
(Relative Risk 0.63, 95% CI, 0.41-0.99%; P = 0.044). Probabilities of survival for patients 
treated with and without anthracyclines are summarized in Table 3.
Leukemia-free survival.
The projected 5-year probability of LFS after T cell-depleted SCT was 44% (95% CI, 31­
57%) for AML-CR1, 53% (95% CI, 41-65%) for ALL-CR1,2 and 48% (95% CI, 34-62%) 
for CML-CP1. The projected 5-year probability of LFS in all patients conditioned with 
anthracyclines was 56% (95% CI, 46-66%). This is significantly better than the 36% (95%
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CI, 25-47%) probability of LFS obtained in all patients conditioned without 
anthracyclines (P  = 0.004), (Figure lc). In multivariate analysis LFS was significantly 
better after conditioning with anthracyclines (Relative Risk 0.62, 95% CI, 0.41-0.94%; P 
= 0.025). Probabilities of LFS for patients treated with and without anthracyclines are 
given in Table 3. Increased survival and LFS can be explained by the significantly lower 
relapse in patients treated with anthracyclines (probability of relapse: Odds ratio 0.50; P = 
0.044). Projected at 5 years, probability of relapse, survival, and leukemia-free survival 
for all patients conditioned with and without anthracyclines are summarized in Table 3.
Table 3 Projected 5 year-probability o f survival, leukemia-free survival, relapse and p-values in 
patients transplanted fo r AML-CR1, ALL-CR1, CR2, CML-CP1 and fo r patients conditioned 
with and w ithout the addition o f anthracyclines
Per cent probability (95% confidence interval)
Survival Leukemia-free survival Relapse
All PATIENTS 57 (51-63) 50 (43-57) 34 (24-44)
no anthracyclines 44 (33-55) 36 (24-47) 52 (38-66)
anthracyclines 62 (52-72) 56 (46-66) 26 (16-36)
P = 0.010# P = 0.004# P = 0.015#
AML-CR1 45 (32-58) 44 (31-57) 39 (25-53)
no anthracyclines 38 (15-61) 34 (10-58) 51 (29-73)
anthracyclines 51 (36-66) 51 (34-68) 31 (13-49)
P = 0.149# P = 0.053# P = 0.079#
ALL-CR1, CR2 54 (42-66) 53 (41-65) 32 (14-50)
no anthracyclines 41 (16-66) 41 (21-61) 50 (27-73)
anthracyclines 64 (52-76) 62 (44-70) 20 (4-36)
P = 0.094# P = 0.107# P = 0.020#
CML-CP1 70 (62-78) 48 (34-62) 39 (13-65)
no anthracyclines 64 (44-84) 36 (11-61) 55 (26-84)
anthracyclines 72 (65-79) 55 (35-75) 31 (13-49)
P = 0.193# P = 0.063# P = 0.072#
# P value of differences in treatment outcome of patients conditioned with anthracyclines versus no 
anthracyclines using two-tailed Log Rank test.
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In multivariate analysis LFS was significantly better after conditioning with anthracyclines 
(Relative Risk 0.62, 95% CI, 0.41-0.94%; P = 0.025). Probabilities of LFS for patients 
treated with and without anthracyclines are given in Table 3. Increased survival and LFS 
can be explained by the significantly lower relapse in patients treated with anthracyclines 
(probability of relapse: Odds ratio 0.50; P = 0.044). Projected at 5 years, probability of 
relapse, survival, and leukemia-free survival for all patients conditioned with and without 
anthracyclines are summarized in Table 3.
Hematopoietic chimerism
Hematopoietic chimerism was assessed at 6 and 12 months after SCT. Methods used were 
red blood cell phenotyping and cytogenetic analysis of bone marrow metaphases as
29described previously. At 6 and 12 months after SCT, respectively, 131 and 100 patients 
were in complete remission. Nineteen patients had no discriminating marker at 6 months 
after SCT and 14 patients had no discriminating marker at 12 months after SCT. They 
were excluded from further analysis. If at one time point there was disagreement between 
the results obtained by cytogenetic analysis and that obtained by red blood cell 
phenotyping and one of these methods showed mixed chimerism, patients were considered 
to be mixed chimera. The results of this analysis including relapse rates are shown in 
table 4. The influence of chimerism status at either 6 or 12 months on subsequent relapse 
is demonstrated in Figure 2a and 2b. The 5-year probability of relapse in patients who 
were mixed chimera at 6 months after SCT did not differ significantly from patients who 
were complete donor chimera at 6 months after SCT (P  = 0.376). However, patients who 
were mixed chimera at 12 months after SCT were significantly more at risk to develop 
relapse of their original disease compared to patients who were complete donor chimera at 
12 months after SCT (P  = 0.004). In multivariate analysis the addition of anthracyclines to 
the conditioning regimen was the only significant factor contributing to a lower number of 
mixed chimeras in patients at 6 months (Odds 0.54; P = 0.027) and at 12 months (Odds 
0.47; P = 0.032) after SCT.
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m o n t h s
months
Fig 1b. Probability of survival in 
standard risk patients (AML-CR1, 
ALL-CR1,2 and CML-CP1) 
conditioned with and without 
anthracyclines. Marks denote 
patients who are alive.
Fig 1a. Probability of relapse in 
standard risk patients (AML-CR1, 
ALL-CR1,2 and CML-CP1) 
conditioned with and without 
anthracyclines. Marks in the 
relapse curves denote leukemia­
free survivors
months
Fig 1c. Probability of leukemia free 
survival in standard risk patients 
(AML-CR1, ALL-CR1,2 and CML- 
CP1) conditioned with and without 
the addition of anthracyclines. Marks 
in the curves indicate leukemia-free 
survivors.
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Probability of relapse in patients who were mixed chimera and patients who were donor chimera at 6 months 
(fig 2a.) and at 12 months (fig 2b.) after SCT, respectively.
Marks denote patients who are alive.
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Table 4 Chimerism at 6 and 12 months after SCT using cytogenetic analysis and/or red blood cell 
phenotyping and 5-year probability o f relapse in patients as a consequence o f chimerism at 
6 and 12 months.
CHIMERISM
6 months 12 months No. of patients
Donor Chimera Donor Chimera 30
Donor Chimera Mixed Chimera 6
Donor Chimera Died 5
Donor Chimera Relapse 2
Donor Chimera Follow-up < 12 months 7
Mixed Chimera Donor Chimera 18
Mixed Chimera Mixed Chimera 32
Mixed Chimera Died 1
Mixed Chimera Relapse 7
Mixed Chimera Follow-up < 12 months 3
CHIMERISM 5-year probability of relapse
(% probability (95% confidence interval))
Donor Chimera, 6 months after SCT 33 (20-46)
Mixed Chimera, 6 months after SCT 29 (16-32)
P = 0.376#
Donor Chimera, 12 months after SCT 10 ( 0-18)
Mixed Chimera, 12 months after SCT 29 (14-34)
P = 0.004#
# P value of differences in relapse rate in patients who were donor chimera and mixed chimera at 6 and 12
months after SCT.
Discussion
Stem cell transplantation with grafts depleted of lymphocytes is associated with a higher 
incidence of graft failure. Graft failure occurred in 2-20% of HLA-identical T cell- 
depleted sibling transplants compared to 0-2% of recipients of HLA-identical
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10 21 29 35unmanipulated bone marrow. ’ ’ " In the present study take failure occurred in 5% of
30 35 38cases which is less than previously reported in recipients of T cell-depleted grafts. ’ " 
Since residual autologous immunocompetent T lymphocytes are responsible for graft 
rejection, the low incidence of graft failure in our patients may be caused by the number 
and nature of lymphocytes given within the graft, the relatively high midline average TBI 
dose rate and the addition of anthracyclines to the conditioning regimen.
T cell depletion is an effective prevention of GVHD as has been shown in experimental 
animal models and in man.22,39,40 In the present analysis the probability of acute GVHD > 
grade 2 at day 100 after SCT compares favourably with the actuarial incidence of 40-80% 
in recipients of HLA-identical unmanipulated grafts and is comparable with figures from 
other studies on T cell-depleted marrow.10,15,16,21,22,31,34 The incidence of acute GVHD > 
grade 2 was significantly higher in the patients conditioned with anthracyclines and in 
patients with AML-CR1 compared to patients with ALL-CR1,CR2 or CML-CP1. The 
addition of anthracyclines to the conditioning regimen may eliminate more 
immunocompetent autologous T lymphocytes. As a consequence the balance may be 
tipped to the relatively low number of donor T lymphocytes given within the graft leading 
to more GVHD and the with GVHD associated graft-versus-leukemia effect. In patients 
with AML-CR1 the higher cumulative dose of anthracyclines already used for remission 
and consolidation may have contributed to the increased probability of acute GVHD in 
this group of patients.
The 5-year probability of chronic GVHD and its extensive manifestation is in the same 
range of HLA-identical T cell-depleted transplants in other studies.21,22,31,33,34,39,41,42 In
multivariate analysis we observed a relation between the T cell dose and the probability of
6
developing chronic GVHD. Increasing the T-cell dose with only 1.0 x 10 /kg body weight 
doubled the risk for chronic GVHD. Patients conditioned with anthracyclines also 
developed more chronic GVHD although this difference was not significant (P  = 0.056). 
In contrast to other studies we observed a significantly lower incidence of chronic GVHD 
if the donor was female. At present we cannot explain this observation other than that this 
may have occurred by chance. Although the addition of anthracyclines to the conditioning 
regimen is correlated with significantly more acute GVHD > grade 2 and associated with 
a trend towards more chronic GVHD, no higher transplant-related mortality was observed 
in this group of patients.
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Prevention of leukemic relapse is the ultimate goal in allogeneic SCT. In general, T cell 
depletion significantly reduces LFS after SCT and this is caused by higher relapse rates. 
LFS after T cell-depleted SCT for leukemia in CR1 or CP1 varied from 48% at 2 years to
22 34 4125% at 7 years. , , In standard-risk recipients of HLA-identical unmanipulated grafts, 
LFS varied from 70% at 2 years to 40% at 10 years.1,6,8,10,11,22,41,43,44 Recent cumulative 
clinical data from the International Bone Marrow Transplant Registry (IBMTR) showed a 
2-year probability of relapse of 30% after transplantation with lymphocyte depleted grafts 
for acute leukemia in first complete remission and 44% for chronic myeloid leukemia in
first chronic phase. These percentages were 17% and 10%, respectively, in recipients of
22HLA-identical unmanipulated transplants. In the present study the intensification of the 
conditioning regimen with anthracyclines in 116 patients increased 5-year LFS to between 
51% and 62%. In the patients conditioned with the addition of anthracyclines, the 5 year
probability of relapse was 26% and compared favourably with the 37% at 2-years from
22the IBMTR. In multivariate analysis, intensification of the conditioning regimen with 
anthracyclines reduced the risk of relapse with 50% and was the only significant factor 
contributing to an increased probability of LFS. Using multivariate analysis, 
chemotherapy before allografting had no effect on the probability of engraftment, GVHD, 
mortality, relapse, survival and LFS after SCT. No other additional variables met the 0.05 
significance level for entry in the statistical model. Anthracyclines, like other additional 
chemotherapeutics, may contribute to an increased eradication of the tumour burden 
especially in CML and result in lower relapse rates.31,45 We have also shown that the 
addition of anthracyclines was correlated with increased probabilities of acute and chronic 
GVHD. This may have further enhanced the graft-versus-leukemia effect.
Especially in patients with a relapse from CML after SCT, treatment with infusion of 
lymphocytes from the original marrow donor may induce second complete remission.28,46-
48 Eleven patients who relapsed from CML-CP1 were treated with lymphocyte infusions 
from the donor and 9 patients (82%) responded. If we correct our data for patients in first 
and second remission, the 5-year probability of LFS from T cell-depleted SCT onward 
would increase from 48% (95% CI, 34-62%) to 67% (95% CI, 58-76%).
Using red blood cell phenotyping and cytogenetic analysis of the bone marrow, evaluation 
of chimerism at 6 months and 1 year after SCT showed high incidences of mixed 
chimerism. These findings are comparable with other chimerism studies after 
transplantation with T cell-depleted stem cell grafts.29,49,50 In a previous analysis we
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showed that mixed chimerism at 6 months after SCT was not correlated with higher
20 29incidence of relapse. ’ The data in this study confirm this conclusion. However, if  we 
evaluate the chimerism status at 12 months after SCT, mixed chimerism is correlated with 
an increased probability of relapse. The differences in relapse rate may be explained by a 
relatively high number of patients who were still mixed chimera at six months after SCT 
and changed to complete donor chimera at 12 months after SCT. Another explanation 
may be selection of patients transplanted for CML. Patients transplanted for AML and 
ALL usually relapse early after SCT and progression to relapse is usually very rapid 
resulting in a relatively higher number of observed donor chimeras that relapse. Data in 
the literature concerning the influence of mixed chimerism at one time point post-SCT on 
the risk of leukemic relapse are conflicting.51 Investigating chimerism using serial 
analysis over time is essential in order to validate the significance of mixed chimerism 
after SCT and is being assessed in an ongoing study.
In the present analysis we show that SCT with grafts deleted of lymphocytes by 
counterflow centrifugation resulted in low graft failure. Intensification of the conditioning 
with the addition of anthracyclines decreased relapse rate and increased the probability of
22 30 34 38 41LFS. This data compares favourably with other studies using T cell depletion. , , - , 
The probability of survival and LFS is equivalent to that reported in the literature for 
recipients of untreated grafts, but the morbidity due to GVHD is low. In patients 
transplanted for CML, relapse can be treated with donor lymphocytes. This may be very 
important for the future of T cell-depleted SCT. In patients with AML and ALL further 
efforts should be made to reduce relapse rate. Pre-emptive immunotherapy by delayed or 
selected lymphocyte add-back after T cell-depleted SCT in patients with a high 
probability of relapse is one of the possibilities currently under investigation.
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Abstract
Using red cell phenotyping (RCP) and/or cytogenetics (CYT) we identified 19 patients 
with persisting mixed chimerism (MC) among 231 patients transplanted with partially T 
cell-depleted stem cell grafts from HLA-identical siblings. Persisting MC is defined as 
MC for more than 2 years in patients without any evidence of relapse. Median leukemia­
free survival in these patients was 150 (range, 50-218) months. Diagnoses were ALL (n = 
10); AML (n = 2); CML (n = 2); NHL (n = 2); MDS (n = 1); MM (n = 1), and SAA (n = 
1). Purpose of this study was the long- term follow-up of MC and definition of patterns of 
chimerism in the various subsets of PBMCs and granulocytes. Using a PCR-STR 
technique CD3+/CD4+ (T4 lymphocytes), CD3+/CD8+ (T8 lymphocytes), 
CD45+/CD19+ (B lymphocytes), CD45+/CD14+ (monocytes), CD45+/CD15+ 
(granulocytes) and CD3-/CD56+ (NK cells) were analyzed. The majority of patients with 
persisting MC were conditioned with a less intensive conditioning regimen and had little 
GVHD. Sequential monitoring of the chimerism resulted in a group of patients (n = 7) 
with very slow transient mixed chimerism that resulted in complete DC after median 7 
years. Another nine patients had a relatively high percentage of persisting autologous cells 
for a median of 12 years and in 3 patients we observed a stable low percentage of 
autologous cells. Only two out of 19 patients (AML-CR1, CML-CP1) relapsed during 
follow-up. Both patients had a relatively high percentage of autologous cells. Chimerism 
in granulocytes and PBMC-subsets was analyzed at a median 8 years after SCT in nine 
patients. In five patients mixed chimerism simultaneously detected by RCP and CYT was 
associated with MC in all subsets. Within each individual patient the percentages of donor 
and recipient cells were very different between the different subsets. Two CML-CP1 
patients were mixed chimera in only two subsets and in one patient these subsets 
represented pending relapse. In another two patients mixed chimerism with a very low 
number of autologous red cells was not found in the PBMCs because of the different 
sensitivity level of the RCP and the PCR-STR technique. We conclude that in patients 
with persisting mixed chimerism after partially T cell-depleted SCT a remarkable number 
of patients had lymphoid malignancies, the majority of the patients were conditioned with 
less intensive conditioning regimens and the mixed chimerism was not correlated with
60
relapse. Chimerism in granulocytes and PBMC subsets did show great intra-individual 
differences in the subsets and these data correlated well with RCP and CYT data with 
exception of the NK cells.
___________________________________ Persisting mixed chimerism after T cell-depleted SCT
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Introduction
The major goal of allogeneic stem cell transplantation (SCT) for hematological 
malignancies is complete eradication of malignant cells together with the development of 
complete donor chimerism. With the use of increasingly sensitive techniques, mixed 
chimerism, defined as a mixture of both donor- and recipient-derived hemopoietic cells, is
1 3frequently observed after allogeneic SCT. - The presence of mixed chimerism depends on 
several factors such as the intensity of the conditioning regimen, the use of T cell
4 12depletion and the number of stem cells infused. - Mixed chimerism with an increasing 
number of autologous cells may be a significant risk factor for subsequent relapse.10,13-15 
The significance of persisting stable mixed chimerism is not clear yet. Using more 
sensitive methods to evaluate chimerism after SCT, residual host cells may represent 
normal hematopoiesis without any evidence of recurrent disease.10,11,16-18 We showed high 
incidences of mixed chimerism at 6 months and 1 year after SCT in patients who were 
transplanted with HLA-identical grafts that were partially depleted of lymphocytes by 
density gradient and counterflow centrifugation. Mixed chimerism at 6 months after SCT 
did not correlate with higher incidence of relapse in further follow-up. However, mixed 
chimerism at 12 months after SCT indicated a higher relapse risk.4,19 Using red blood cell 
phenotyping (RCP) and/or cytogenetic analysis we also identified a remarkable number of 
patients with persisting mixed chimerism for more than two years after SCT in a 
population of patients transplanted with HLA-identical T cell depleted grafts. Our aim has 
been to determine prospectively the course and significance of MC in these patients. 
Additionally, we wished to evaluate chimerism in the various subsets of blood cells 
involved in this stable mixed chimerism. During follow-up chimerism was monitored 
sequentially in these patients and patients were evaluated frequently for residual disease. 
In a substantial number of patients we were able to determine chimerism in the 
granulocytes and in various subsets of PBMCs such as monocytes, T cells, natural killer 
(NK) cells and B cells by a quantitative PCR-based technique for the analysis of 
microsatellite DNA regions.
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Patients and methods
Patient characteristics
All patients who had a discriminating patient and/or donor marker and who underwent 
allogeneic T cell-depleted stem cell transplantation at the University Medical Centre St 
Radboud Nijmegen, between 1983 and 1999, were sequentially monitored for chimerism. 
A cohort of 231 consecutively transplanted patients with a discriminating patient/donor 
marker survived for more than two years after SCT without any evidence of relapse from 
their original disease. These 231 consecutive patients were transplanted for acute myeloid 
leukemia (AML) (n = 53), acute lymphoid leukemia (ALL) (n = 41), chronic myeloid 
leukemia in first chronic phase (CML-CP1) (n = 67), myelodysplastic syndrome (RA, 
RAEB and RAEB-t) (n = 25), intermediate and high grade B-cell non-Hodgkin lymphoma 
(NHL) (n = 9), low grade NHL (n = 14), multiple myeloma (MM) (n = 12), chronic 
lymphoid leukemia (CLL) (n = 3) and severe aplastic anaemia (SAA) (n = 7). Donors 
were HLA A, B, DRB and DQB-identical siblings. Chimerism was investigated using red 
blood cell phenotyping and cytogenetic analysis of bone marrow and/or blood. Using 
these techniques we identified nineteen patients with persisting, relatively stable mixed 
chimerism. Persisting chimerism is defined as being mixed chimera for more than two 
years after SCT without any evidence of cytogenetic or hematological relapse. Patient 
characteristics of the 19 patients with persisting mixed chimerism are listed in table 1.
Conditioning regimen, GVHD prophylaxis and supportive care
The majority of patients (n = 165) were conditioned with an intensified conditioning 
regimen consisting of idarubicine 42 mg/m by continuous intravenously (i.v.) infusion on 
day -12 and -11 followed by cyclophosphamide 60 mg/kg b.w. i.v. on each of two 
consecutive days (days -6 and -5). Fractionated total body irradiation (TBI) was given on 
days -2 and -1 to a total dose of 9 Gy (4). In 25 patients TBI was intensified to 12 Gy 
midline dose and anthracyclines were omitted. Thirty-four patients were given 
cyclophosphamide 60 mg/kg b.w. i.v. on each of two consecutive days and TBI 9 Gy on 
days -2 and -1. The 10 patients transplanted for SAA were conditioned with a reduced 
intensity conditioning regimen consisting of 12 Gy total lymphoid irradiation given in
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three consecutive days followed by cyclophosphamide 50 mg/kg bodyweight on each of 4 
consecutive days. Donor marrow was partially depleted of lymphocytes by density 
gradient centrifugation followed by counterflow centrifugation as previously 
described.20,21 The median number of T cells in the marrow grafts was 0.7 (range, 0.4-1.9) 
x 106 CD3+ cells/kg b.w. All patients received prophylactic antibiotics according to 
institutional guidelines. Immunoprophylaxis after transplant consisted of cyclosporine A 
(CsA) 3 mg/kg/d by continuous i.v. infusion from days -1 to +14, followed by 2 mg/kg/d 
as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally at 
a dose of 6 mg/kg/d until 8 to10 weeks after SCT. In the absence of GVHD CSA was 
gradually tapered and discontinued at 12 weeks post-grafting. All patients were managed 
in single rooms with filtered air under positive pressure during their hospital stay.
Assessment ofGVHD
Acute GVHD was classified from grade 0-4 according to the criteria described by
22 23Glucksberg et al. Chronic GVHD was graded as none, limited or extensive.
Chimerism analyzed by cytogenetic analysis and red blood cell phenotyping
Chimerism in all 240 patients was investigated prospectively by cytogenetic analysis of 
blood and bone marrow and/or by RCP. Cytogenetic analysis of unstimulated bone 
marrow cells (myelo-monocytic and erythrocytic progenitor cells) and PHA-stimulated 
PBMCs (T cells) were performed routinely before SCT, 6 and 12 months after SCT and
24 25annually thereafter as described previously. , The median number of bone marrow 
metaphases analyzed was 30 (range, 12-35) and the median number of metaphases of 
lymphocytes was 32 (range, 7-32), allowing a sensitivity level of 10-12%.26 When the 
recipient and donor were of different sex, heterosome determination of 400 interphases 
(fluorescent in situ hybridization: FISH) allowed additional differentiation between donor 
and host cells, resulting in a sensitivity of 1% for the demonstration of a minor cell 
population. RCP was performed using a flow cytometric and/or fluorescent microscopic
27 29microsphere method as described previously. - The sensitivity level is 0.1-0.3% for the 
flow cytometric method and 0.01% for the fluorescent microscopic technique.
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Table 1 Characteristics o f 19 patients w ith persisting mixed chimerism
UPN Age Sex Diagnosis Conditioning T-cells in graft 
(x106/kg)
GVHD
acute/chronic
EFS
(months)
4 32 F AML, CR1 Cy/TBI-9 0.40 0 / 0 218
15 22 F Pre-B-ALL, CR2 Cy/TBI-9 0.30 0 / 0 198
31 16 F T-ALL, CR1 Cy/TBI-9 0.70 0 / L 186
40 30 F Comm. B-ALL, CR1 Cy/TBI-9 0.40 0 / 0 178
44 19 M T-ALL, CR2 Cy/TBI-9 0.80 0 / 0 175
47 35 F Pre-B-ALL, CR1 Cy/TBI-9 0.30 2 / 0 173
60 16 F Pre-B-ALL, CR1 Anthra/Cy/TBI-9 0.30 0 / 0 165
66 22 M T-ALL, CR1 Anthra/Cy/TBI-9 0.60 0 / 0 161
88 26 M Pre-B-ALL, CR1 Anthra/Cy/TBI-9 0.95 0 / L 148
89 41 F RAEB-t, CR1 Anthra/Cy/TBI-9 0.85 0 / L 150
108 41 M T-ALL, CR1 Anthra/Cy/TBI-9 1.10 0 / 0 140
122 22 M Pre-B-ALL, CR1 Anthra/Cy/TBI-9 1.11 1 / L 134
157 48 F B-NHL, HIGH, PR2 Cy/TBI-12 0.72 0 / L 105
160 46 F MM, PR Cy/TBI-12 0.80 2 / L 119
161 33 F CML, CP1 Cy/TBI-12 0.70 1 / L 118
206 46 F B-NHL, LOW Cy/TBI-12 1.40 2 / L 103
237 39 F SAA TLI12/Cy 1.30 1 / 0 93
268 37 F CML, CP1 Anthra/Cy/TBI-9 1.00 1 / 0 82
388 51 F AML, CR1 Anthra/Cy/TBI-9 0.75 1 / 0 50
Abbreviations: UPN, unique patient number; GVHD, graft-versushost disease; EFS, event-free-survival; 
No, number; AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; CML, chronic myeloid 
leukaemia, NHL, non-Hodgkin lymphoma; RAEBt, refractory anaemia with excess of blasts; MM, multiple 
myeloma; CLL, chronic lymphoid leukaemia; SAA, severe aplastic anaemia; Comm., common; CR1, first 
complete remission; CR2, second complete remission; CP1, first chronic phase; PR2, second partial 
remission; Cy, cyclophosphamide; TBI, total body irradiation; Anthra, anthracyclines; TLI, total lymphoid 
irradiation; L, limited.
At the level of 0% patient or donor red cells, the flow cytometric results were always 
controlled by the fluorescent microscopic method in order to increase the sensitivity to a 
level of 0.01%. The time schedule for analysis was 1, 2, 3, 6 and 12 months after SCT and 
annually thereafter.
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Chimerism in granulocytes and PBMC 's subsets using PCR-STR analysis.
In nine out of nineteen patients with persisting mixed chimerism as found with RCP 
and/or cytogenetics, chimerism was analysed in granulocytes and PBMC subsets by 
amplification of short tandem repeats (STR) markers. Immunophenotypical markers used 
to discriminate between the different subsets were CD3+/CD4+ (T4 lymphocytes), 
CD3+/CD8+ (T8 lymphocytes), CD45+/CD19+ (B lymphocytes), CD45+/CD14+ 
(monocytes), CD45+/CD15+ (granulocytes) and CD3-/CD56+ (NK cells). Analysis of 
these subsets was performed at a median of 8 (range, 3-12) years after SCT. A panel of 
four microsatellite markers (CSF1PO, TPOX, THO1 and vWA; Promega GenePrint™ 
Fluorescent STR Systems, Madison, USA) in one multiplex PCR was used in the initial 
screening process to identify at least one polymorphic marker. Samples were analysed 
using only the informative primer pair. Shortly, genomic DNA was isolated from whole
30EDTA blood of the donor and recipient (pre-transplant) by salt extraction. A serial 
dilution was prepared by mixing donor DNA with recipient DNA. The sorted subsets were
31lysed. The samples were amplified using the manufacturer's directions with 100 ng DNA 
or 14,000 lysed cells as template.
Granulocytes were separated from mononuclear cells by Ficoll-Hypaque density gradient 
centrifugation. Mononuclear cells were further purified using a magnetic cell separation 
technique (MiniMacs; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
manufacturer's instructions. After direct staining with anti-CD4, anti-CD8, anti-CD14, and 
anti CD 19-Microbeads (Miltenyi Biotec), these cells were magnetically isolated on 
MiniMacs columns. After washing twice with staining buffer, followed by elution with 
staining buffer in the absence of any magnetic field, subsets with a purity of 93-97% were 
obtained. Granulocytes were directly isolated after lysing the red blood cells and after 
incubating with anti-CD45-FITC and anti-CD 15-PE using flow cytometric sorting 
(Coulter-Elite, Miami, Fl, USA). NK cells were directly sorted after incubating with anti- 
CD56-PE, and anti-CD3-FITC, respectively. All magnetic sorted subsets were re­
incubated with fluorescent antibodies specific for each cell population and were resorted 
on the flow cytometer to obtain a purity of more than 98% in each subset.
PCR products were detected and quantified by capillary electrophoresis (Beckman P/ace 
system 5000 with LIF detector; Beckman, Fullerton, CA, USA) with a 37 cm x 50 Tm
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capillary (Applied Biosystems; Norwalk, CT, USA) using Performance Optimised
32Polymer 4 (Applied Biosystems). PCR products were diluted 50x in dH2O, denatured 
for 5 minutes and stored on ice for 5 minutes before loading. Samples were injected 
electrokinetically for 7 seconds 10 kV and separated at 10 kV at 550 C in 2x genetic 
analyser buffer (Applied Biosystems). Quantification was done by comparing the samples 
with the serial dilution.
Calibration of product (Y) was done with a series of serial diluted samples with donor 
concentration C, (0 < C <1). The data were fitted with Y ~ C/(1-C) (Ultra-Fit, Biosoft, 
Cambridge, UK). Quantification was performed by root finding in the fitted curve.
The sensitivity of this technique varies between 0.5 to 1% and is also dependent on the
33-35amount of DNA tested and the specific discriminating STR locus. -
Results
Sequential monitoring of patient- and donor-derived blood cells using RCP and/or 
cytogenetic analysis in 231 consecutive patients resulted in the identification of nineteen 
patients with persisting mixed chimerism (table 1).
Only eight of 165 (5%) patients conditioned with the addition of anthracyclines developed 
persisting mixed chimerism. In contrast 11 of 66 (17%) patients conditioned without the 
addition of anthracyclines became persisting mixed chimera (P  = 0.0031, chi square). 
Persisting mixed chimerism was found in 12 out of 67 patients (18%) transplanted for 
lymphoid malignancies compared to 7 out of 164 patients (4%) transplanted for non­
lymphoid diseases (P  = 0.0006, chi square). These two groups did not differ from each 
other in the conditioning regimens used, T cell dose in the stem cell grafts and graft- 
versus-host characteristics.
The median number of CD3+ T-cells in the stem cell grafts did not differ between the 
patients who did develop persisting mixed chimerism after SCT and those who did not. 
The median T cell dosages were 0.7 (range, 0.3-1.4) x 106/kg body weight and 0.7 (range, 
0.4-1.9) x 106/kg body weight, respectively.
Three out of 19 patients (16%) with persisting mixed chimerism suffered from acute 
GVHD > grade 2 and none had extensive chronic GVHD. Twelve out of 212 (6%) patients
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without persisting mixed chimerism had acute GVHD > grade 2 and 23 of 212 patients 
(11%) had extensive chronic GVHD (P  = 0.09 and P = 0.13, respectively, chi square).
Follow-up of19 patients by red blood cellphenotyping and cytogenetics
In four out of 19 patients (UPN 15, 40, 60, and 388) early after SCT a relatively high and 
stable number of autologous cells was detected with recipient cells ranging from 50 to 
100% at end of follow-up (figure 1). Figure 1 depicts the percentages of autologous cells 
detected by RCP and cytogenetic analysis. If cytogenetic analysis resulted in different 
percentages of autologous cells detected simultaneously in unstimulated bone marrow 
cells (myelo-monocytic and erythrocytic progenitor cells) and PHA stimulated PBMC (T 
cells) the highest percentage is given in Figure 1. In UPN 388 transplanted for AML-M5 
one year after SCT 99% of the blood and marrow cells were of recipient origin and after 3 
years also the cytogenetic marker of the original disease (Xp-) reappeared. Peripheral 
blood counts remained normal during 4 years and the cytogenetic marker did not 
disappear after repeated donor leukocyte infusions. After 4 years this patient developed a 
hematological relapse of the acute leukemia and subsequently died. Four patients (UPN 4, 
88, 237 and 268) slowly progressed towards significant percentages (30-72%) of recipient 
cells during follow-up.
One patient (UPN 31) developed 52% autologous cells in a period of five years. From this 
moment onwards, annual bone marrow evaluation stopped but at 12 years after BMT still 
19 % of the bone marrow cells turned out to be of autologous origin. This patient lacked a 
red blood cell marker. Seven out of the nine patients mentioned above had both a 
discriminating red blood cell and cytogenetic marker (Figure 1). In all these patients the 
relatively high number of recipient red blood cells was simultaneously represented by a 
relatively high number of recipient bone marrow cells (Figure 1). In one of these 9 patients 
(UPN 268) the increasing number of recipient cells represented a pending relapse of CML. 
The Bcr/Abl fusion protein increased in blood and bone marrow and cytogenetic relapse 
was detected 4 years after SCT. The patient subsequently received an infusion of 0.7 x 10 
CD3+ cells/kg from the original donor and developed a second complete remission with 
conversion to complete donor chimerism.
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In the 10 other patients (UPN 44, 47, 66, 89, 108, 122, 157, 160, 161 and 206) the number 
of autologous cells detected by red cell phenotyping and cytogenetic analysis did not 
exceed 15%. Dynamics of autologous cells varied between the individual patients. In six 
of these patients (UPN 47, 89, 108, 122, 160 and 206) a very slow progression towards 
complete donor chimerism was observed in a period of median 7 (range, 4-12) years. In 
the other four patients (UPN 44, 66, 157 and 161) a persistently low number of autologous 
red blood cells remains present. Cytogenetic analysis in these patients resulted in no 
detectable recipient cells in UPN 44, a low percentage autologous cells in UPN 157 (9%) 
and a variable percentage recipient cells in UPN 66 (6-43%). UPN 161 always showed 
autologous red cells but never autologous cells were found using cytogenetic analysis. In 
the majority of the patients with < 1% autologous red cells these cells could not be 
quantified using cytogenetics as a consequence of the difference in sensitivity levels 
between these tests. UPN 31 lacked a discriminating red cell marker but cytogenetically 
the percentage of autologous cells varied between 3% and 52% with a most recently 
observed percentage of 19%.
Chimerism in granulocytes and PBMC subsets analysed by PCR-STR
The percentages of recipient cells detected by PCR-STR technique in granulocytes and 
PBMC subsets are listed in table 2.
Comparing the results of cytogenetic analysis of the bone marrow (myelo-monocytic and 
erythrocytic progenitor cells) with de results of the red blood cell phenotyping and PCR- 
STR analysis of the myeloid subsets (CD45+/CD14+, CD45+/CD13+) in the blood, we 
observe a high concordance of the different methods used. Only in one patient (UPN 31) 
transplanted for T-ALL, were 23% recipient cells found by bone marrow cytogenetics not 
represented by a corresponding percentage autologous cells in the myeloid subsets in the 
blood using PCR-STR. In this patient a remarkably high percentage (22%) of autologous 
B cells was found.
Cytogenetic analysis of PHA-stimulated T cells from the peripheral blood correlated well 
with the mean percentages of recipient lymphoid subsets (CD3+/CD4+, CD3+/CD8+) in 
the peripheral blood analyzed by PCR-STR. In two patients (UPN 157, UPN 237) the 
number of CD3+/CD4+ cells was higher compared to the number of autologous cells in
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the CD3+/CD8+ T lymphoid subsets. In seven patients the percentages CD3+/CD4+ and 
CD3+/CD8+ recipient cells were equal.
The percentage of CD3-/CD56+ NK-cells did not correlate with that of any of the other 
subpopulations of blood nor with that of bone marrow cells.
As expected no correlation was found between the recipient B lymphoid and T lymphoid 
subsets with the exception of the two patients who were complete donor chimera at time 
of the PCR-STR analysis (UPN 108, UPN 161).
Within each individual patient the percentages of donor and recipient cells were very 
different between the subsets investigated (table 2). Patient UPN 60 transplanted for pre- 
B-ALL had almost complete autologous reconstitution in all cell lines except in the 
CD45+/CD19+ B lymphocyte subset in which 42% from the sorted cells were still donor- 
derived. In contrast, patient UPN 157 transplanted for high grade B-cell NHL had a low 
number of recipient cells in the CD45+/CD14+, CD45+/CD15+, CD3+/CD8+ and CD3- 
/CD56+ subset and 14% and 58% autologous cells, respectively, in the CD3+/CD4+ and 
CD45+/CD19+ subset. Eight percent recipient red blood cells in patient UPN 268 (CML- 
CP1) were associated with 12% granulocytes and 2 % CD45+/CD14+ cells of recipient 
origin as part of an ongoing relapse. In two patients (UPN 108 and 161) the number of 
recipient derived red blood cells was less than 1%. The PCR-STR technique could not 
detect any host cells in the various subsets because of the lower sensitivity level. In patient 
UPN 237 transplanted for SAA after a reduced intensity conditioning regimen, mixed 
chimerism was present in all subsets although the number of autologous CD3+/CD4+, 
CD3+/CD8+ and CD3-/CD56+ NK-cells was low.
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Figure 1.
Sequentially chimerism data obtained in 19 patients with persisting mixed chimerism.
The solid bars represent autologous red blood cells, the shaded bars represent autologous cells 
detected by cytogenetic analysis. The percentage of autologous cells is shown in a logarithmic 
scale. A percentage of 0% autologous cells detected by red blood cell phenotyping and/or 
cytogenetic analysis is represented by •  and X , respectively. The arrow in UPN 268 represents 
the date of donor leukocyte infusion in this patient.
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Table 2 Percentage autologous cells in separated subsets in peripheral blood
UPN Diagnosis Sort: yrs RCP CYT CD45+ CD45+ CD45+ CD3+ CD3+ CD3-
after BM/Blood CD14+ CD13+ CD19+ CD4+ CD8+ CD56+
SCT % % % % % % % %
31 T-ALL 12 n.m. 23 / 0 0 0 22 0 0 7
47 B-ALL 11 3.3 5/8 2 2 9 17 16 6
60 Pre-B-ALL 10 94 91 / 88 92 93 58 87 89 95
88 Pre-B-ALL 9 21 16 / 5 20 22 6 3 3 7
108 T-ALL 8 0.03 n.m. 0 0 0 0 0 0
157 NHL-High 7 1.2 5 / 9 3 2 58 14 4 8
161 CML 7 0.68 0 / 0 0 0 0 0 0 0
237 SAA 5 28 14 / 6 14 27 1 12 1 3
268 CML 3 8.4 5 / 0 2 12 0 0 0 0
phenotyping; CYT, cytogenetic analysis; BM, bone marrow; n.m., no marker.
Abbreviations: UPN, unique patient number; yrs, years; SCT, stem cell transplantation; RCP, red blood cell
Discussion
Since the introduction of more sensitive techniques to investigate chimerism after SCT, 
the persistence or reappearance of autologous cells has been observed more frequently,
26 36 37especially in patients who received T-cell depleted grafts. , , Mixed chimerism after 
allogeneic SCT may represent very different modalities and is influenced by a number of 
interacting parameters like the underlying malignancy, the conditioning regimens, the 
number of T cells in the graft and graft-versus-host disease after SCT. Also, the techniques 
used to detect the chimerism and their sensitivity have influenced its significance after 
SCT.38-40 Residual autologous hemopoiesis may represent residual normal cells belonging 
to one ore more specific subsets that survived the conditioning regimen and that are 
tolerated by the transplanted donor immune system. However, these cells may also 
originate from the malignant clone and represent residual disease controlled by an active 
donor-derived immune system. Chimerism after SCT is a dynamic process and its 
significance can only be investigated by sequential monitoring of the co-existence of
74
Persisting mixed chimerism after T cell-depleted SCT
donor and patient cells. The long-term clinical significance of mixed chimerism after SCT 
remains a matter of discussion. Some studies found high relapse rates in patients with 
mixed chimerism after T cell-depleted SCT.41-45 Other studies could not demonstrate this 
correlation.7,15,46 It may be very important to distinguish between patients with slowly 
decreasing number of autologous cells, patients with increasing number of autologous 
cells and patients who are complete donor chimera and subsequently become mixed 
chimera again. The different subsets of hemopoietic cells involved in the mixed chimerism 
may also influence outcome in further follow-up of these patients.40 Several studies using 
sequential analysis of post-transplant chimerism showed that patients with increasing 
mixed chimerism had the highest risk of relapse. 45,47,48 Using RCP and/or cytogenetic 
analysis we showed that mixed chimerism at six months after partially T cell-depleted 
SCT was not correlated with relapse. However, if  we extended our observations, the 
presence of mixed chimerism at 12 months after transplantation was correlated with an 
increased probability of relapse.4 The differences in these relapse rates were explained by 
a relatively high number of patients with an decreasing number of recipient cells who were 
still mixed chimera at 6 months after SCT and who had changed to complete donor 
chimeras at 12 months after BMT. In a relatively high number of patients this would have 
been transient T cell chimerism as demonstrated by decreasing numbers of autologous 
cells in the peripheral blood as shown by cytogenetic analysis. We also demonstrated that 
the reappearance of autologous red blood cells in CML patients with complete donor 
chimerism was a very sensitive marker for a pending relapse.49
In this study we describe 19 patients who were sequentially monitored for chimerism 
during a long (median 150 months) period after SCT and who were persisting mixed 
chimera for more than 2 years after SCT without any evidence of cytogenetic or 
hematological relapse of their original disease. These patients were analyzed sequentially 
using red blood cell phenotyping and cytogenetics to study the dynamics of the 
chimerism. The incidence and severity of acute and chronic GVHD was low although the 
number of CD3+ cells in the stem cell grafts did not differ between these nineteen patients 
and the remaining 219 patients who developed complete donor chimerism after 
transplantation. During further follow-up only two out of nineteen patients with persisting 
mixed chimerism relapsed from the original disease (AML, CML). The findings on these
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serially collected samples from patients in long-term continuous complete remission show 
the kinetics of residual recipient cells, with almost no apparent correlation with post 
transplant events. An important factor that influenced chimerism after SCT was the 
introduction of anthracyclines to the conditioning regimen. Mixed chimerism occurred 
significantly more frequently in the patients conditioned without anthracyclines. An earlier 
performed multivariate analysis on 181 standard risk patients already underlined the 
importance of the addition of anthracyclines to the conditioning regimen in relation to the 
development of acute GVHD, mixed chimerism and relapse.4 Another remarkable 
observation is the overrepresentation of patients with lymphoid malignancies in the group 
of patients with persisting mixed chimerism. Compared to the patients with non-lymphoid 
malignancies, these patients did not differ in the conditioning regimens, the amount of 
CD3+-cells present in the stem-cell grafts and the incidence and severity of GVHD. This 
observation may be explained by the presence of re-emerging autologous lymphocytes not 
belonging to the malignant clone that escaped from the primary GVL effect. It is known 
that patients with ALL may escape the GVL effect more easily compared to patients 
suffering from myeloid or mature lymphoid malignancies like low grade NHL, multiple 
myeloma or CLL.50,51 This phenomenon is also correlated with low response rates after
52therapeutic donor lymphocyte infusions in patients with relapsed ALL. The reappearance 
of recipient cells may weaken the GVL effect of donor effector cells, possibly as a result 
of the induction of immune host and/or donor tolerance or as a result of indirect
39mechanisms such as negative signalling. In patients with complete donor chimerism 
after SCT, alterations in expression of surface co-stimulatory molecules might lead to 
anergy or to a lack of allo-reactivity in donor lymphocytes grown in a donor environment 
giving the opportunity to benign or malignant autologous cells to expand.50,53 
Persisting mixed chimerism without relapse as described in this study may be explained by 
complete eradication of the malignant clone with selective survival of residual normal 
autologous hemopoietic stem cells after transplantation. In seven patients we observed a 
very slowly transient mixed chimerism with a low number of recipient cells that 
disappeared gradually after median 7 years post SCT. In these patients a small number of 
autologous cells must have survived the conditioning regimen and also must have been able 
to escape from the graft-versus-leukemia effect. Finally, in these patients the
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immunological balance was tipped towards complete donor hemopoiesis with no detectable 
autologous cells using the described techniques, which means that either residual host 
hemopoiesis represents a transient event or it persists longer but below the detection level 
of the method used to evaluate chimerism.54
Another explanation for the survival of autologous blood cells after SCT may have been 
the presence of cytotoxic T lymphocytes in the stem cell graft directed towards leukaemia- 
associated minor histocompatibility antigens.55 This specific cytotoxicity may result in 
reactivity only directed at the malignant lymphoid cells and not directed towards residual 
host hemopoietic cells lacking the leukemia-specific antigen and consequently creating an 
opportunity for mixed chimerism without relapse of the original disease.
To obtain additional information about the specific subsets of blood cells involved in the 
mixed chimerism, STR analysis on highly purified PBMC subsets and granulocytes was 
performed in nine patients. In this analysis red blood cell phenotyping correlated well with 
cytogenetic analysis of the bone marrow. We also found concordant data comparing 
cytogenetics of the bone marrow with myelo/monocytic subsets analysed using PCR-STR. 
The PCR-STR analysis also established the difference of mixed chimerism observed using 
cytogenetic analysis of the blood and cytogenetics of the bone marrow, respectively. 
Another observation was the good correlation between PHA-stimulated T cells in the 
peripheral blood and the mean number of recipient T cells represented as the percentage of 
autologous cells in CD3+/CD4+ subset and CD3+/CD8+ subset of the peripheral blood 
divided by two.
Chimerism patterns between these patients were very different, varying from mixed 
chimerism in only the CD45+/CD19+ (B lymphocytes) and CD3-/CD56+ (NK cells) 
subsets in a patient transplanted for T-ALL to mixed chimerism in all investigated subsets 
in four patients transplanted for B-lymphoid malignancies (ALL, n = 3 and high grade 
Non-Hodgkin's lymphoma, n = 1). Patients had a long-lasting event-free survival without 
any evidence of residual disease.
Chimerism studies in purified subpopulations during the first year after SCT resulted in 
mixed T lymphoid chimerism represented by host-type cells in the T cell lineage that only 
gradually disappeared in the first year after SCT.47,56 This type of chimerism could only be 
demonstrated in the peripheral blood and was not found in the bone marrow, however the
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number of evaluable patients was low. In the present study subpopulations were analysed 
late after SCT (median of 8 years) and only peripheral blood samples were analyzed for 
chimerism in subsets. Chimerism restricted to the T cell lineage only could not be 
demonstrated. Using cytogenetics we did not identify patients with autologous cells 
restricted to the peripheral blood only (T cells) and complete donor chimerism in the bone 
marrow which is concordant with the PCR-STR results in PBMC subsets. Patient UPN 268 
showed a chimerism pattern specific for relapsing CML with autologous cells detectable in 
the red blood cells, granulocytes and monocytes and complete donor T-cell chimerism. The 
low number of patient red blood cells in UPN 108 and UPN 161 may also represent 
microchimerism in all other subsets, however this could not be proved because of the lower 
sensitivity level of the PCR-STR technique.
In conclusion, this is the first study in which patients are described with long term stable 
mixed chimerism who have been followed for many years. We show the dynamics of this 
chimerism resulting in a very slowly transient chimerism, almost autologous repopulation 
and relatively stable mixed chimerism in different subgroups, respectively. We also 
demonstrate a great individual difference in hemopoietic cells involved in this chimerism. 
Mixed chimerism did not correlate with relapse in further follow-up despite the fact that the 
majority of these patients were conditioned with less intensive conditioning regimens and 
they had also little GVHD. There was a relationship between the type of leukemia and the 
incidence of persisting mixed chimerism although this difference disappeared after 
intensifying the conditioning regimen by the introduction of anthracyclines. We think that 
these observations may contribute to the interpretation of chimerism especially in the 
context of mixed chimerism after reduced intensity conditioning regimens in allogeneic 
SCT. The impact of anthracyclines in the conditioning regimens on outcome and 
chimerism after SCT is currently under investigation in a randomised prospective 
multicenter trial.
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Abstract
Fifteen consecutive patients with Philadelphia chromosome positive chronic myeloid 
leukemia who relapsed from partially T cell-depleted SCT were successfully treated with 
donor leukocyte infusions (DLI). Chimerism was analyzed using red blood cell 
phenotyping (RCP), and the results were compared with cytogenetic analysis and 
outcome of qualitative and quantitative polymerase chain reaction for breakpoint 
molecules. In all patients, an increase of autologous erythrocytes and/or a decrease in 
donor red cells indicated relapse. Donor erythrocytes started to increase from 4 to 20 
(median, 12) weeks after DLI. At 6 and 12 months after DLI, complete donor chimerism 
was found in 11 and 15 patients, respectively, and all patients were in cytogenetic 
remission. A high percentage of autologous red cells at the time of DLI predicted 
pancytopenia. During relapse and after DLI, the percentage of autologous red cells was 
strongly correlated with the reappearance and disappearance of Philadelphia chromosome 
positive metaphases (r = 0.90; P  < 0.001 and r = 0.96; P  < 0.001, respectively). The same 
was true for the correlation between the percentage of autologous red cells and 
positivity/negativity in PCR for Bcr/Abl breakpoint molecules (r = 0.94; P  <0.001). A 
normalized Bcr/Abl dose of greater than 10- in real-time quantitative PCR correlated 
well with relapse and the presence of autologous blood cells (r = 0.77; P  < 0.001). We 
conclude that RCP is a sensitive, easy to perform and fast technique for the prediction of 
pending relapse after SCT for CML RCP also predicts the response to DLI and the 
occurrence of bone marrow aplasia after DLI.
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Introduction
Tcell-depleted allogeneic SCT for chronic myeloid leukemia (CML) is associated with a 
high incidence of relapse.1 Until recently, therapeutic options for CML relapsing after 
SCT were limited. A major breakthrough, especially in patients with relapsed CML, was 
treatment with lymphocytes from the original donor. Several authors have reported on
3 11this form of adoptive immunotherapy. - The outcome of donor leukocyte infusion (DLI) 
is more favorable if the number of leukemia cells is low at the time of DLI.9 This implies 
that methods are needed for early detection of pending relapse. Chimerism studies after 
SCT may provide information about residual autologous hematopoiesis. Discrimination 
between malignant and nonmalignant autologous hematopoiesis is only possible if the 
malignant cells can be distinguished from normal autologous cells by a specific marker 
(e.g. the Philadelphia (Ph) chromosome or Bcr/Abl breakpoint in CML patients). 
However, for cytogenetic analysis a bone marrow puncture is needed and this method is 
not very sensitive, time consuming and expensive. Qualitative polymerase chain reaction 
(PCR) results on Bcr/Abl transcripts are sensitive but do not provide any information 
about an increasing number of malignant cells. In the present study we used red blood cell 
phenotyping (RCP) for the sequential analysis of chimerism in fifteen CML patients from 
SCT until relapse and in the period after DLI. The results obtained by RCP were
compared with cytogenetic data and with results from qualitative PCR of Bcr/Abl
12transcripts. In seven patients RCP date were compared with real-time quantitative PCR. 
We showed that RCP is a very sensitive and easy method for the detection of a pending 
relapse. This technique can also be used to evaluate accurately the response of the patient 
to DLI. Using RCP we could predict the development of aplasia after DLI and we 
observed a strong correlation between RCP, cytogenetics, and residual disease measured 
by qualitative PCR of Bcr/Abl breakpoint molecules. Correlation between RCP and real 
time quantitative was less strict. However, an increase in autologous red blood cells was 
always accompanied by an increase in normalized Bcr/Abl dose. A normalized Bcr/Abl
-3dose of greater than 10- correlated well with relapse, and presence of autologous red 
blood cells.
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Patients and methods
Patients
All 15 patients were transplanted for CML in first chronic phase (CP1). Fourteen donors 
were HLA-A, B, DR-identical, Mixed Lymphocyte Culture (MLC)-negative or A, B,
13DRB, DQB-identical siblings. One donor had one class I locus mismatch (UPN 91). 
Characteristics are shown in table 1. All patients were conditioned with 
cyclophosphamide and fractionated total body irradiation as described previously.14 In 
eight patients an intensified conditioning regimen was used with the addition of 
anthracyclines.14 Marrow grafts were depleted of lymphocytes by density gradient 
centrifugation followed by counterflow centrifugation as described previously.15,16 The 
median number of T cells left in the marrow graft was 0.7 (range 0.4 to 1.6) x 106/kg 
body weight. Immunoprophylaxis post-transplant consisted of cyclosporine A.
In 10 patients DLI was given for hematological relapse and in five patients for 
cytogenetic relapse only. At the moment of DLI four patients were treated with 
chemotherapy and/or interferon. Follow-up ended on December 1, 1998.
Infusion of donor leukocytes
DLIs were performed as reported previously.4 In summary: unstimulated peripheral blood 
mononuclear cells were obtained from the original bone marrow donor by leukapheresis 
using a blood cell separator Baxter CS 3000 (Baxter, Deerfield, IL, USA) or the Fresenius 
AS 104 (Oberursel, Germany). The median total number of CD3+ lymphocytes infused 
was 1.1 (range, 0.1 to 2.8) x 10 /kg body weight. Lymphocytes were infused from 0.5 to 
51 (median, 3) months after diagnosis of relapse. Patients who did not respond within 
three months after the first infusion were given a second course of DLI (UPN 51, 162, 
182 and 389). Leukocytes were administered to the patient within 3 hours of completion 
of the leukapheresis procedure at the outpatient clinic. All infusions were without 
complications.
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Table 1 patient characteristics
UPN Patient 
Age (yr) / 
Sex
Donor 
Age (yr) / 
Sex
SCT
Conditioning
Interval 
SCT - Rel 
(months)
Interval 
Rel - DLI 
(months)
Treatment of Relapse 
before DLI
Disease Status 
at the time of
DLI
51 46 / m 32 / m CYC/TBI 12 51 / 53* Bus/IFN a Hem Rel
64 31 / m 38 / m CYC/DNR/TBI 24 27 Bus Hem Rel
75 28 / m 38 / f CYC/IDA/TBI 84 3 none Cyt Rel
91 25 / f 20 / m CYC/TBI 36 5 Bus Hem Rel
125 32 / m 42 / f CYC/IDA/TBI 24 1 none Hem Rel
132 27 / m 28 / f CYC/IDA/TBI 12 7 IFN a Hem Rel
136 42 / m 39 / m CYC/IDA/TBI 47 29 none Cyt Rel
162 30 / m 32 / m CYC/TBI 23 11 / 13* none Cyt Rel
182 47 / f 49 / m CYC/TBI 40 1 / 4.5* none Hem Rel
184 40 / m 35 / m CYC/TBI 24 2 none Cyt Rel
268 37 / f 38 / m CYC/IDA/TBI 45 1 none Cyt Rel
337 43 / f 37 / m CYC/IDA/TBI 11 2 none Hem Rel
354 40 / m 39 / m CYC/IDA/TBI 20 0.5 none Hem Rel
387 26 / f 20 / m CYC/IDA/TBI 6 3 none Hem Rel
389 35 / f 33 / m CYC/IDA/TBI 9 1 / 3* none Hem Rel
Abbreviations: UPN, unique patient number; SCT, bone marrow transplantation; DLI, donor leukocyte 
infusion yr, year; Rel, relapse; m, male; f, female, CYC, cyclophosphamide; DNR, daunorubicine; IDA, 
idarubicine; TBI, total body irradiation; Bus, busulphan (2mg/day); IFN, interferon; Hem, hematological.
* These patients received a second DLI after not responding to the first DLI.
Red blood cell phenotyping
RCP was performed as described previously.17-19 In summary: as soon as the donor is 
known, a complete red cell phenotyping of patient and donor is performed using the 
following antigens: A, B, C, c, E, D, K, Fya, Fyb, Jka, Jkb, M, N, S and s. Red cell 
phenotyping of the patient was performed on a blood sample that was frozen before any 
erythrocyte transfusion was given. Once the discriminating markers were known, follow- 
up results could be obtained within 4 hours after blood sampling. A fluorescent 
microsphere method was used in which RBC were first incubated with an IgG antibody 
directed against the marker antigen under investigation. After washing the erythrocytes
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several times, anti human IgG coated fluorescent microspheres were added. The contact 
between cells and microspheres was enhanced by centrifugation. Marker antigen positive 
erythrocytes can be visualized and counted under a fluorescent microscope. Recently we
developed a flow-cytometric method for routine follow up of red cell populations after
20SCT. The sensitivity level is 0.01% for the fluorescent microscopic and 0.1 to 0.3% for 
the flow-cytometric method. At the level of 0% patient or donor red cells the flow- 
cytometric results were always controlled by the microscopic technique in order to 
increase the sensitivity of this test. This means that the sensitivity level for RCP in this 
analysis was 0.01%. All 15 patients could be analyzed efficiently by RCP. Markers 
discriminating for patient cells, donor cells or both were found in 13 of 15, 13 of 15 and
11 of 15 cases, respectively (table 2). Time schedule for analysis was 0.5, 1, 2, 3, 6, 9 and
12 months after SCT and annually thereafter. The same intervals were used after DLI.
Cytogenetic analysis
Chromosome studies on peripheral blood cells and bone marrow cells were routinely 
performed before SCT, 6 and 12 months after SCT and annually thereafter as described 
before.21,22 The median number of bone marrow metaphases analyzed was 30 (range, 10­
35) and the median number of metaphases of lymphocytes was 32 (range, 5-32) allowing
23,24a sensitivity level of 10-12%. , When recipient and donor were of different sex, 
heterosome determination of 400 interphases with Fluorescent in situ hybridization 
(FISH) allowed additional differentiation between donor and host cells resulting in a 
sensitivity of 1% for the demonstration of a minor cell population. A signal that 
discriminated one to five cells out of 400 was considered background. If more than five 
autologous marrow metaphases were found, bone marrow cells were analyzed for the 
presence of the Ph-chromosome using GTG banding. After DLI, these chromosome 
studies were performed on bone marrow at 1, 3, 6, 12 months and annually thereafter.
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Table 2 number of donor lymphocytes infused and response to DLI
UPN No of CD3+ 
lymph. 
x 108/kg.
a-GVHD 
after DLI
Interval
DLI-a-GVHD
(wk.)
c-GVHD 
after DLI
Response recipient 
RBC (wk.)
Response 
donor RBC 
(wk.)
51 2.74 1 16/6* E 20/10* 100/90*(AB0)
64 0.26 2 7 E 11 8
75 0.9 3 4 E 9 20
91 1.1 3 3 E 4 12
125 1.1 2 6 L N.M. 4
132 1.7 3 4 E 13 N.M
136 0.1 0 - 0 14 7
162 2.75 0 - L 12/6* 72/64*(AB0)
182 1.7 0 - L N.M* 20/4*
184 1.1 2 7 E 10 12
268 0.8 1 4 0 12 N.M.
337 0.4 2 7 E 8 8
354 0.19 1 8 L 16 16
387 0.4 1 4 0 12 12
389 0.8 1 24/18* L 16/6* 40/34*(AB0)
Abbreviations: No, number; lymph, lymphocytes; a-GVHD, acute graft versus host disease; c-GVHD, 
chronic graft versus host disease; wk., weeks; DLI, donor lymphocyte infusions; RBC, red blood cells; N.M., 
No Marker.* these patients received a second DLI.; ABO, in these patients donor red blood cell 
reconstitution was delayed by major ABO incompatibility.
Qualitative determination ofBcr/Abl breakpoint molecules
The procedure to detect Bcr/Abl breakpoint molecules in the bone marrow has been 
described before.4 In summary: RNA was isolated from 106 bone marrow derived
25nucleated cells in a modification of the method described by Chomczynski and Sacchi. 
Primers for the synthesis of c-DNA (A21) and for the two series of PCR were derived 
from the Sequence, EMBL/Genebank accession no. M30828 (Heidelberg, Germany). In 
the first 30-cycle series primers B11 and A21 were used. In the second series, B12 and 
A22 primer were used in a 35 cycle PCR. To assess the quality of each RNA sample, a 
reverse transcriptase reaction followed by PCR on ^2-microglobulin RNA was used. 
Strict precautions were taken to prevent contamination. In each PCR, both positive and
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negative controls were used. A 15% aliquot of the PCR products was analyzed by
32hybridization after Southern transfer using a radioactivity 32P labeled c-Abl 
oligonucleotide recognizing the 5’ part of exon 2 of the c-Abl gene. Using this PCR, we 
were able to detect one Bcr/Abl positive cell amongst at least 105 normal cells. The 
qualitative determination of Bcr/Abl breakpoint molecules was performed at 6 and 12 
months and then annually after SCT and at 1, 3, 6, and 12 months after DLI and annually 
thereafter.
Quantitative determination ofBcr/Abl breakpoint molecules
Consecutive paired bone marrow samples taken at consecutive time points were available 
from seven patients (UPN 51, 75, 132, 162, 184, 337, 387). Bone marrow samples were 
taken before DLI and at several time points after DLI. RNA was extracted from 106 cells 
using the guanidinium thiocyanate acid phenol chloroform procedure with minor 
modifications.26 Using the Primer Express software program (Perkin-Elmer, foster City 
CA, USA Demo version 1.0 ppd.), PCR primers were designed for the amplification of c- 
DNA derived from the Bcr/Abl transcript and porphobillinogen dehydrogenase gene 
(pbgd) transcript. The Taqman probes carried a 5’ TET reporter label and a 3’ TAMRA
27quencher group and were synthesised according to Lee et al, (PE-Applied Biosytems, 
Warrington, UK). As positive controls for the PCR we used c-DNA derived from the 
t(9;22) positive cell line K562. Negative control c-DNA was generated from RNA of cell
line HL-60. Real-time quantitative PCR was performed using the ABI/PRISM 7700
12Sequence Detection System as described before. The Bcr/Abl mRNA expression in 
patient samples was related to this standard curve and presented as the number of ng of 
K562 RNA with the same level of expression. The expression of PBGD was used to 
normalise the Bcr/Abl expression.
Definitions
Hematological remission was defined as the disappearance of all signs and symptoms of 
CML and normalization of blood counts and bone marrow cellularity. Cytogenetic 
remission was defined as a hematological remission associated with disappearance of the 
Philadelphia chromosome from the bone marrow. When the PCR for Bcr/Abl converted
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to negative, the patient was defined as in molecular remission. The clinical manifestations
of acute graft-versus-host disease (GVHD) were graded 1 to 4 according to the criteria
28described by Glucksberg et al. Chronic GVHD was classified as limited or extensive as
29described by Shulman et al. If GVHD occurred within 3 months after DLI it was 
defined as acute. If patients had GVHD beyond 3 months it was defined as chronic. Bone 
marrow aplasia was defined as leukocytes <1.0 x 109/l and thrombocytes < 15 x 109/l and 
hemoglobin level < 6.0 mMol/L.
Statistical analysis
The significance of correlation between RCP and cytogenetics was calculated using the 
Statistica Release 4.1 program (Apple Computer, Cupertino, CA, USA). This method was 
also used to calculate the correlation between RCP and quantitative real-time PCR. 
Correlation between RCP and PCR on Bcr/Abl was calculated using the Spearman rank 
order test. The significance of correlation after a cut off point of 10- normalized Bcr/Abl 
dose was calculated using the same spearman rank order test. The influence of the 
percentage autologous RBC at time of DLI on the development of bone marrow aplasia 
was calculated using the Mann-Whitney U test. P  values < .05 were considered 
statistically significant.
Results
Occurrence of relapse
Ten patients had hematological relapse at 9-45 (median, 22) months after SCT and five 
patients had cytogenetic relapse only at 6-84 (median, 24) months after transplantation.
Graft-versus-host disease after SCT and after DLI
The incidence and severity of GVHD was as low as could be expected in patients who 
relapse after T cell-depleted transplantation. Only one out of fifteen patients developed 
acute GVHD > grade 1 after SCT. Two patients had limited and one patient suffered from 
extensive chronic GVHD.
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The occurrence of acute and chronic GVHD after DLI is summarized in Table 2. Five 
patients developed grade 1 acute GVHD, four patients had grade 2 acute GVHD and three 
patients suffered from grade 3 acute GVHD. The interval from first DLI to the onset of 
acute GVHD was median 6.5 (range, 3-24) weeks. Thirteen out of fifteen patients 
developed chronic GVHD which was extensive in seven cases. In 12 out of 15 patients, 
acute GVHD preceded a decrease of the percentage of autologous and/or an increase of 
the percentage donor red blood cells.
Chimerism after SCT and DLI analyzed with RCP
Seven patients (UPN 75, 91, 136, 162, 184, 268 and 354) had complete donor red blood 
cell chimerism at a median of 6 (range, 3-6) months after SCT. In these seven patients, 
recipient red blood cells (RBCs) reappeared at a median of 15 (range, 12-74) months after 
SCT. Relapse was confirmed hematologically and/or by the reappearance of the Ph- 
chromosome at 20-84 (median, 36) months after SCT (table 1). After DLI, autologous 
RBCs started to decrease after a median of 12 (range, 4-16) weeks in six out of these 
seven patients (table 2). The median time to complete disappearance of autologous RBCs 
was 7.5 (range, 4-20) months. One patient (UPN 162) who had no decrease of autologous 
erythrocytes after first DLI received a second infusion and RBCs started to decrease 6 
weeks later. After DLI, donor erythrocytes started to increase at a median of 12 (range, 7­
20) weeks in five out of seven patients (table 2). One patient (UPN 268) had no 
discriminating donor marker and in one patient (UPN 162), major ABO incompatibility 
delayed red cell reconstitution. Complete remission was confirmed by cytogenetic 
analysis and by the disappearance of breakpoint molecules.
The percentage of autologous RBCs of six patients (UPN 51, 64, 132, 337, 387 and 389) 
decreased initially after transplantation but the autologous red cells persisted and 
increased at a median of 8 (range, 4-18) months. In these patients relapse was confirmed 
at a median of 11.5 (range, 6-24) months after transplantation (table 1). After DLI in four 
out of six patients autologous red cells started to decrease at a median of 11.5 (range, 8­
13) weeks. The median time to complete disappearance of autologous RBCs was 8.5 
(range, 5-10) months. Two of these six patients (UPN 51 and 389) did not show GVHD 
and/or decrease of autologous RBCs after the first course of DLI. They received a second
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leukocyte infusion. Recipient RBCs started to decrease at 10 and 6 weeks after the second 
DLI, respectively. Five and thirteen months after the second DLI, both patients showed 
complete donor RBC chimerism. After DLI, donor erythrocytes started to increase at a 
median of 8 (range, 8-12) weeks in three out of these six patients (table 2). One patient 
(UPN 132) had no discriminating donor marker and, in two patients (UPN 51 and 389), 
major ABO incompatibility delayed red cell reconstitution (table 2). Complete remission 
was confirmed by cytogenetic analysis and by the disappearance of breakpoint molecules. 
In two patients with only a discriminating donor marker (UPN 125 and 182), the donor 
red blood cells started to decrease at 19 and 36 months after SCT, respectively. In these 
patients, relapse was confirmed cytogenetically and/or hematologically at 24 and 40 
months, respectively. Donor red cells started to increase four weeks after first DLI in 
UPN 125 and 4 weeks after second DLI in UPN 182.
Chimerism after SCT and DLI analyzed with chromosome studies
At 6 months after SCT 10 out of 15 patients had only bone marrow cells of donor origin. 
In these 10 patients autologous cells and the Ph-chromosome reappeared at a median of 
30 (range, 12-84) months after SCT.
Five patients had mixed chimerism at 6 months after SCT. These 5 patients never became 
Ph-chromosome negative. In further follow-up, they remained mixed chimaeras with an 
increasing number of Ph-chromosome positive metaphases. Chimerism assessed by 
cytogenetic analysis of the bone marrow correlated strongly with RCP (r = .90; P  < .001). 
Complete donor chimerism was restored in 4, 11 and 15 pts at 3, 6 and 12 months after 
DLI, respectively, and all patients were Ph-chromosome negative at 12 months. We found 
a strong correlation between the percentage autologous cells measured with cytogenetic 
analysis and RCP (r = .96; P  < .001).
Fourteen patients were in continuous complete remission at the end of follow-up. The 
patient transplanted with the bone marrow from her one locus mismatched brother (UPN 
91) died 8 months after DLI from E.Coli sepsis in complete hematological and 
cytogenetic remission.
In Figure 1A-H the percentage of autologous and donor marrow cells after SCT and DLI 
is given for four representative patients (UPN 51, 162, 337 and 387).
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Pancytopenia after DLI
Seven out of 15 patients developed bone marrow aplasia at a median of 12 (range, 2-32) 
weeks after DLI. All but one received DLI for hematological relapse. In five patients 
blood counts normalized spontaneously within 4 weeks and two patients with a prolonged 
marrow aplasia received a booster of T cell-depleted marrow cells. In these seven 
patients, the median percentage of autologous RBCs at time of DLI was relatively high 
and varied from 82% to 94% (median, 89%).
The remaining eight patients did not suffer from aplasia. Six of these patients had a 
discriminating autologous marker and the median percentage of autologous red cells was 
relatively low with a median of 17% (range, 3%-49%). Only one patient with a high 
percentage (100%) of autologous red cells did not develop aplasia after DLI. A high 
percentage of autologous erythrocytes at time of DLI was significantly associated with the 
occurrence of aplasia after DLI (P = 0.04).
Qualitative determination ofBcr/Abl breakpoint molecules
The results of the sequential qualitative determination of Bcr/Abl transcripts combined 
with the RCP results that were analyzed at the same time are depicted in Figure 2. In 11 
patients the presence of autologous RBCs was highly concordant with Bcr/Abl transcript 
positivity (r = .94; P  < .001), despite the difference in sensitivity of both methods (0.01% 
for RCP and 0.001% for the molecular analysis of Bcr/Abl). From two patients (UPN 91 
and 354) no Bcr/Abl data were available after DLI.
Quantitative determination ofBcr/Abl breakpoint molecules by real time PCR
Sequential data obtained by quantitative real-time PCR were available from seven 
patients. In all patients, cytogenetic and/or hematological relapse was preceded by an 
increase in normalized Bcr/Abl dose. After DLI, the normalized Bcr/Abl dose decreased 
in all seven patients. Below a normalized dose of 10- , no patient RBCs could be 
detected, and the patients were always in cytogenetic and hematological remission. The 
overall correlation between RCP and quantitative real-time PCR was not strong. 
However, the curves depicting the chronological increase and decrease in the percentage 
autologous red cells and normalized Bcr/Abl dose showed the same trend. If we consider
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-3a single normalized Bcr/Abl dose of < 10- as a negative value and compare these data 
with RCP, the correlation between RCP and Bcr/Abl dose was 77%.
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Fig 1 (A-H). sequential detection of autologous and donor red blood cells combined with cytogenetic 
data on patient and donor cells measured from SCT onwards to last follow up in four patients. (A and B) 
UPN 337; (C and D) UPN 387; (E and F) UPN 51; (G and H) UPN 162. ( • )  Red blood cell phenotyping; 
(□ )  cytogenetic analysis. The vertical arrows indicate Donor Leukocyte Infusion. In UPN 51 and UPN 
162, major ABO incompatibility delayed red blood cell reconstitution.
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Figure 1 (continued).
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Fig 2. sequential detection of autologous RBCs in 11 patients using RCP from SCT onwards (months) 
combined with data on Bcr/Abl transcripts measured by RT-PCR. (■ ) RCP positive, percentages of 
autologous red blood cells are shown above positive results; (□ )  RCP negative; ( • )  PCR positive; (O) 
PCR negative. The vertical arrows indicate donor leukocyte infusion.
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Discussion
Serial and quantitative analysis of chimerism after SCT showing an increasing number of 
host cells may herald relapse.30-36 We have shown previously that mixed chimerism, as 
found with cytogenetic analysis of bone marrow and RCP at six months after SCT was 
not associated with higher incidence of relapse. However, persisting mixed chimerism at 
twelve months after SCT correlated with an increased probability of relapse.14 Low levels 
of persistent recipient cells are not always associated with an increased risk of leukemic
33 36 39relapse. , - In CML, at the time of relapse, recipient granulocytes, monocytes, and 
erythrocytes appear and progressively replace their counterparts of donor origin. Other 
lineage’s such as B and NK cells remain of donor origin.39-44 In the present study, 15 
patients transplanted for CML were monitored frequently by RCP. An increasing 
percentage of autologous red blood cells and/or an decreasing number of erythrocytes 
from donor origin always heralded relapse. Relapse was confirmed with qualitative PCR 
for breakpoint molecules, cytogenetic analysis and/or hematologically. The advantages of 
RCP are clear: it can be performed on blood samples, the assays are simple, accurate, 
very sensitive; and results can be obtained within 24 hours. The recently developed flow 
cytometric method even increased speed and efficacy of RCP.45
After the first encouraging results reported by Kolb et al 8 and Slavin et al, 46,47 we started 
to administer DLI infusions to all patients relapsing from CML after SCT. Application of 
DLI to treat relapsed CML after SCT has been shown to induce a powerful antileukemic
48effect resulting in remission in 75%-80% of patients. However, responses after DLI are 
worse in more advanced stages of relapsed CML, especially in patients in blast phase. In 
the more advanced stage, the number of leukemic cells is higher and residual donor 
hematopoiesis is lower, leading to fewer remissions and more frequent and longer 
duration of aplasia.9,49-52 In the present study eight patients had a high percentage of 
autologous RBCs at the time of DLI and this predicted aplasia very accurately. All but 
one of the six patients who did not develop aplasia after DLI had a low number of 
recipient erythrocytes at the time of leukocyte infusion. Early detection of relapsing CML 
is mandatory to improve response and to prevent aplasia after DLI. In this study, an
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increase of recipient erythrocytes correlated strongly with a positive PCR for Bcr/Abl and 
the reappearance of the Philadelphia chromosome. However, RCP is an almost two-log 
more sensitive method compared with conventional chromosome studies and in situ 
hybridization. Consequently, RCP can predict a pending relapse of CML earlier and more 
accurately. The sensitivity and specificity of RCP is high. No false-positive or false- 
negative results have been observed using RCP in this study of fifteen patients. In two 
patients, increasing autologous red cells were found at two time points despite negative 
PCR values. We performed real-time PCR on these samples, and all four samples had a
-3normalized Bcr/Abl dose of > 10- .
Despite the success and increased use of DLI to treat relapsed leukemia, the kinetics and 
underlying mechanisms of the graft-versus-leukemia (GVL) response are poorly 
understood. The time between DLI and onset of GVHD and GVL varies widely from
48patient to patient. This makes it necessary to customize DLI therapy in every individual 
patient and therefore, reliable parameters of early response and probable outcome are 
essential. In every responding patient, we observed a decreasing number of recipient 
RBCs that was gradually replaced by donor-type erythrocytes. During this response a 
strong correlation was observed between chimerism in the RBC population and 
chimerism detected by cytogenetic analysis of bone marrow cells. Despite a one-log 
difference in the sensitivity of the two methods, absence of autologous RBCs also 
correlated very well with the absence of minimal residual disease, as measured by 
qualitative PCR of Bcr/Abl transcripts. This may be explained by, on the one hand, the 
longer survival of RBCs and, on the other hand, the higher sensitivity of the PCR method 
to detect minimal residual disease. Our data show that sequential monitoring of 
chimerism in CML patients after SCT and DLI by RCP can, at least partially, replace the 
standard cytogenetic techniques.
A promising technique for quantification of minimal residual disease in CML is a
12recently developed system for real-time quantitative reverse transcriptase (RT)-PCR. In 
this study, we found no strong correlation between RCP and quantitative real-time PCR.
-3After introducing a threshold of 10- normalized Bcr/Abl dose, the correlation increased 
significantly. A threshold was also found in an earlier comparison of real-time PCR and
53cytogenetic data. This can be explained by the difference in methods used and by the
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higher sensitivity of real-time PCR. Using RCP or cytogenetics, the number of autologous 
red cells, usually representing the malignant clone is analyzed, whereas in quantitative 
PCR, the normalized expression of the Bcr/Abl oncogene is determined. A low number of 
cells with high Bcr/Abl expression may theoretically give the same results as a high 
number of cells with low Bcr/Abl expression. The higher sensitivity of quantitative PCR 
creates values below the sensitivity level of RCP.
If RCP is used for assessing chimerism, an individual adapted transfusion policy is 
mandatory.17,19 Only red cells that do not carry the discriminating markers may be given. 
If the patient is no longer dependent on red cell transfusions and the interval between the 
last transfusion and RCP is more than 150 days, RCP is no longer influenced by third- 
party red cells.54 Consequently, RCP can also be used for detection of relapse and 
evaluation of response after DLI in institutes that do not have the policy to transfuse with 
marker negative erythrocytes.
From this study, we conclude that, in patients transplanted for CML, RCP is a sensitive 
method for the detection of the onset of relapse. RCP could also be used to evaluate 
accurately the response of the patient to DLI. Using RCP, we could predict the 
development of aplasia after DLI. A strong correlation was found between RCP, 
cytogenetics and residual disease measured by qualitative PCR of Bcr/Abl breakpoint 
molecules.
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Abstract
Donor leukocyte infusions (DLI) from the original marrow donor have been shown to 
induce remission in patients with relapse after SCT. We analyzed factors that were 
associated with remission. Twenty-six patients with a relapse after T cell-depleted SCT 
received DLI. The following pre-DLI factors were analyzed: sex and age of the patients 
and donors, GVHD after SCT, indication for DLI, percentage of donor T lymphocytes in 
the patient at the time of DLI, interval between relapse and DLI, and number of T 
lymphocytes infused. Remission was achieved in 11 of 15 patients (73%) treated for 
relapsed CML and in one of 11 patients (9%) treated for relapsed AML, ALL or RAEB-t 
(P  =.002). Two of 13 patients (15%) with < 40% of T lymphocytes from donor origin 
attained remission compared with 10 of 13 patients (77%) with > 40% (P  = .002). Two of
13 patients (15%) with an interval of < 18 months between SCT and first DLI entered 
remission compared with 10 of 13 patients (77%) with an interval of > 18 months (P  = 
.002). Multivariate analysis demonstrated that indication for DLI (CML versus AML/ALL 
and RAEB-t) and the percentage T lymphocytes from donor origin (< 40 versus >40) were 
significantly correlated with remission (P  = .03). The occurrence of GVHD post DLI was 
highly associated with achievement of remission (P  = .0001). DLI results in remission in a 
high percentage of patients with relapsed CML after SCT. The percentage of T 
lymphocytes from donor origin still present in the patient at the time of DLI is highly 
correlated with achievement of remission.
108
DLI in relapsed SCT patients
Introduction
Relapse after allogeneic bone marrow transplantation remains a serious problem and
1 2-4
treatment options are limited. Conventional chemotherapy alone is disappointing. In a 
minority of patients with relapsed chronic myeloid leukemia (CML), interferon alpha
induced cytogenetic remission and the 2-year probability of survival was significantly
6
improved in comparison with patients who did not receive any therapy. Retransplantation 
is associated with a high treatment-related morbidity and mortality. Following a second 
transplant for acute or chronic leukemia, two-year probabilities of treatment-related 
mortality, relapse and leukemia-free survival were 41%, 65%, and 21%, respectively.
Retransplantation for CML may be more successful since transplant-related mortality can
8
be reduced by less intensive conditioning regimens, such as high-dose busulphan alone. 
Several authors have reported on the treatment of relapse after stem cell transplantation
9-14
with the infusion of leukocytes from the original stem cell donor. In a previous 
analysis, we reported on 6 patients who were treated with the infusion of donor
15
leukocytes.
In the present study, we extend our observations to 26 patients. We demonstrate that in our 
patients outcome is significantly associated with the percentage of donor T lymphocytes at 
the time of DLI and the indication for DLI.
Patients, materials and methods
Patients and donors
Twenty-six patients relapsed after transplantation with HLA A, B, DRB, DQB-identical,
mixed lymphocyte culture (MLC)-negative sibling marrow that was T cell-depleted using
16
counterflow centrifugation. Patients were given leukocytes from their original stem cell 
donors. The median age of the patients (8 females and 18 males) was 41 (range, 19-60) 
years and of the donors (10 females and 16 males) 43 years (range, 16-64). Fifteen patients 
relapsed from CML (6 had only cytogenetic relapse and one patient relapsed in blastic 
phase), 6 from acute myeloid leukemia (AML), 4 from acute lymphoid leukemia (ALL),
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and one from refractory anemia with an excess of blasts in transformation (RAEB-t). All 
patients who relapsed from AML/ALL or RAEB-t had a hematological relapse. Donor 
leukocyte infusions were given between March 1991 and January 1997.
Leukapheresis
Informed consent was obtained from both patient and donor. Leukapheresis was performed 
as described before. In summary: the blood cell separator Baxter CS 3000 (Baxter, 
Deerfield, IL, USA) or the Fresenius AS 104 (Fresenius, Oberursel, Germany) were used. 
Leukaphereses were without complications and performed within three hours. Since one
patient died from acute GVHD, the number of CD3 positive cells given within one
8
leukapheresis procedure was limited to 0.7 x 10 /kg body weight of the recipient. If this 
number of CD3 positive cells was not reached within one procedure, leukapheresis was 
repeated within 2 to 5 days. Patients who did not respond within 3 months after infusion 
were given a second (n = 8) or a third course of DLI (n = 1). The interval between the first 
and last infusion of donor leukocytes in these nine patients varied from 65 to 276 (median, 
115) days. Leukocytes were infused into the recipient in an outpatient setting. Infusions 
were without complications.
Diagnosis of relapse
In patients transplanted for leukemia or RAEB-t, diagnosis of a hematological relapse was 
made on the recurrence of clinical signs and laboratory findings of leukemia or MDS, 
respectively. If a patient had only reappearance of chromosomal abnormalities, he had a 
cytogenetic relapse. CML patients were in chronic phase if  they had the characteristics of 
chronic phase disease. Patient was defined in accelerated phase if the criteria for blast 
phase were not fulfilled and blasts in blood or marrow were > 10% or blasts plus 
promyelocytes were > 20% or eosinophils plus basophils were > 20% or he had increasing 
splenomegaly and did not respond on conventional chemotherapy. Blast phase was an 
increase of blasts plus promyelocytes in blood or bone marrow to 30% or more.
Routinely, in all patients cytogenetic analysis of bone marrow samples was performed at
0.5 and one year after transplantation, and annually thereafter. If there were any signs or 
symptoms of hematological relapse, cytogenetic analysis was performed earlier.
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Analysis ofthe origin ofT-lymphocytes in the patient at the time of infusion
In two patients the origin of blood lymphocytes was determined by standard cytogenetic
17
techniques as described previously. In the other 24 patients T cells were sorted by an 
Epics Elite flow cytometer (Coulter, Hialeah, FL, USA) after incubation of mononuclear 
cells with fluoresceine isothiocyanate (FITC)-conjugated CD3 monoclonal antibodies 
(UCHT 1, Dakopatts, Glostrup, Denmark). CD4 positive and CD8 positive T cells were 
isolated by positive selection using immunomagnetic beads (Dynabeads and Detachabead,
Dynal, Oslo, Norway). An aliquot of sorted cells was reanalyzed and purity always
18
exceeded 95%. Cell lysates were prepared as described previously. Aliquots of cell 
lysates were used for the polymerase chain reaction of DNA segments with variable 
numbers of tandem repeats (PCR-VNTR) to distinguish between recipient and donor cells. 
Specific primer sets and locus specific oligonucleotide probes for VNTR regions (33.1,
19
33.6, H-ras and YNZ-22) were generated and used as previously described. The relative
amount of donor and recipient DNA was calculated using samples with mixtures of both
18
donor and recipient DNA as described before.
Detection ofBcr/Abl breakpoint molecules
The procedure to detect Bcr/Abl molecules has been described before. In summary, RNA
6
was isolated from 10 bone marrow cells in a modification of the method of Chomczynski
20
and Sacchi. Primers for the synthesis of cDNA (A21) and for the two series of PCR were 
derived from the Sequence, EMBL/Genebank accession no. M30828 (Heidelberg, 
Germany). In the first 30-cycle series primers B11 and A21 were used, in the second 35- 
cycle PCR we used primers B12 and A22. The quality of each RNA sample was assessed 
in a reverse transcriptase reaction followed by PCR on B2-microglobulin RNA. Strict 
precautions were taken to avoid contaminations. In each PCR, both positive and negative 
controls were used. PCR products were analyzed by hybridization after Southern blotting
32
with a P labeled c-Abl probe recognizing the 5' part of exon 2 of the c-Abl gene. With
5
this PCR, we were able to detect one Bcr/Abl positive cell among 10 normal cells.
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Definitions
In patients treated for relapsed leukemia or RAEB-t, hematological remission was defined 
as the disappearance of all signs and symptoms and normalization of blood counts and 
bone marrow cellularity. The percentage of blast cells in the bone marrow had to be less 
than 5%. Cytogenetic remission was defined as a hematological remission associated with 
disappearance of cytogenetic markers of the disease. If the patient was treated for 
Philadelphia-chromosome positive leukemia and PCR for Bcr/Abl converted to negative, 
the patient entered molecular remission.
In patients who relapse after SCT, the simultaneous presence of T lymphocytes from 
patient and donor origin is not defined as mixed chimerism since the definition of mixed 
chimerism has to be restricted for patients with cells from patient and donor origin who 
remain in continuous remission.
The clinical manifestations of acute GVHD were graded 1 through 4 according to the
21
criteria described by Glucksberg et al. Chronic GVHD was classified as limited or
22
extensive as described by Shulman et al. If GVHD occurred < 3 months after the infusion 
of lymphocytes it was defined as acute. If the patients had GVHD beyond 3 months, 
GVHD was defined as chronic.
A patient became cytopenic after the infusion of donor leukocytes if leukocytes diminished 
to < 1.0 x 10 /L and/or thrombocytes lowered to < 15 x 109/L, and/or hemoglobulin level 
decreased to < 6.0 mMol/L.
Follow-up was until death or until May 1, 1997. This means that in surviving patients 
follow-up was at least 4 months.
Statistical analysis
Data were analyzed using the Statistica™  Release 4.1 program (Apple Computer, Inc., 
Cupertino, CA, USA). Fisher’s exact test was used for pre DLI factors influencing 
remission after DLI. A stepwise logistic regression analysis was used with remission as 
dependent variable. Independent variables were indication for DLI, percentage of donor T 
lymphocytes present in the patient at the time of DLI (< 40 versus > 40), and the interval 
between SCT and first DLI ( < 1 8  months versus >18 months). P  values <.05 were 
considered statistically significant.
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Results
Disease response
Twelve of 26 patients (46%) attained remission. Characteristics of the responding patients 
are given in Table 1. Eleven of the 12 patients (92%) who entered remission were treated 
for relapsed CML and one (8%) was given DLI for relapsed AML. Fourteen of 26 patients 
(54%) did not attain remission. Characteristics of these patients are given in Table 2. 
Among them were 4 patients treated for relapsed CML (29%) and 10 (71%) treated for 
relapsed AML / ALL or RAEB-t.
Patients treated for relapsed CML
Eleven of 15 patients (73%) treated for relapsed CML attained remission and all 11 were 
confirmed to be in molecular remission. Conversion to negativity for Bcr/Abl breakpoint 
molecules occurred 1 to 18 months (median, 6) after the first DLI. In all but one case 
(UPN 136, Table 1) achievement of remission was associated with acute and/or chronic 
GVHD. Interval between SCT and first DLI varied from 13 to 90 (median, 41) months. 
The median percentage of T lymphocytes from donor origin in the patients at the time of 
infusion was > 90 (range, < 10 to > 90). Eight patients were given one course of 1 to 4
(median, 2) DLI and 3 patients received two courses to a total number of 4 to 6 (median,
8
6) infusions. The total number of lymphocytes infused varied from 0.1-3.0 x 1 0 /kg
8
(median, 1.1 x 10 /kg). UPN 26 was given one course of three infusions to a total number 
of 3.0 x 10 lymphocytes/kg and died from acute GVHD grade 4 two months after DLI. 
Ten CML patients remain in continuous molecular remission at 13 to 73 (median, 47) 
months after the first DLI.
Four of 15 CML patients (27%) did not show any response. Interval between SCT and first 
DLI varied from 7 to 123 (median, 58) months. The median percentage of T lymphocytes 
from donor origin in the patients at the time of infusion was < 15 (range, < 10-50). UPN 
391 (Table 2) was given only one DLI, two patients received two courses to a total number
of 3 and 5 infusions, respectively, and UPN 166 was given 3 courses to a total number of
8
11 DLI. The total number of lymphocytes infused varied from 1.0 to 3.8 x 10 /kg (median,
8
2.2 x 10 /kg). In these patients DLI was not associated with GVHD. UPN 18 and UPN 391
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died from relapse 10 and one months after DLI, respectively. UPN 166 was successfully 
retransplanted with an unmanipulated graft after conditioning with busulphan alone. He 
remains in molecular remission 49 months after retransplantation. UPN 36 died from 
second relapse 5 months after retransplantation.
Patients treated for relapsed AML, ALL or RAEB-t
Only one of 11 (9%) patients treated for relapsed AML, ALL or RAEB-t entered 
remission. This patient (UPN 159, Table 1) suffered from hematological relapse of AML 
15 months after SCT. DLI was given within one month of relapse. At that time 70% of T
lymphocytes were from donor origin. He received one course of three infusions to a total
8
number of 1.9 x 10 lymphocytes/kg. Six weeks later, patient developed acute GVHD 
grade 2 that proceeded to extensive chronic GVHD. He attained a hematological remission 
6 months after DLI. Forty-five months after DLI this patient suffered from extramedullar 
relapse in his right testis. After hemi-orchiectomy and local radiotherapy (26 Gy) but 
without additional systemic treatment, the patient remains in complete remission 21 
months after surgery.
Ten patients (5 with AML, one with RAEB-t, and 4 with ALL) did not enter remission 
after DLI (Table 2). Interval between SCT and DLI varied from 4 to 28 (median, 8) 
months. At the time of DLI the median percentage of T lymphocytes from donor origin 
present in the patients was 15 (range 0 to > 90). Seven patients were given one course of 1
to 3 (median, 2) infusions and three patients received 2 courses of 5 to 6 (median, 5)
8
infusions. The total number of lymphocytes infused varied from 0.3 to 4.0 x 10 /kg
8
(median, 1.2 x 10 /kg). The two patients with > 90% donor lymphocytes (UPN 247 and 
UPN 381) died at 2 and one months after DLI, respectively. Probably, in these patients 
follow-up was to short for attaining remission. None of the ten patients showed any sign of 
GVHD after DLI. All died from relapse 1 to 7 (median, 4) months after the first DLI.
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Table 1 Characteristics of the 12 patients who attained remission after DLI
UPN* Diagnosis 
at DLI
GVHD 
after SCT 
acute / 
chronic
Interval 
SCT- 
first DLI 
(months)
T-cells of 
donor origin
(%)
Number of 
lymphocytes 
infused 
(x 108/kg)
GVHD 
after DLI 
acute / 
chronic
status/follow- 
up 
after DLI 
(months)
26 CML-cyt 0/0 90 > 90 3.0 4/NA died#/2
125 CML-AP 0/0 25 > 90 1.1 2/lim alive/69
184 CML-cyt 1/lim 26 > 90 1.1 2/ext alive/47
162 CML-cyt 0/lim 34 > 90 2.8 0/lim alive/46
182 CML-CP 0/0 41 > 90 1.7 0/lim alive/33
75 CML-cyt 0/0 87 > 90 0.9 3/ext alive/31
136 CML-cyt 0/0 76 > 90 0.1 0/0 alive/14
337 CML-CP 0/0 13 > 90 0.4 2/ext alive/13
51 CML-CP 0/0 63 50 2.7 1/ext alive/68
64 CML-CP 0/0 51 10 0.3 2/ext alive/73
132 CML-CP 1/lim 19 < 10 0.3 3/ext alive/72
159 AML-REL 0/0 16 70 1.9 2/ext alive/66
DLI, donor lymphocyte infusion; * Unique Patient Number; cyt, cytogenetic relapse only; AP, accelerated 
phase; CP, chronic phase; REL, relapse; NA, not applicable; # from GVHD.
Note: patients have been arranged according to diagnosis and declining percentage of T-cells from donor 
origin.
Pre-DLI factors predicting remission following DLI
Pre-DLI factors predicting remission are given in Table 3. In univariate analysis, indication 
for DLI (CML versus AML/ALL/RAEB-t), the percentage of T lymphocytes from donor 
origin at the time of DLI (< 40 versus > 40), and the interval between SCT and first DLI (< 
18 months versus >18 months) were significantly associated with the achievement of 
remission.
Eleven of 15 patients (73%) treated for relapsed CML entered remission. In contrast, only 
one of 11 patients (9%) treated fro relapsed AML, ALL or RAEB-t attained remission ( P = 
.002). Two of 13 patients (15%) with < 40% of T lymphocytes from donor origin at the
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time of DLI achieved remission compared with ten of 13 patients (77%) with > 40% of T 
lymphocytes from donor origin (P  = .002). Achievement of remission was significantly 
associated with the interval between SCT and first DLI. Two of 13 patients (15%) with an 
interval of < 18 months entered remission compared with ten of 13 (77%) with an interval 
of >18 months (P =.002)
In a stepwise logistic regression analysis, indication for SCT (CML versus 
AML/ALL/RAEB-t, P  = .03) and the percentage of T lymphocytes from donor origin at 
the time of DLI (< 40 versus > 40), (P  = .03) were independent variables for entering 
remission after DLI.
Table 2 Characteristics of the 14 patients who did not attain remission after DLI
UPN* Diagnosis GVHD Interval T-cells of Number of GVHD status/follow-
at DLI after SCT SCT-first DLI donor lymphocytes after DLI up
acute / (months) origin (%) infused acute / after DLI
chronic (x 108/kg) chronic (months)
18 CML-CP 0/lim 123 50 1.0 0/0 died/10
391 CML-BP 1/lim 7 20 1.6 0/NA died/1
166 CML-cyt 0/0 15 < 10 3.8 0/0 alive#/66
36 CML-CP 1 /0 100 < 10 2.8 0/0 died$/22
247 AML-REL 1/lim 28 > 90 0.4 0/NA died/2
393 AML-REL 1/lim 7 30 0.5 0/0 died/4
192 AML-REL 1 /0 8 20 3.4 0/0 died/6
259 AML-REL 0/0 7 10 1.2 0/NA died/3
188 AML-REL 0/0 8 < 10 0.3 0/0 died/4
233 ALL-REL 1 /0 8 20 4.0 0/NA died/3
212 ALL-REL 0/0 4 10 2.0 0/NA died/3
152 ALL-REL 1/lim 16 < 10 1.2 0/0 died/4
171 ALL-REL 0/0 8 0 3.2 0/0 died/7
381 RAEB-t-REL 1 /0 4 > 90 0.7 0/NA died/1
DLI, donor lymphocyte infusion; * Unique Patient Number; NA, not applicable; cyt, cytogenetic relapse
only; CP, chronic phase; BC, blastic phase; REL, relapse; # 49 months after retransplantation; $ 5 months 
after retransplantation. Note: patients have been arranged according to diagnosis and declining 
percentage of T-cells from donor origin.
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Complications after DLI
Nine of 26 patients (35%) developed acute GVHD (one grade 1, 5 grade 2, two grade 3, 
and one grade 4). Ten of 19 assessable patients (53%) suffered from chronic GVHD (3 
limited and 7 extensive). Acute GVHD occurred at 28 to 49 (median, 42) days after the 
last DLI. One patient died from acute GVHD, in the other patients acute GVHD proceeded 
to chronic GVHD.
Pancytopenia related to DLI developed in 3 of 26 patients (12%) 14 to 56 (median, 28) 
days and was only observed in patients who attained remission (UPN 337, UPN 64, and 
UPN 159). Pancytopenia resolved without treatment after 103 to 1260 (median, 162) days.
Comparison ofGVHD after SCT with that after DLI
Eight of 14 patients (57%) who did not suffer from GVHD after SCT, developed GVHD 
after DLI. In contrast, 3 of 12 patients (25%) with GVHD after SCT had GVHD after DLI 
( P =.10). GVHD after SCT was not a predicting factor of GVHD after DLI.
Relation between GVHD and achievement ofremission
Remission was attained by all nine patients who suffered from acute GVHD after DLI and 
by 3 of 17 patients (18%) without acute GVHD after DLI. Entering remission was 
significantly associated with the occurrence of acute GVHD after DLI (P  =.0001). 
Remission occurred in all 10 patients with chronic GVHD and in one of 9 patients (11%) 
without chronic GVHD. This means that achievement of remission was significantly 
associated with chronic GVHD after DLI ( P =.0001).
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Table 3 Pre-DLI predicting factors of remission following DLI
Patients P
Factor No. evaluable Remission Fisher's exact Stepwise Logistic
No. (%) test Regression
Sex of the patient 
Female 
Male
8
18
3 (38) 
9 (50)
.44 NI
Age of the patient at DLI
< 41 yrs 13 6 (46) .35 NI
> 41 yrs 13 6 (46)
Sex of the donor
Female 10 3 (30) .18 NI
Male 16 9 (56)
Age of the donor at DLI
< 43 yrs 14 9 (64) .05 NI
> 43 yrs 12 3 (25)
GVHD after SCT
No 14 9 (64) .05 NI
Yes 12 3 (25)
Indication for DLI
CML 15 11 (73) .002 .03
AML/ALL/RAEB-t 11 1 (9)
% of T lymphocytes from
donor origin at DLI
< 40 13 2 (15) .002 .03
> 40 13 10 (77)
Interval between SCT and
first DLI
< 18 months 13 2 (15) .002 .60
> 18 months 13 10 (77)
No. of T lymphocytes
infused
< 1.2 x 108/kg 14 7 (50) .49 NI
> 1.2 x 108/kg 12 5 (42)
DLI, donor leukocyte infusion; NI, variable not included in the multivariate analysis.
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Discussion
The first patient successfully treated with the infusion of lymphocytes from the original
9
stem cell donor for relapsed leukemia after SCT was described by Slavin et al. More than
8 years after DLI this patient was still in complete remission of his relapsed pre-B ALL.
12
Kolb et al reported on the effect of DLI in 135 patients. Cytogenetic remission was 
achieved in 54 of 75 evaluable CML patients (72%) and these remissions were molecular 
in 42 of 44 patients. In contrast, only 6 of 33 (18%) patients treated for AML, ALL or 
myelodysplastic syndrome (MDS) entered complete remission. In CML patients response 
was closely associated with either GVHD or myelosuppression or both. However, 13 of 29 
CML patients (45%) had a response without clinical evidence of GVHD or 
myelosuppression. Collins et al observed complete cytogenetic remission in 33 of 55
13
(60%) CML patients and remissions were molecular in all 23 patients analyzed. 
Complete response was observed in 10 of 55 patients (18%) treated for relapsed AML, 
ALL or MDS. Acute GVHD occurred in 75 of 125 patients (60%) and was graded 3 or 4 
in 28 cases. The correlation of acute and chronic GVHD with complete remission was 
statistically significant. Three of 23 patients (13%) who did not suffer from either acute or
12 13
chronic GVHD entered complete remission. Analogous to Kolb et al and Collins et al 
we found a high response rate in patients treated for CML (73%) and a low number of 
responders in patients treated for AML, ALL or MDS (9%). We observed remission 
without clinical evidence of GVHD or myelosuppression in one of 12 patients (8%).
Only three of 12 patients (25%) who had GVHD after T cell-depleted SCT developed 
GVHD after DLI (UPN 184, UPN 162, and UPN 132, Table 1). This is remarkable, since 
the number of T lymphocytes given within the DLI was more than 100 times higher than 
the number of T cells left in the depleted bone marrow graft. This means that mechanisms
23 24
other than minor histocompatibility antigens or leukemia-associated antigens play an 
important role in the development of GVHD after DLI. In contrast to patients undergoing 
allogeneic SCT, patients treated with DLI are not conditioned and have immunocompetent 
cells at the time of infusion. If these immunocompetent cells are from patient origin, these 
cells will exert an allo-reactivity against freshly infused donor leukocytes and in most 
cases the infused cells will be rejected. This means that the infused cells cannot cause
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GVHD and/or graft-versus-tumor reactivity and these patients cannot enter remission. If a 
percentage of T lymphocytes in the patient is from donor origin no allo-reactivity of the 
recipient is exerted against infused donor leukocytes. The donor leukocytes are not 
rejected and these cells may cause GVHD and/or graft-versus-tumor reaction leading to 
remission. Using multivariate analysis we demonstrate in the present analysis that the 
presence of more than 40% of T lymphocytes from donor origin was significantly 
associated with achievement of remission.
However, two patients with relapsed CML and with 10% and < 10% donor T lymphocytes 
at the time of DLI, respectively, also attained complete molecular remission. In these 
patients acute GVHD grade 2 and 3 developed and both patients suffered from extensive 
chronic GVHD. One patient was pretreated with interferon, the other with busulphan and 
we cannot exclude that this pretreatment changed the immunological balance to an 
advantage of the donor T lymphocytes.
The second independent variable in multivariate analysis that was significantly associated 
with outcome of DLI was the indication for DLI. It remains unclear why CML responds 
better to DLI than AML/ALL or RAEB-t. An explanation may be that CML cells produce
25 26
pro-inflammatory cytokines such as tumor necrosis factor-a and interleukin 1p that act 
as cofactors for T cell activation and thus for the development of GVHD and the 
associated graft-versus-leukemia activity. It is less likely that the Bcr/Abl fusion protein 
acts as a leukemia-specific antigen since only proliferative T cell responses but not
24
cytotoxic responses against a peptide of this protein have been described.
In summary, in multivariate analysis, indication for DLI and the percentage of donor T 
lymphocytes at the time of DLI are significantly associated with the achievement of 
remission after DLI. Best results are obtained in patients treated for relapsed CML who 
have > 40% of T lymphocytes from donor origin. In patients with relapsed AML/ALL or 
RAEB-t and with < 40% of T lymphocytes from donor origin, DLI seems not indicated. 
We are investigating now if more remissions can be achieved in these patients by 
elimination of autologous T lymphocytes with a DLI preparative immunosuppressive 
regimen consisting of total lymphoid irradiation or anti-thymocyte globulin.
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Abstract
In this prospective study we analyzed pre-emptive donor leukocyte infusions (DLI) in 82 
consecutive patients transplanted with partially T cell-depleted stem cell grafts for acute 
myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, myelodysplastic 
syndrome and multiple myeloma. Donors were HLA-identical siblings. Patients without 
significant acute (>grade 1) and/or chronic GVHD were scheduled to be treated with DLI 
(35 patients) and 31 actually received DLI. Patients who developed acute GVHD > grade 
1 and/or chronic GVHD were not scheduled to receive DLI and served as a comparison 
group (47 patients). The median interval between SCT and DLI was 22 weeks. The first
o
six patients received 0.7 x 10 CD3+ cells/kg body weight (b.w.). Five out of these 6 
patients developed acute GVHD (grade 1: n = 2, grade 3: n = 2 and grade 4: n = 1) which 
was more frequent and more severe than we had anticipated. In the next 25 patients the 
number of T lymphocytes was diminished to 0.1 x 10 CD3+ cells/kg b.w. which resulted 
in less frequent and less severe GVHD. Eight patients in this group developed acute 
GVHD (grade 1: n = 4, grade 2: n = 4) and 3 patients had limited chronic GVHD. Patients 
in the DLI group needed more time to establish complete donor chimerism confirmed by a 
higher number of mixed chimeras at 6 months after SCT. The projected 3-year probability 
of disease-free survival was 77% for the 35 patients intended to treat with DLI and 45% 
for the patients of the comparison group (P  = 0.024). Relapse rate at 36 months after 
transplantation was 18% in the patients who were intended to treat with DLI and 44% in 
the comparison group (P  = 0.026). We conclude that pre-emptive DLI is feasible and 
generates favorable relapse rates in patients who are at high risk for relapse. Furthermore, 
the incidence and severity of GVHD disease after DLI is dependent on the number of 
CD3+ cells infused.
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Introduction
Allogeneic stem cell transplantation (SCT) has become the treatment of choice for acute
12 3 9and chronic leukemias. , , - Outcome and success of SCT has been limited by post­
transplant complications such as graft failure, graft-versus-host disease (GVHD), and 
relapse of the original disease. Moderate to severe GVHD occurs in about 30% to 70% of 
HLA matched recipients and contributes to death in 20% to 70% of those affected 4,10 The 
incidence and severity of acute GVHD can be reduced by removal of immunocompetent 
T-lymphocytes from the graft using different techniques.11 T cell depletion, however, is 
associated with increased incidence of graft rejection and leukemic recurrence.3,12-14 
Relapse rates are dependent on the number of residual tumor cells after conditioning for 
SCT and the number of immunocompetent donor lymphocytes after transplantation that 
may exert graft versus leukemia (GVL) reactivity. The association between GVHD and 
GVL reactivity has been documented in several clinical trials.15,16 We showed that 
intensification of the conditioning regimen in patients transplanted for acute and chronic 
leukemia's with grafts partially depleted of lymphocytes decreased significantly relapse
17rate and increased significantly leukemia-free survival (LFS). Relapse rates varied from 
20 to 32%, which was still considered high.
Both animal and man experimental data support the hypothesis that GVL reactivity can be 
generated by post-transplant infusion of donor leukocytes while GVHD is controlled. The 
risk of acute GVHD after DLI depends on the number of lymphocytes infused and the
18 27time interval between SCT and DLI. - Additional add-back of donor lymphocytes
28shortly after transplantation resulted in severe GVHD. Delayed donor leukocyte
5 7infusions (DLI) with T cell doses of 105-107/kg resulted in less severe GVHD varying in
29incidence from 42-53% in these patients.
In the present study, we analyzed the influence of pre-emptive DLI on relapse rate, 
survival disease-free survival and chimerism in patients who were at high risk for relapse 
and who did not suffer from significant acute nor chronic GVHD after partially T cell- 
depleted SCT. We compared results with those obtained in patients who were transplanted 
in the same period but who were excluded from pre-emptive DLI because they had 
significant GVHD.
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Patients and methods
Patient Characteristics
A total of 82 consecutive patients who underwent allogeneic stem cell transplantation 
(SCT) at the University Medical Center St. Radboud Nijmegen between May 1995 and 
June 1999 were included in this prospective non-randomized study. Patients were 
transplanted for acute myeloid leukemia (AML) (n = 28), acute lymphoid leukemia (ALL) 
(n = 10), chronic myeloid leukemia (CML) (n = 27), refractory anemia with excess of 
blasts (RAEB) (n = 3), refractory anemia with excess of blasts in transformation (RAEB-t) 
(n = 4) and multiple myeloma (MM) (n = 10). Patients who died from treatment-related 
causes within 3 months after SCT were excluded from the study. Donors were HLA A, B, 
DRB and DQB identical siblings. Patients were eligible for pre-emptive DLI if they 
fulfilled all three of the following criteria: (1) they had not suffered from acute GVHD 
greater than grade one; (2) they had no persisting chronic GVHD; (3) all additional 
immunosuppression given for prophylaxis of GVHD had been withdrawn for a minimum 
of two months without developing any symptoms of GVHD. Patients who had GVHD 
greater than grade 1 and/or chronic GVHD were not eligible for DLI and served as a 
comparison group. Informed consent was obtained from each patient (or their guardians) 
and all treatment was administered under protocols approved by the local ethical 
committee of the University Medical Center St Radboud Nijmegen. Clinical 
characteristics of the 82 patients included in this study are listed in table 1. Thirty-five 
patients did not develop significant GVHD after SCT and were eligible for DLI. Sixteen 
out of these 35 patients (46%) had bad risk prognostic factors: Six patients were 
transplanted for MM in partial remission (PR), two patients had accelerated CML, four 
patients had RAEB(-t) from which two still had cytogenetic abnormalities (deletion of 
chromosome 7) at the time of SCT. One patient had ALL in second complete remission 
(CR) and one patient had AML in second complete remission with cytogenetic 
abnormalities at SCT (5q-). One patient was transplanted for AML in partial remission 
and another patient needed two remission induction courses to enter first CR and had 
residual cytogenetic abnormalities (11q-) at time of SCT.
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Two patients transplanted for AML relapsed before they were eligible for DLI and 2 
patients with MM showed rapid progressive disease before DLI was given. These patients 
were included in the DLI-group on the basis of intention-to-treat. Thirty-one patients 
actually received DLI.
Forty-seven patients developed acute GVHD > grade 1 and/or chronic GVHD and were 
included in the non-DLI group. In this non-DLI group 13 patients (28%) had additional 
bad risk prognostic factors: Four patients were transplanted for MM in partial remission, 
three patients had AML in second CR, three patients had RAEB(t), two patients had 
accelerated CML and one patient received SCT for ALL in second CR. In the non-DLI 
group there were no patients who had residual cytogenetic abnormalities detected at time 
of transplantation.
Although not significant, the non-DLI group contained a relatively higher number of 
patients transplanted for ALL in first CR (Table 1). None of the ALL patients was 
Philadelphia chromosome positive at time of diagnosis. The numbers of patients with bad 
risk prognostic factors were not significantly different between the two groups.
Conditioning regimen, GVHD prophylaxis and supportive care
2
Seventy-nine out of 82 patients were conditioned with idarubicine 42 mg/m by 
continuous intravenously (i.v.) infusion on day -12 and -11 followed by 
cyclophosphamide 60 mg/kg b.w. i.v. on each of two consecutive days (days -6 and -5). 
Fractionated total body irradiation (TBI) was given on days -2 and -1 to a total dose of 9 
Gy. In three patients TBI was substituted by busulphan 4 mg/kg b.w. on each of 4 
consecutive days (day -8 to day -5). Donor marrow was depleted of lymphocytes by 
density gradient centrifugation followed by counterflow centrifugation as previously
30 31described. , The median number of T cells in the marrow grafts was 0.7 (range, 0.6-1.5) 
x 106 CD3+ cells/kg b.w. All patients received prophylactic antibiotics according to 
institutional guidelines. Immunoprophylaxis after transplant consisted of cyclosporine A 
(CsA) 3 mg/kg/d by continuous i.v. infusion from days -1 to +14, followed by 2 mg/kg/d
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Table 1 Patient, disease and graft-versus-host characteristics
DLI-group (N=35) No DLI-group (N=47) P value
Age at SCT (yrs)
Median 43 45 .27
Range 18-61 12-59
Sex
Male 19 20 .37
Female 16 27
Diagnosis
AML-CR1 12 11 .32
AML-CR2 1 3 .63
AML-PR 1 0 .43
ALL-CR1 1 7 .13
ALL-CR2 1 1 1.00
CML-CP1 7 16 .22
CML-acceleration 2 2 1.00
MM-PR 6 4 .31
RAEB 2 1 .57
RAEB-t 2 2 1.00
Acute GVHD after SCT
Grade 0 25 2 < .001
Grade 1 10 19 .35
Grade 2 0 21 < .001
Grade 3 0 3 .26
Grade 4 0 2 .51
Chronic GVHD after SCT
Non 35 11 < .001
Limited 0 28 < .001
Extensive 0 8 .01
Bad risk prognosis 16 13 .11
Abbreviations: DLI, donor leukocyte infusion; yrs, years; AML, acute myeloid leukemia; ALL, acute 
lymphoid leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma; RAEB(-t), refractory anemia 
with excess of blasts (in transformation); CR1, first complete remission; CR2, second complete remission; 
PR, partial remission; CP1, first chronic phase; GVHD, graft-versus host-disease.
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as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally at 
a dose of 6 mg/kg/d until 8 to10 weeks after SCT. In the absence of GVHD CSA was 
gradually tapered and discontinued at 12 weeks post-grafting. All patients were managed 
in single rooms with filtered air under positive pressure during their hospital stay.
Assessment ofGVHD, relapse and chimerism
Acute GVHD was classified from grade 0-4 according to the criteria described by
32 33Glucksberg et al. Chronic GVHD was graded as none, limited or extensive. Acute 
GVHD after pre-emptive DLI was defined as GVHD occurring within 100 days from 
infusion. Chronic GVHD after DLI was defined as GVHD present after day 100 from 
infusion. Relapse was defined as hematologic and/or cytogenetic relapse. Durable 
engraftment and chimerism was investigated by cytogenetic analysis of blood and bone 
marrow and/or by red blood cell phenotyping. Chromosome studies on peripheral blood 
cells and bone marrow cells were performed routinely before SCT, 6 and 12 months after 
SCT and annually thereafter as described previously.34,35 The median number of bone 
marrow metaphases analyzed was 30 (range, 12-35), and the median number of 
metaphases of lymphocytes was 32 (range, 7-32), allowing a sensitivity level of 10-12%.36 
When the recipient and donor were of different sex, heterosome determination of 400 
interphases (fluorescent in situ hybridization; FISH) allowed additional differentiation 
between donor and host cells, resulting in a sensitivity of 1% for the demonstration of a 
minor cell population. After DLI, these chromosome studies were performed on bone 
marrow at 3, 6 and 12 months and annually thereafter. Red blood cell phenotyping was 
performed using a flow cytometric and/or fluorescent microscopic microsphere method as
37 39described previously. - The sensitivity level is 0.1-0.3% for the flow cytometric method 
and 0.01% for the fluorescent microscopic technique. At the level of 0% patient or donor 
red cells, the flow cytometric results were always controlled by the fluorescent 
microscopic method in order to increase the sensitivity of this test to a level of 0.01% in 
this analysis. The time schedule for analysis was 1, 2, 3, 6 and 12 months after SCT and 
annually thereafter. The same intervals were used after DLI.
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DLI
Donor leukocytes were obtained from the original bone marrow donor by leukapheresis 
using the blood cell separator Baxter CS 3000 (Baxter, Deerfield, IL, USA) or the 
Fresenius AS 104 (Oberursel, Germany) as previously described .40 Nucleated cells were 
administered without further processing within 3 hours after completion of the procedure 
at the outpatient clinic. The infused nucleated cells consisted mainly of mononuclear cells 
in all patients. The first six patients treated with DLI received median 0.7 (range, 0.52­
0.72) x 10 /kg b.w. CD3+ lymphocytes as determined by flow cytometric analysis. In the 
next 25 patients the number of CD3+ was decreased and fixed to 0.1 x 10 /kg b.w. 
Immunophenotypic data of the infused cells were available in 26 patients. The median 
number of CD3+, CD4+, CD8 +, CD3-/CD56+, CD19+ and CD14+ cells infused were 0.1 
(range, 0.07-0.56), 0.06 (range, 0.04-0.3), 0.04 (range, 0.01-0.21), 0.02 (range, 0-0.05),
0.02 (range, 0.01-0.1) and 0.03 (range, 0-0.07) x 106/kg body weight, respectively. The 
interval between SCT and pre-emptive DLI was a median of 22 weeks (range, 12-40). No 
GVHD prophylaxis was administered to any of the patients after the infusion of the donor 
lymphocytes.
Statistics
Patient, disease and graft versus host characteristics were compared between groups with 
the Wilcoxon signed rank test and Fisher's exact test using the Statistica 4.5 release 
program for MS Windows (Statsoft). The Kaplan-Meier product limit method41 was used 
to estimate the rate of relapse, disease-free survival (DFS), and overall survival. The two­
tailed log-rank test was used to compare the clinical end points between the two groups. 
Endpoints were calculated at the date of last follow up being August 1, 2000. The duration 
of follow-up since SCT in the DLI group and control group was a median of 30 (range, 
14-66) and 26 (range, 13-62) months, respectively (P  = 0.63).
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Results
Graft versus Host disease after SCT
Thirty-five patients had grade 0 or grade 1 acute GVHD without any signs of chronic 
GVHD (Table 1). They were included in the DLI group on the basis of intention-to-treat. 
The 10 patients who developed grade 1 acute GVHD were not treated with additional 
systemic steroids. The interval between date of SCT and date of withdrawing 
cyclosporine-A (CsA) was a median of 3.5 (range, 2-7) months in these 35 patients. 
Twenty-one patients developed grade 2 acute GVHD and consequently were included in 
the non-DLI group (Table 1). Eleven out of these 21 patients showed progression to 
chronic GVHD (limited: n = 9, extensive: n = 2). Three patients had grade 3 acute GVHD 
after SCT and two of them developed chronic GVHD (extensive: n = 2). Two patients had 
grade 4 acute GVHD and both progressed to extensive chronic GVHD. Twenty-one 
patients were included in the non-DLI group because they developed chronic GVHD 
(limited: n = 19, extensive: n = 2) without pre-existent significant (>grade 1) acute 
GVHD. Thirty-seven out of 47 patients in the non-DLI group (79%) received additional 
systemic steroids as GVHD treatment. The median interval between SCT date and 
cessation of all immunosuppressive drugs in the non-DLI group was 4 months (range, 2­
2 2 ).
Graft versus Host Disease after DLI
o
The first 6  patients treated with pre-emptive DLI received a T cell dose of 0.7 x 10 CD3+ 
cells/kg b.w. Five out of these six patients developed acute GVHD. Two patients had 
grade 1, two patients had grade 3 and 1 patient had grade 4 acute GVHD, respectively. 
The patient with grade 4 acute GVHD died from complications of GVHD. One of the two 
patients with grade 3 acute GVHD developed limited and the other patient extensive 
chronic GVHD. In the next 25 patients, the T cell dose was reduced to 0.1 x 108 CD3+ 
cells/kg b.w. Eight out of these 25 patients developed acute GVHD (grade 1: n = 4, grade 
2: n = 4) and 3 out of these 8  patients developed chronic (limited) GVHD. Seventeen 
patients treated with 0.1 x 108 CD3+ cells/kg b.w. did not develop any GVHD at all. The 
reduction of the number of CD3+ cells infused resulted in less frequent (P  = 0.059, Fisher
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exact) and less severe acute GVHD and consequently hardly any chronic GVHD. The 
interval between DLI and onset of acute GVHD in the 13 patients was a median of 7 
weeks (range, 2-9). Twelve out of 13 patients with acute GVHD after DLI were treated 
with immunosuppressive drugs. CsA was given in seven patients and CsA plus systemic 
steroids were given in five patients. The median duration of this immunosuppressive 
therapy was 4 months (range, 2-31).
In table 2 GVHD after DLI is related to GVHD after SCT. One of the seven patients who 
had grade 1 acute GVHD after SCT developed acute GVHD grade 1 after DLI and another 
patient developed acute GVHD grade 3 after DLI. These two patients also developed 
limited chronic GVHD. Five patients with grade 1 acute GVHD after SCT did not develop 
GVHD after DLI. Eleven patients who initially had no GVHD after SCT, developed acute 
GVHD after DLI (grade 1: n = 6 , grade 2: n = 3, grade 3: n = 1 and grade 4: n = 1). Only 
three patients developed chronic GVHD (limited: n = 2, extensive: n = 1). Thirteen 
patients did not have GVHD at all, either after SCT or after DLI. The incidence of GVHD 
after SCT did not correlate with the incidence of GVHD after DLI (Spearman rank order 
test P  = 0.17).
Mortality
Seven out of 35 patients (20%) in the DLI group have died at the end of follow-up. Four 
patients (11%) relapsed or had progressive disease before they were eligible for DLI 
(AML: n = 2, MM: n = 2). One patient relapsed from RAEB 34 months after pre-emptive 
DLI and did not respond to escalating doses DLI. He was then retransplanted and died 
three months after second SCT of severe GVHD. Another patient died from severe GVHD 
following pre-emptive DLI and a third patient died 9 months after DLI from cerebral 
hemorrhage without any signs of relapse. In the non-DLI group 17 out 47 patients (36%) 
died, 12 died from relapse (AML: n = 2, ALL: n = 2, CML: n = 4, RAEB(-t): n = 2, MM: 
n = 2) and 5 patients died from GVHD (AML: n = 3, ALL: n = 1, CML: n = 1). Overall 
mortality was lower in the DLI group although not significant (P  = 0.14). Treatment- 
related mortality (i.e. mortality while in continuous complete remission) did not differ 
between the two groups (P  = 0.36).
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Table 2 The incidence of graft versus host disease after donor lymphocyte infusion in relation to 
the incidence of GVHD after SCT in 31 patients
GVHD after DLI
+
2 (29%)* 5 (71%)
11 (46%) 13 (54%)
The percentage is expressed as the number of patients with or without GVHD after DLI divided 
by the number of patients with GVHD and without GVHD after SCT, respectively
Relapse
From the 35 patients who were included in the DLI group, 4 patients (AML n = 2, MM: n 
= 2) relapsed or had progressive disease at 2, 5, 7, and 8  months after SCT, respectively, 
and before they were eligible for DLI. Only three (AML-CR1, ALL-CR2 and RAEB) out 
of 31 patients who actually received DLI relapsed at 7, 11 and 41 months after SCT and at
1, 5 and 35 months after DLI, respectively. In the non-DLI group 19 out of 47 patients 
relapsed from their original disease (CML-CP1: n = 8 , CML in acceleration: n = 2, AML: 
n = 2, ALL: n = 2, MM: n = 3, RAEB: n = 1, RAEB-t: n = 1) at a median of 11 months 
(range, 5-22) after SCT. The projected 3-year probability of relapse for all 35 patients in 
the DLI group was 18% (95% CI, 5%-31%). This was significantly lower than the 
projected 3-year probability of relapse of 44% (95% CI, 28%-60%) for the patients in the 
non-DLI group (P  = 0.026) as shown in Figure 1a. The four patients who relapsed before 
they were eligible for pre-emptive DLI were all therapeutically treated with high dose DLI
135
Chapter 6
8
(1 x 10 CD3+ cells/kg b.w.) but all died of progressive disease. Two out of three patients 
who relapsed after pre-emptive DLI did not respond to repetitive higher doses of DLI and 
died of progressive disease (ALL-CR2) and because of severe GVHD after a second SCT 
(RAEB), respectively. The patient who relapsed from AML had only cytogenetic relapse 
and was in continuous hematological remission with normal peripheral blood counts at 
end of follow-up. All 19 patients who relapsed in the non-DLI group were treated with 
high dose DLI (1 x 10 /kg b.w.). Five out of eight patients with CML in first chronic 
phase responded and are currently free of leukemia. Two patients in the non-DLI group 
with MM showed partial response to high dose DLI. However, this response was only 
temporary (3 and 4 months, respectively) and both patients died from progressive disease. 
All other 12 patients did not respond to high dose therapeutic DLI and died from relapse.
Survival
In the DLI group 28 of 35 patients (80%) are alive at a median of 30 months (range, 14-65 
months) after SCT. In the non-DLI group 30 out of 47 patients (64%) are alive at a median 
of 26 months (range, 13-62 months) after SCT. The projected 3-year probability of 
survival in the patients included in the DLI group was 79% (95% CI, 63%-95%). 
Although there is a trend, this is not yet significantly better than the 63% (95% CI, 47%- 
79%) obtained in the patients not treated with pre-emptive DLI (P  = 0.07) (Figure 1b).
Leukemia-free survival
The projected 3-year probability of leukemia-free survival in the patients included in the 
DLI group was 77% (95% CI, 63%-91%) which is significantly better compared to the 
projected 3-year probability of LFS of 51% (95% CI, 36%-66%) of the patients in the 
non-DLI group (P  = 0.024) (Figure 1c). If we consider the 5 patients with relapsed CML 
and who responded to therapeutic DLI as patients who are in current leukemia-free 
survival the projected 3-year probability of LFS in the non-DLI group is 60% (95% CI, 
45%-75%) (P  = 0.14).
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m o n t h s
months
months
Figure 1. Probability of relapse (1a), survival (1b), and leukemia-free survival (1c) in patients who were 
included in the DLI group on base of intention to treat and patients included in the non-DLI group. 
Symbols in the curves denote patients who are alive (1b) or leukemia free survivors (1a, 1c)
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Hematopoietic chimerism
Hematopoietic chimerism was assessed at regular intervals after SCT and DLI. In the 35 
patients who were included in the DLI group, 18 patients (51%) had complete donor 
chimerism at time of DLI. The median time from SCT onwards to the establishment of 
complete donor chimerism in these patients was 5 months (range, 3-9 months). Nine 
patients (26%) had mixed chimeras at the time of DLI and in these patients the majority of 
the cells were usually of donor origin (median 98%, range 17-99%). The interval between 
DLI and the conversion to complete donor chimerism was a median of 3 months (range, 3­
6 ) in seven evaluable patients. One patient died of GVHD before chimerism was evaluated 
and one patient has stable mixed chimerism with predominantly autologous cells (98%) 
but without any sign of relapse of the original disease. Four patients relapsed before DLI. 
These four patients never reached complete donor chimerism after SCT. Another four 
patients had no informative marker to evaluate chimerism.
In the non-DLI group 37 out of 47 patients (78%) had complete donor chimerism at a 
median of 3 months (range, 3-9) after SCT. Eight patients who had complete donor 
chimerism regained autologous cells and relapsed of their disease. Three out of these eight 
patients responded to high-dose DLI and are in current complete remission with 100% 
donor chimerism. Five patients (11%) had persisting autologous cells after SCT and 
relapsed. Two out of these five patients responded to high dose DLI with the development 
of complete donor chimerism and remission of the underlying disease. One patient is alive 
without responding to DLI and with stable disease and two patients died of relapse. Five 
patients in the non-DLI group (11%) did not have a discriminating marker.
Considering all patients who developed complete donor chimerism after SCT, the patients 
in the non-DLI group developed significantly earlier complete donor chimerism compared 
to the patients in the DLI group, a median of 3 vs 6  months, respectively (P  = 0.02).
Discussion
We observed that pre-emptive DLI in patients who were at high risk for relapse after 
partially T cell-depleted SCT was associated with a relatively low probability of relapse. 
Despite the lower incidence of GVHD in the DLI-group, the probability of relapse in this
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group was significantly lower compared to the probability of relapse of the patients who 
were included in the non-DLI group. Previous studies in murine models and in SCT 
patients who relapsed from their original disease show a dose-and time-dependent 
probability of developing GVHD after DLI. These studies also show the possibility of a
28 42 45graft-versus-leukemia effect that is not associated with GVHD. , - Only a few studies 
report on pre-emptive administration of DLI after T cell-depleted SCT .29 ,46 In the study by 
Naparstek et al. DLI was given in escalating doses starting immediately after SCT. 
However, this resulted in clinically significant GVHD and no significant benefit on the 
overall probability of relapse. In the study by Barrett et al., escalating DLI were given 
within the first three months after SCT during cyclosporine A immunosuppression. 
GVHD incidence and severity were low but beneficial influence on relapse and leukemia 
free survival could not be demonstrated. In our study in the majority of patients, we 
selectively administered a single, relatively low and fixed dose of 0.1 x 10 CD3+ donor 
lymphocytes/kg b.w. at a median of 22 weeks after SCT in patients who had no significant 
GVHD after withdrawing all immunosuppressive therapy. Only a minority of patients 
(42%) developed GVHD after DLI. However, the first 6  patients in this study who were 
treated with a higher dose of 0.7 x 10 CD3+ cells/kg b.w. developed GVHD more 
frequently and more severely than we had anticipated. GVHD in one patient did not 
respond to intensive immunosuppression and this patient died from complications of 
GVHD. After treating the first six patients with pre-emptive DLI we decided to decrease 
the CD3+ cell content of the mononuclear cells infused to 0.1 x 10 /kg b.w. The patients 
who received the lower dose CD3+ cells in the DLI developed mild GVHD, which did not 
contribute to severe morbidity or mortality. These observations of a dose and time 
dependent probability of developing GVHD after DLI are concordant with the data from 
previous studies. 19,43-45 The interval between DLI (median 7 weeks) and onset of GVHD 
did not differ between patients who were treated with a higher dose DLI for relapse of 
their original disease and the patients in this study who received pre-emptive DLI. 46 Fifty- 
eight percent of the patients in the DLI group did not develop any GVHD after 
lymphocyte infusion. It is probable in these patients that GVL reactivity is present 
independent of clinical GVHD. High relapse rates caused by T cell depletion may be 
counterbalanced by the induction of GVL in these patients.
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One of the arguments against pre-emptive DLI may be the risk of exposing patients to 
GVHD who otherwise would not have suffered from this potentially life-threatening 
complication. Especially in CML patients whose relapse can be detected early and high 
dose DLI has proven to be very effective in overt relapse, one could argue against pre­
emptive DLI. However, CML patients transplanted in the chronic phase may relapse 
subsequently in accelerated phase or in blast crisis. DLI has been shown to be less 
effective in these patients. Even if DLI is given during early relapse 10 to 20% of the
47patients do not respond to DLI. In these patients the donor T cells may not recognize 
leukemia specific target antigens on the cell surface or may be rejected early after infusion 
by autologous T cells that have survived after SCT or that are part of the malignant 
clone . 48 ,49 In relapsed AML and especially ALL, DLI is only effective in a minority of 
patients .20,45,50,51 Pre-emptive DLIs are administered during clinical, hematological, 
cytogenetic, and/or molecular remission of the disease. The number of residual tumor 
cells, if  present, is relatively low, chimerism is predominantly of donor origin, and the 
immunological balance between donor cells and autologous cells is in the advantage of 
donor cells. These circumstances may be optimal for additional donor lymphocytes to 
exert their GVL reactivity even in hematological malignancies, such as ALL that usually 
do not respond to DLI when relapse has occurred.
In the present analysis we show that the incidence and severity of GVHD after pre­
emptive DLI is low when using 0.1 x 10 CD3+ cells/kg b.w. Five out of seven patients 
who had grade 1 acute GVHD after SCT did not develop GVHD after DLI. We are now 
considering giving DLI also to patients with acute GVHD grade 2 that has resolved after a 
short course of additional immunosuppression. The majority of the patients with acute 
GVHD in the non-DLI group had grade 2 GVHD and consequently they were included in 
the non-DLI group. These patients may also benefit from this pre-emptive immunotherapy 
without developing life-threatening GVHD.
In our study four patients relapsed or had progressive disease already before they were 
eligible for DLI. Three out of these patients showed only GVHD grade 1 of the skin after 
SCT that disappeared within 6  weeks after SCT. One patient had no GVHD at all. 
Currently, we taper all immunosuppressive drugs earlier after SCT to provoke GVL in
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these patients. If no GVHD or reactivation of GVHD occurs after cessation of these drugs, 
we treat the patients with pre-emptive DLI.
One of the major problems after high-dose DLI that is given for overt relapse is aplasia 
which develops in up to 50% of responders to this therapy and contributes significantly to 
mortality. The development of aplasia in patients who relapse after SCT is at least partly
18,52,53dependent on residual donor hematopoiesis at time of lymphocyte infusion . 18,52,53 Since 
pre-emptive DLI is given at the moment of near complete or complete donor 
hematopoiesis, aplasia is not expected as we observed in our patients. Only a minority of 
the patients (26%) had mixed chimerism at time of DLI and in the patients who had mixed 
chimerism the majority of the cells was of donor origin. Sequential monitoring chimerism 
after SCT showed that the patients in the DLI group needed more time to establish 
complete donor chimerism. The number of patients that had mixed chimeras at 6  months 
after SCT (26%) was slightly higher than in the control group (19%). The higher incidence 
and severity of GVHD in the control group may have contributed to a lower number of 
mixed chimeras. Surprisingly, the GVL reactivity in these patients was ultimately less 
effective in preventing relapse than that in the patients who received pre-emptive DLI. 
Despite the higher incidence of severe GVHD in the non-DLI group, the relapse rate was 
significantly higher in this group. This somewhat paradoxical result may be caused by the 
intensive and prolonged immunosuppression given to treat GVHD leading to early 
suppression of the GVL effect.
The relapse rate among CML patients was quite different between the two groups and 
appears to account for much of the difference in outcomes observed between the two 
groups. If we exclude the CML patients from the analysis, the number of non-CML 
patients in both groups is too low to draw any conclusions with regard to relapse. The 
GVL effect of pre-emptive DLI in non-CML patients can only be demonstrated in a much 
larger randomized study. However, concerning the number of high risk patients in this 
study, the observed relapse rates were low for this category of patients transplanted with 
partially T cell-depleted grafts.
The ultimate goal of cellular allogeneic immunotherapy after stem cell transplantation is 
optimal GVL effect without severe GVHD. The optimal strategy for the amelioration of 
GVHD in DLI patients has yet to be defined. Several strategies are presently under
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investigation, such as manipulation of DLI by selective depletion of CD8 + cells, 54-56 
incorporation of a suicide gene into T cells in an effort to more specific modulate
57,58 59GVH/GVL activity57,58 and custom made leukemia reactive cytotoxic T lymphocytes. 59
However, these techniques are often time-consuming, labor intensive and their value has
to be established.
Our data have not been obtained in a randomized prospective trial and selection bias may 
have influenced our results. However, the total cohort of patients consisted of consecutive 
transplanted patients, patients were only selected on base of GVHD characteristics and all 
patients were included in the study on base of intention-to-treat. An alternative control 
group would have been a historical matched control group. Because of changes in 
conditioning regimen and advances in supportive care we did not consider a historical 
matched group as a representative control group. Another argument against selection bias 
is demonstrated by the survival and relapse curves that are almost identical in the first nine 
months after SCT. A multicenter prospective randomized trial will start soon.
This is the first study that shows that pre-emptive DLI in patients who had no significant 
GVHD after SCT and who were not on immunosuppressive therapy is feasible and results 
in low relapse rates in patients who are at high risk for relapse. The incidence and severity 
of GVHD disease after DLI is low. However, we found this to be dependent on the 
number of CD3+ cells administered. The results, so far, suggest that in patients who suffer 
from more than grade 1 acute GVHD, this early, more intense GVHD followed by 
immunosuppressive therapy resulted in less GVL effect when compared to less severe 
GVHD followed by DLI. This category of patients SCT may also be safely treated with 
pre-emptive DLI to reduce relapse rate and increasing leukemia-free survival after T cell- 
depleted stem cell transplantation.
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Abstract
Analysis of changes in recipient and donor hemopoietic cell origin is extremely useful to 
monitor the effect of stem cell transplantation (SCT) and sequential adoptive 
immunotherapy by donor lymphocyte infusions (DLI). We developed a sensitive and 
accurate method to quantify the percentage of recipient and donor cells by real-time PCR 
using single nucleotide polymorphisms (SNP) as markers. Allele specific PCR of seven 
SNP resulted in specific markers for donor or recipient in 97% of HLA-identical sibling 
pairs. Both, recipient and donor derived hemopoietic cells can be simultaneously analyzed 
in 67% sibling pairs. We expect this can be increased to approximately 99% by 
developing three additional SNP-PCR. Serial dilution of SNP-positive DNA into either 
SNP-negative DNA or water revealed a detection limit of 0.1-0.01% depending on the 
amount of input DNA and start Ct of the used SNP-PCR. Application of our real-time 
SNP-PCR method for a CML patient treated by allogeneic SCT and DLI demonstrated its 
feasibility to follow donor T cell chimerism and early detection of residual and recurrent 
autologous hemopoiesis in response to treatment. This detailed monitoring of the genetic 
origin of hemopoietic cells, in particular immune effector cells and target cells after SCT 
and DLI, may substantially contribute to understanding mechanisms that play a role in the 
success of treatment.
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Introduction
Transplantation with hematopoietic stem cells from HLA-identical sibling donors has 
been successfully used to treat patients with hemopoietic malignancies. Allogeneic SCT 
results in effective replacement of eradicated recipient stem cells. Moreover, immune 
reactivity of donor effector cells against residual malignant cells contributes significantly 
to the success of treatment. This immune reactivity of donor T cells also limits the success 
rate of the therapy by transplantation related mortality due to severe graft versus host 
disease (GVHD ) . 1 T cell depletion of the stem cell graft reduces the incidence and severity 
of GVHD but results in an increase of relapse rate, which confirms the contribution of 
donor derived immunocompetent cells in eliminating residual malignant cells. In 
addition, the significantly higher relapse rates in patients who received stem cells of 
genetically identical twins compared to patients who received stem cells of HLA-identical 
siblings strongly supports the hypothesis that allo-antigens significantly contribute to 
immune reactivity of donor lymphocytes against malignant cells. Attempts are made to 
further exploit the immune reactivity of donor cells against recipient hemopoietic cells, 
including leukemia and lymphoma cells using a nonmyeloablative conditioning regime 
prior transplantation, followed by delayed donor lymphocyte infusion (DLI) . 4,5 
Interestingly, this treatment regime has also been applied to treat solid tumors and 
revealed that achievement of full donor T cell chimerism was a prerequisite for response
6-9to treatment.
DLI can be very effective in preventing and curing relapse of leukemia but harbors the 
risk of inducing fatal GVHD . 10-13 Although the response rate of CML patients to DLI is 
quit high, the majority of patients with acute myeloid or lymphoid leukemia (AML and 
ALL) do not respond to DLI. 14 Success of DLI may be improved when dose and timing of 
given donor T cell infusion can be adapted to each individual patient thereby minimizing 
the risk of GVHD and maximizing the reactivity against malignant cells . 15 Mackinnon at 
al. 16 have shown that repetitive administration of increasing numbers of donor 
lymphocytes resulted in complete remission in CML patients who did not respond to low 
dose DLI. Moreover, infusions of escalating numbers of donor T cells induced less GVHD
17compared to DLI given as bulk dose. In addition, in vitro activation of donor cells can
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18improve DLI. Slavin et al. showed that recurrent leukemia cells in patients not 
responding to DLI could be effectively eliminated by donor T cells activated by IL-2 ex 
vivo. Furthermore, early detection of relapse may enhance the success rate of DLI by
treatment before the onset of overt clinical relapse . 19 Increasing numbers of Bcr/Abl
10 22expressing cells can indicate early relapse of CML. - Other fusion transcripts can be
23 24indicative for relapse of acute leukemia patients. , It has also been suggested that 
monitoring of chimerism in lymphoid and myeloid subsets, isolated from peripheral blood
25 27of patients after SCT, allows detection of residual or recurrent leukemia cells. - 
Imminent relapse of leukemia lacking a genetic marker, may be prevented by adoptive
27cellular immunotherapy given early after increase of percentage of recipient cells.
The mechanisms responsible for failure to immunotherapy after SCT are not clear. 
Patients with a high percentage of autologous T cells showed reduced allo-reactivity of 
infused donor T cells which may suggest rejection of infused T cells or induced T cell
28,29tolerance. , Donor derived regulator T cells may also suppress reactivity of infused
30donor lymphocytes. Frequent analysis of chimerism in lymphoid and myeloid cells after 
SCT may be of great value to identify patients with high risk for relapse or graft 
rejection .24-26,31 Several techniques have been used in these studies to monitor chimerism 
after SCT. PCR of DNA sequences with tandem repeats (VNTR, STR) or satellite DNA
25-27has applied frequently. - FISH analysis to discriminate male and female cells have been 
utilized in sex mismatched sibling pairs.
We have developed a real-time PCR method based on the detection of bi-allelic SNP. Bi-
31allelic SNP exist with a very high frequency in the human genome. We show that the 
method is applicable for almost all recipient/donor pairs and can accurately quantify at 
least 0.1% recipient cells among donor cells and vice versa. Detailed monitoring of the 
genetic origin of hemopoietic cells after SCT and DLI can substantially contribute to 
understanding of the mechanism involved in response to therapy and guide adoptive 
immunotherapy strategies.
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Material and methods
Patient and cell samples
Chimerism of hemopoietic cells was studied in patients who received T cell-depleted SCT 
with, stem cells from a HLA-identical sibling donor. CML patient (UPN 480) with 
Philadelphia chromosome positive (Ph+) CML cells was conditioned with 120 mg 
cyclophosphamide per kg body weight and total body irradiation (9 Gy). Cyclosporine A 
was given until two months after SCT to prevent GVHD. PBMC from peripheral blood 
collected before and following SCT and DLI were isolated by Ficoll density gradient 
centrifugation. T cells and myeloid cells were isolated by flow cytometry (Epics Elite, 
Beckman Coulter, Fullerton, CA) after staining with CD3-FITC conjugated mAb (UCHT1 
Beckman Coulter) or CD13/CD33-PE conjugated mAb (WM-54, WM 47, respectively, 
Dako, Glostrup, Denmark). Purity of both cell populations was >99.5%.
DNA preparation and SNP-typing by RLFP analysis
Genomic DNA was isolated with QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) from sorted cell populations, PBMC of donors and recipients collected before 
SCT, and from EBV-transformed B cells generated from PBMC of recipients collected 
prior SCT and donors. DNA fragments containing SNP in PECAM1, ICAM1, HA1, 
MLH1, SUR1, and the sequence-tagged sites (STSs) G42863, G42888 were amplified as 
described before . 33-41 Genotype of SNP was determined after digestion with restriction 
enzyme PvuII (PECAM1 and MLH1) and PstI (SUR1) by agarose gel 
electrophoresis.32,33,40,41 Genotype of SNP in ICAM1, HA1, G42863 and G42888 were 
determined by DNA sequencing of PCR products.
Specific amplification of SNP by real-time PCR
DNA isolated from EBV-transformed cell lines bearing homozygously the identified SNP- 
was use to develop and optimize Taqman based real-time PCR for each of the SNP 
(Perkin Elmer Applied Biosystems, ABI Prism 7700).42-44 Allele specific primers were 
designed for annealing at 60°C that allowed efficient screening of patient and donor DNA 
with all SNP. Real-time PCR was performed in a total volume of 50 |il with 1x PE sample
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buffer, 1.25 U of DNA polymerase (AmpliTaq GoldTM, Perkin Elmer), 250 |iM dNTP, 
primers at 300 nM, and TET-labeled probes at 100 nM. Samples were heated for 10 
minutes at 95°C and amplified for 45 cycles for 15 seconds at 95°C and for 60 seconds at 
60°C. Amplification curves were constructed by plotting PCR cycle number versus target 
specific fluorescence signals of the reporter dye ( 6  Rn). The cycle number that generates 
the first fluorescence signal ( 6  Rn) above the threshold is called cycle threshold (Ct) and 
represents the relative amount of input of target DNA.
Quantification of the percentage of cells containing allele specific sequences
To increase amplification efficiency, enlarged allele specific primers were synthesized and 
optimal annealing temperatures were defined. We generated calibration functions from Ct 
obtained by real-time PCR of serially diluted DNA isolated from cell samples 
homozygous, heterozygous or hemizygous harboring each of the SNP. DNA containing 
one polymorphic nucleotide of the SNP was diluted in water (500-0.05ng) and in DNA 
that contained the other polymorphic nucleotide of the SNP (negative DNA). Calibration 
functions were generated using allele specific primer sets amplifying DNA containing the 
seven SNP. In addition to SNP allele specific real-time PCR, we developed SMCY 
specific primers and a TET labeled probe (forward primer 5'-TCTTGCGTCCTCA-3', 
reverse primer 5'-AGTG-TGGTACGAGCCGTCTCA-3', and probe 5'-CTCAGGTG- 
CGGAAGGTCTCACAGGTT-3') to quantify male cells. Optimal annealing temperature 
was 62oC. The amount of input DNA was accurately defined by real-time PCR using a 
DNA fragment encoding albumin as reference .45
Calculation ofthe discriminating capacity ofbi-allelic SNP
Genotype frequencies obtained by SNP-PCR from of 80 SCT recipients and their HLA 
identical sibling donors were compared with frequencies SNP described earlier.33-41 The 
genotype frequencies we obtained by real-time PCR of SNP were used to analyze the 
discriminative capacity of the seven SNP. Calculation of probability that siblings have 
different genotypes with alleles A and B that are located on the autosomes revealed the 
following formula: [(Freq AA + 5/8 * Freq AB + Freq BB) * Freq AB]. The probability 
that siblings have different genotypes of SNP located on the X-chromosome was
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calculated by the formula: [5/8 * Freq AB + 1/2 * Freq A * Freq BB + 1/2 * Freq B * Freq 
AA].
Results
Development of SNP-specific real-time PCR for identification of recipient and donor 
cells
Seven SNP of which high frequency in human populations have been described, were 
selected for the identification of recipient and donor derived cells after SCT (Table 1). 
SNP located on chromosome 6 , that contain the MHC complex encoding the HLA 
molecules, were excluded. RFLP analysis and DNA sequencing of amplified fragments 
were used to define cells bearing the selected SNP, homozygously, heterozygously or 
hemizygously. Using DNA isolated from these cells, we developed real-time PCR with 
SNP-allele specific primers and gene specific probes. To hinder amplification of the non- 
complementary alleles we synthesized SNP-allele specific primers containing one extra 
mismatch in one of the two adjacent nucleotides of the polymorphic nucleotides. We 
replaced these nucleotides for one of the three alternative nucleotides and determined 
which of these mismatched primers resulted in highest specific amplification and lowest 
background amplification. We observed significant differences in amplification efficiency 
and target specificity of allele specific primers as shown for the A allele of MLH1 (Figure 
1). High fluorescence signal early after amplification of the positive allele (MLH1-A, Ct 
24.5) and low fluorescence during amplification of the negative allele (MLH1-G, Ct 35.9) 
was observed using the allele specific primer ending with ATT (primer set 1 in Figure 1). 
In contrast, allele specific primer ending with TAT (primer set 2 in Figure 1) showed 
lower sensitivity for MLH1-A (Ct 28.2) and allele specific primer ending with CTT 
(primer set 3 in Figure 1) showed high background amplification of the negative allele 
MLH1-G (Ct 29.1). Using this approach we developed primer sets that reached the 
detection threshold prior to 25 cycles of amplification, and showed background 
amplification of the non-complementary allele after 35 cycles using 500ng of genomic 
DNA.
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Table 1 Characteristics of SNP used as specific markers for recipient and donor cells
Gene Chromosome SNP Location Frequency (%)* 
AA / AB / BB
Reference
PECAM1 17 C bp 514 28 / 42 / 30 33, 34
G codon 125
ICAM1 19 G bp 1462 20 / 47 / 33 35, 36
A codon 214
HA1 19 C-A bp 500-504 17 / 49 / 34 37, 38
T-G
MLH1 3 G promotor 26 / 55 / 19 39
A bp -93
SUR1 11 C exon 16 32 / 47 / 20 40
T bp -3
STS# Chromosome SNP Frequency (%)** Reference
A / B
G42863 Xq28 A 68 41
C 32
G42888 Xq25 T 60 41
C 40
*genotype frequencies given by literature, **allele frequencies given by literature, 
# sequence-tagged site
Table 2 shows the developed primer sets, the optimum annealing temperature and the 
amplification efficiency obtained by real-time PCR for seven SNP. Cycle threshold of 
amplification of repeated experiments ranged within 0.5 cycle, starting with the same 
amount of target DNA. Differences of more than 10 cycles in reaching the threshold 
between the positive and negative allele allowed theoretically quantification of at least
0.1% target DNA.
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The results shown here, demonstrate that real-time PCR of target sequences with SNP can 
be used to identify the genetic origin of cells. Moreover this method is highly reproducible 
and applicable for detection of very small percentage of cells with specific SNP-markers.
Typing ofallelic differences in recipient and donor cells by SNP
To determine the capacity of the SNP to discriminate between siblings, 80 SCT recipients 
and their HLA identical donors were screened for presence of the seven SNP. First of all 
the genotype frequencies of SNP in 160 paired siblings were defined (Table 3). This 
analysis showed that genotype frequencies of SNP in either donors and recipients were 
similar (data not shown). Moreover, all SNP genotype frequencies that we had determined 
correlated with those published, except one (Table 3). The frequency of the SNP in the 
MLH1 gene we found, differs significantly from that determined in the Japanese
39population by Ito et al. As expected, frequencies of heterozygous genotypes for both 
SNP located on the X-chromosome were low due to single alleles in males (Table 3).
Next, we analyzed the contribution of each SNP regarding their capacity to reveal specific 
molecular markers in sibling pairs. Exclusive appearance of one of the two polymorphic 
alleles in either recipient or donor was determined. The seven SNP revealed a specific 
marker for either recipient or donor in 24-50% of the pairs (Table 4). The SNP in MLH1 
showed the lowest capacity (24%) to genetically mark recipient and donor cells, due to 
high frequency of homozygous MLH1-G in the analyzed population. SNP located on the 
X-chromosome contributed as effective in specific recipient or donor marking as SNP 
located on autosomes (Table 4). A significant number of sibling pairs (28%) allowed 
recipient and donor specific discrimination by both bi-allelic variants of one SNP. 
Hemizygous appearance of allelic SNP-variants on the X-chromosome contributed 
dominantly to this phenomenon (Table 4). Furthermore, the probability of the seven bi- 
allelic SNP to reveal specific markers for recipient and donor was calculated using the 
genotype frequencies that we had determined in 80 sibling pairs. The analyzed frequencies 
of SNP as genomic marker correlate highly with that calculated suggesting that all SNP- 
markers segregate in a Mendelian fashion that is not influenced by the close relationship 
of siblings (Table 4).
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Cycle
Figure 1. Amplification curves of the MLH1 SNP-alleles by real-time PCR.
Amplification plots of PCR using three reverse primers specific for the A allele and a common forward primer 
are shown. Primer set 1, with reverse primer 5'-TCGTGCTCACGTTCTTCCATT-3' reached threshold after 
24.5 cycles for the A allele (■ )  and after 35.9 cycles for the G allele (□ )  (6Ct=11.4). Primer set 2, with 
reverse primer 5'-TCGTGCTCACGTTCTTCCTAT-3' reached threshold after 28.2 cycles for the A allele (A ) 
and after 41.8 cycles for the G allele (A )  (6Ct=13.6). Primer set 3, with reverse primer 5'- 
TCGTGCTCACGTTCTTCCCTT-3' reached threshold after 24.4 cycles for the A allele ( • )  and after 29.1 
cycles for the G allele (O ) (6Ct=4.7). Primer set 1 gave the best results for the MLH1-A allele.
The high percentage that each SNP could discriminate between siblings resulted in 
specific markers for either recipient or donor in 97% of these pairs (Table 4). Probability 
calculations based on genotype frequencies revealed the same discrimination capacity of 
the seven SNP-markers (Table 4). Each dimorphic SNP increased the percentage of pairs 
with a specific marker for both recipient and donor significantly (8-14%). Location of two 
SNP on the same chromosome (19 and X) did not affect the accumulation of the 
percentage of sibling pairs with specific SNP-markers (Table 4). The seven SNP we 
utilized, revealed a specific genomic marker for both recipient and donor in 67% of the 80 
analyzed sibling pairs (Table 4). The PCR specific for SMCY located on the Y-
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chromosome discriminated recipient and donor cells in al sex mismatched sibling pairs 
and increased the percentage of pairs that have a specific marker for both recipients and 
donors with 1 2 % (data not shown).
These results demonstrate that a restricted number of SNP in the human genome can be 
used to genotype the vast majority of sibling pairs. Each SNP with a high heterozygous 
frequency has the ability to discriminate 30-50% of sibling pairs either with a recipient or 
donor specific marker. More importantly, all SNP used for this analysis act as additional 
makers specific for either donor or recipient which results in specific markers for 67% of 
both members of sibling pairs. Addition of three bi-allelic SNP-markers that appear to be 
high discriminative leads to specific markers for both recipient and donor in > 99% of 
sibling pairs.
Quantification of recipient and donor cell ratios
We developed a quantitative assay to measure the percentage of recipient or donor cells by 
allele specific real-time PCR in different cell populations. Calibration curves for each SNP 
were performed. Homozygous and heterozygous DNA for all targeted alleles were diluted 
either in DNA homozygous for the alternative (negative) alleles or in water. Amplification 
signals (Ct) were plotted against amount of input DNA. Real-time PCR of DNA encoding 
the albumin gene was simultaneously performed to normalize the amount of input DNA of 
chimeric test samples to the calibration samples. Figure 2 shows calibration curves of 
amplified-SNP positive DNA (PECAM1-GG and PECAM1-GC) diluted in negative DNA 
(PECAM1-CC) (Figure 2A) and amplified-SNP positive DNA diluted in water (Figure 
2B). All calibration curves of DNA amplified by SNP-specific primer sets reached slopes 
of -3.3 (± 0.2). Calibration curves for samples diluted in both negative DNA and water 
gave similar results for all seven SNP-PCR (data not shown). Deviation in Ct was stable 
and average of twofold standard error of repeated samples did not exceed 0.4 cycle. Since 
the deviation of Ct obtained by real-time PCR is independent of the concentration target 
DNA in the samples, accuracy is directly related to this concentration. Therefore, 
confidential interval is approximately +35% and -25% for all measured values.
159
Table 2. Developed primer sets and probes used for real-time PCR of SNP
gene SNP allele specific primer (5'-3') * common primer (5'-3') PCR
temp.
target site 
probe #
amplification (Ct) 
pos. allele / 
neg. allele
A Ct *
PECAM1 C ( AG )G AC TCACCTTCCAC C AAC C C G (R) GGATCTAT GACT C AGGGAC AT AT AAAT G (F) 63 37- 68 bp 2 2 .9 / 44.8 21.9
G (A)GGACTCACCTTCCACCAACCIC (R) 2 5 .0 /41 .4 16.4
ICAM1 G AGAGCACATTCACGGTCACCCAC (R) GCACTTTCCCACTGCCCAT (F) 60 28-56 bp 25 .5 /38 .1 12.6
A AG AG C AC ATTC AC G GTC AC C ATT (R) 24 .9 /36 .1 11.2
HA1 C-A GCTCTCACCGTCACGCAA (R) T GCTGGCGGACGT GG (F) 62 17-36 bp 2 4 .9 /3 9 .9 15.0
T-G GCT CT CACCGTCATGCCG (R) 24.1 / 40.2 26.1
MLH1 G TCGTGCTCACGTTCTTCCTCC (R) GAGACCCAGCAACCCACAGA (F) 62 40-67 bp 2 3 .9 /38 .5 14.6
A TCGTGCTCACGTTCTTCCATT (R) 2 4 .5 /35 .9 11.4
SUR1 C TGCCACCCTCCCTCCCTAC (F) GTC TTC CAGAGTC C C C GACAG (R) 64 45-65 bp 2 3 .9 /38 .5 14.6
T TGCCACCCTCCCTCCCTAT (F) 2 4 .5 /35 .9 11.4
STS SNP allele specific primer (5'-3') * common primer (5'-3') PCR target site amplification (Ct) A Ct *
temp. probe # pos. allele /
neg. allele
G42863 A (G)GCTTGTGGATGAAGGAGAA (F) T GGCACAT CT GGCAAAATCTC (R) 65 23-52 bp 2 2 .0 /34 .9 12.9
C GGCTTGTGGATGAAGGAGIC (F) 2 2 .5 /34 .8 12.3
G42888 T (G)GGGAGGGGAGGAAGAGACT (F) TTGGTGCTGCTGTAATCAC I I I I CAT (R) 62 54-83 bp 21 .4 /35 .1 13.7
C (G)GGGAGGGGAGGAAGAGAGC (F) 20 .9 /35 .1 14.2
* polymorphic nucleotides are given in bold and mismatched nucleotides introduced to decrease background amplification are underlined 
nucleotides between brackets are removed for annealing at 60 °C used for SNP-screening; (F) = forward primer; (R) = reverse primer
# related to first nucleotide of forward primer; Ct of negative allele minus Ct positive allele
Table 3. Genotype frequencies of SNP
frequency (%)
PECAM1 ICAM1 
GG CG CC GG GA AA
HA1 
CA CATG TG
MLH1 
GG GA AA CC
SUR1
CT TT c/cc
G42863
CA A/AA
G42888 
C/CC CT 'r/TT N
analyzed by PCR 24 46 30 22 42 36 23 42 35 68 25 7 29 48 23 11 34 55 24 47 29 75 female
24 76 49 51 85 male
29* 71* 49* 51* 160 all
literature# 28 42 30 20 47 33 17 49 34 26 55 19 32 47 21 32* 68* 40* 60*
*  allele frequencies; references are given in table 1
Table 4 Recipients and donors (%) that can be discriminated based on SNP-markers
number of
markers for PECAM1 ICAM1 HA 1 MLH1 SUR1 G42863 G42888
recipient or donor * analyzed by PCR 41 45 30 23 44 35 42
recipient and donor ** analyzed by PCR 3 2 2 1 2 10 8
total analyzed by PCR 44 47 32 24 46 45 50
total calculated# 38 35 35 23 39 32 43
cumulative number
of markers for PECAM1 ICAM1 HA1 MLH1 SUR1 G42863 G42888
recipient or donor analyzed by PCR 44 66 76 83 89 94 97
recipient or donor calculated 38 60 74 80 88 92 97
recipient and donor*** analyzed by PCR 3 12 24 32 41 55 67
* either recipient or donor DNA contains exclusively one of the allelic variants o f SNP; ** both recipient and donor DNA contain different variants of SNP 
*** both recipient and donor DNA contain exclusively one or more allelic variants of SNP;
# probability that recipient and donor DNA exclusively contains one allele of the SNP; calculations were performed using genotype frequencies as 
analyzed (table 2)
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As shown in Table 2, all SNP-PCR showed low amplification of DNA containing the 
allele that was not complementary with the specific SNP-primers (Ct >35). Therefore, 
specific amplification of 500ng DNA results in detection up to 0.1% SNP-positive cells in 
SNP-negative cells. Specific amplification of DNA with SNP that reached the threshold 
prior 22 cycles of amplification ( 6  Ct >13) can be quantified up to 0.01%.
The results show that real-time PCR of SNP can be used to quantify chimerism in cell 
samples taken after SCT. Quantification of low percentage target-SNP positive cells in 
mixed samples is very accurate but standard errors are high for samples with high 
percentage target-SNP positive cells. Analysis of hemopoietic cell populations of patients 
after SCT by both recipient and donor specific SNP-markers may result in significant 
information about chimerism present in these patients.
Analysis of recipient derived hemopoietic cells following SCT and adoptive 
immunotherapy
To apply our SNP-method for the determination of the origin of lymphocytes and myeloid 
cells after allogeneic transplantation, we studied in detail chimerism of one CML patient 
who relapsed and was subsequently treated with DLI (Figure 3). The patient relapsed at 9 
months after SCT and received 0.7x10 T cells/kg body weight 2 weeks later. Acute 
GVHD was not observed but the patient developed extensive chronic GVHD 3 months 
after DLI. The percentages of recipient derived T cells and myeloid cells in blood were 
determined by real-time PCR of the ICAM1-G allele. Remarkably, a high percentage of T 
cells of recipient origin were detected in this patient at 1, 3 and 6  months after SCT.
Within one month after DLI the percentage of recipient derived T cells decreased very 
rapidly and became below the detection limit prior to the development of chronic GVHD 
(Figure 3). A small percentage of autologous cells could be detected in the purified 
myeloid cells at 1 and 3 months after SCT (0.3 and 0.6% respectively). However, myeloid 
cell samples were 99.5% pure, thus contaminating T cells may contribute to this signal. 
The percentage of myeloid cells of recipient origin was significantly increased at 7 months 
after SCT. Shortly after DLI the percentage of recipient derived myeloid cells still 
increased (Figure 3). Two months after DLI the myeloid cells of recipient origin dropped 
very fast to below 0.05% (Figure 3).
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S N P-pos it ive  DNA d i lu te d  in SNP n e g a t ive  DNA (ng)
S N P-pos it ive  DNA d i lu te d  in SNP n e g a t ive  DNA (ng)
Figure 2. Calibration curves of DNA.
Serial dilutions of DNA containing homozygous (■ )  or heterozygous (□ )  the G allele of PECAM1 (PECAM1- 
GG and PECAM1-GC respectively). Standard errors of Ct are ± 0.25 cycle and presented by sizes of the 
boxes. A) SNP-target sequence positive DNA diluted in target sequence negative DNA (PECAM1-CC). B) 
SNP-target sequence positive DNA diluted in water.
A high percentage (50%) Ph+ cells was observed in bone marrow by FISH analysis of at 6  
months after SCT. The percentage of Ph+ cells in bone marrow increased up to 90% prior 
DLI and did not decrease until 1.5 months after DLI. All Ph+ cells disappeared within 5
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month after DLI (data not shown). The data show persistence of high percentage of 
recipient derived T cells in this patient after SCT. These T cells decreased immediately 
after DLI prior the onset if  clinical GVHD symptoms, which suggests that allo-reactivity 
of infused donor cells can be early detected by this method. Moreover, kinetics of myeloid 
cells of recipient origin in blood after SCT and DLI parallel that of Ph+ cells in BM as 
analyzed by FISH. This indicates that monitoring of chimerism in myeloid cells may be 
informative regarding relapse and response to treatment for those myeloid leukemia 
patients whose leukemia cells do not bear a specific tumor marker.
months after SCT
Figure 3. Analysis of cells of recipient origin after SCT. T cells and myeloid cells are purified by flow 
cytometry after staining PBMC with cell lineage specific mAb. The percentage recipient derived T cells (O ) 
and myeloid cells (■ )  are detected by real-time PCR with allele specific primers for polymorph DNA of the 
ICAM1 gene. Gray bars represent the confidential interval of real-time PCR of SNP.
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Discussion
The aim of the present study was to develope an accurate, sensitive and fast method to 
quantify the percentage of recipient and donor cells present after transplantation of HLA- 
identical stem cells. Following SCT the majority of transplanted patients have 
hemopoietic cells of both recipient and donor origin (mixed chimerism) at least for a short 
period of time. Hemopoietic cells of some of these patients remain of mixed origin for a 
long period of time or revert to autologous hemopoiesis. 46 The influence of mixed 
chimerism on leukemic relapse, graft rejection, and treatment failure after SCT have been
8 47 48studied extensively. , , It has become clear that the hemopoietic cell lineages in which 
mixed chimerism occurs contribute to the choice for adoptive immunotherapy after 
SCT . 49,50 T cell mixed chimerism contributes clearly to graft tolerance and resistance
28 30 51against graft-versus-host disease. , , Mixed myeloid cell chimerism in acute and 
chronic myeloid leukemia patients may reflect residual disease and may be an early 
indicator of imminent relapse of the original disease.24-26 Particularly, the kinetics of 
recipient and donor ratios in these cell lineages would be very informative about immune 
reactivity and course of disease and may be useful in determining strategies of additional
26,27treatment.
We developed a real-time PCR method using seven genomic SNP markers that are 
capable to discriminate either recipient or donor cells in 95% of HLA identical sibling 
pairs. Logarithmic diluted concentrations of input target DNA are proportionally linear 
with Ct. Deviation in Ct is independent of the concentration DNA. Therefore, the 
sensitivity is very high for low concentrations of target DNA but low for high 
concentrations of target DNA. However, to reach high sensitivity in both directions, two 
discriminative SNP can be used with two calibration curves. One calibration curve to 
quantify a range from 0.1 to 50% recipient cells in donor cells using one SNP-PCR and 
one calibration curve to quantify a range from 0.1 to 50% donor cells in recipient cells by 
another SNP-PCR. One recipient specific and one donor specific SNP-PCR can be utilized 
for sensitive monitoring after SCT and DLI. By this approach seven bi-allelic SNP- 
markers resulted in very sensitive monitoring of chimerism in 6 7 % of our patients. 
Additional real-time PCR analysis with 3 SNP allows a screening that can routinely
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applied to determine specific markers for 99% of both recipients and donors. In addition 
to SNP-PCR, we developed an SMCY-gene specific real-time PCR to quantify male cells 
in sex mismatched recipient donor pairs. A similar approach has been described for the
52DFRY gene by Fehse et al. A male specific PCR may be used as a discriminating marker 
in 50% of in randomly selected recipient and donor pairs and can be utilized as a bi-allelic 
marker for either recipient or donor. Dimorphic SNP revealed to be specific markers for 
either recipient or donor of sibling pairs comparable to male specific markers.
As mentioned earlier, very small percentages of recipient cells in donor cells and vice 
versa can be detected by real-time PCR. A detection limit of 0.01% can be reached using 
SNP-specific primers that efficiently amplify the positive allele (Ct < 22) and show low 
amplification (Ct > 35) of the negative alleles. Standard errors in repeated PCR are small 
(± 0.2 cycle) which results in confidence interval of +/- 25% of the measured values. 
However, quantification of SNP-specific DNA by real-time PCR is more accurate than 
quantification of products by conventional PCR that amplify DNA samples to a fixed 
number of cycles. PCR products that differ in length by the number of tandem repeats 
sequences (STR/VNTR) utilize electrophoresis to quantify both, recipient and donor 
specific products amplified in the same PCR. Analysis of recipient cells and donor cells 
by separate real-time PCR of SNP exclude interference with non specific signals, like 
spectral overlap of recipient and donor specific fluorescence signals and stutter peaks as 
frequently observed by amplification of STR (53, 54). In addition, real-time PCR of SNP 
is less hampered by competition for reagents that may occur by amplification of PCR 
products that significantly differ in length. Moreover, the use of a reference gene 
amplified by real-time PCR may better define the amount of input DNA compared to 
conventional PCR. However, sensitive quantification of recipient and donor derived cells 
in leukocyte subsets may be limited by a low efficiency of purification. This efficiency is 
largely dependent on the cell separation techniques used.
The percentage recipient and donor pairs that have an SNP-marker is significantly higher 
than the number of patients and donors that have markers applicable for FISH analysis and 
can compete with STR makers (55-57). Use of specific PCR primers for about 10 SNP 
with high heterozygous frequencies will result in a discriminative marker for both 
recipient and donors in approximately 99% of all sibling pairs. The reproducibility of our
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SNP-marker analysis is very high and the method is significantly less laborious compared 
to marker analysis by FISH. High percentage of recipient and donor cells can be
58quantified more exactly using FISH analysis. Real-time PCR can sensitively detect a low 
percentage of cells with recipient or donor specific sequences due to the restricted number 
of cells that is analyzed using FISH. Specific target sequences in recipient and donor DNA 
can be separately utilized for quantification by real-time PCR and consequently result in 
sensitive quantification of both recipient and donor DNA present in one cell sample.
In summary, monitoring of hemopoietic chimerism after SCT may be an early indicator of 
graft rejection and relapse. Moreover, it provides significant information about the 
immunological response after SCT and DLI. We show that real-time PCR of SNP is a 
sensitive and very reliable method to analyze chimerism. The method is less laborious 
compared to FISH analysis and quantification is more accurate than obtained after gel 
electrophoresis and conventional PCR.
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Abstract
Eighty-nine patients were transplanted for CML-CP1 with partially T cell-depleted 
(counterflow centrifugation) stem cell grafts from HLA-identical siblings. Nineteen 
patients received a standard conditioning with cyclophosphamide ( 2 x 60 mg/kg) and TBI 
(2 x 4.5 Gy) and 70 patients received a conditioning regimen intensified by the addition of 
Idarubicine (Ida) 42 mg/m . The 5-year probability of hematological and/or cytogenetic 
and/or molecular relapse was 70% in the standard conditioned patients. The introduction 
of Ida in the conditioning regimen resulted in a significantly (P  = 0.002) lower 5-year 
probability of relapse (41%). The addition of Ida correlated with significantly more acute 
GVHD (P  = 0.015). Addition of idarubicine did not influence transplant-related mortality. 
The 5-year probability of current leukemia-free survival defined as survival in first or 
second remission (after therapeutic DLI) was identical for both conditioning regimens 
(64% and 63%, respectively). Eleven patients were randomized prospectively between the 
standard and the intensified conditioning. In 10 out of 11 patients chimerism was 
monitored frequently in highly purified subsets of PBMCs and granulocytes using a newly 
developed real-time quantitative PCR for the detection of recipient/donor-specific single 
nucleotide polymorphic alleles and/or the male-specific SMCY gene. Patients conditioned 
with Ida had significantly lower percentages of recipient T cells at 1 and 3 months after 
SCT (P  = 0.02) and developed earlier (median, 3 versus 12 months) complete donor 
chimerism in the T lymphoid (CD3+/CD4+ and CD3+/CD8+ ) subsets compared to the 
patients conditioned with the standard regimen. The addition of Ida in the conditioning 
had no influence on the time to reach complete donor chimerism in the investigated non-T 
lymphoid subsets of peripheral blood cells. We conclude that the addition of Ida to the 
conditioning regimen in the setting of allogeneic T cell-depleted SCT resulted in a rapid 
clearance of autologous T lymphocytes that may explain the increased probability of acute 
GVHD and the decreased relapse rates. However, in patients transplanted for CML, 
conditioning without Ida did not influence current leukemia-free survival due to rescue 
with DLI. In patients with other hematological malignancies that do not respond well to 
therapeutic DLI this observation may have consequences for the conditioning regimens 
before T cell-depleted SCT.
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Introduction
Allogeneic stem cell transplantation is a curative treatment option for patients suffering
1 2from chronic myeloid leukemia. , Eradication of the CML clone depends on the graft- 
versus-leukemia (GVL) effect caused by immunocompetent donor derived blood cells
3
recognizing host specific antigens. The details of the GVL-effect are poorly understood. 
Despite major progress in the last two decades graft-versus-host disease (GVHD) remains 
one of the major causes of morbidity and mortality after non T cell-depleted SCT. 
Moderate to severe acute GVHD (grade 2-4) occurs in about 45% of recipients of HLA- 
identical marrow grafts and contributes to death in 20-70% of those affected .4-6 
Approximately 30%-50% of the patients develop chronic GVHD which is also associated 
with significant morbidity and mortality (50%) as a result of long term 
immunosuppression and severe immune dysfunction. One of the most effective methods 
to reduce GVHD after allogeneic SCT is depletion of T cells from the donor graft.
However, the removal of immunocompetent T lymphocytes is associated with increased
2 8 12graft rejection and increased relapse rate. , - Adoptive and pre-emptive immunotherapy 
using donor leukocyte infusions has emerged as a potential approach for the treatment of
13-17increased relapse rates after T cell-depleted SCT. - In relapsed CML patients salvage
therapy with DLI is compensating for the higher relapse rate associated with partially T
18 20cell-depleted SCT resulting in 5-year survival rates up to 80%. - Another strategy to 
prevent relapse after T cell-depleted SCT, especially in hematological malignancies that 
do not respond very well to therapeutic DLI, is the intensification of the conditioning
regimen. We already demonstrated a favorable outcome after intensifying the conditioning
21regimen with the addition of anthracyclines in standard risk leukemia patients. In this 
study we present the outcome of transplantation with and without an intensified 
conditioning regimen in 89 patients transplanted for CML-CP1. We were interested in 
relapse rates, leukemia-free survival (LFS), current leukemia-free survival, graft-versus 
host-disease and in particular in the influence on chimerism dynamics in purified subsets 
of white blood cells after an intensified conditioning with anthracyclines. In previous 
analyses we hypothesized that the addition of anthracyclines may exert an
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21immunomodulatory effect. Chimerism studies demonstrate this effect in the present 
analysis.
Patients and methods
Patients and donors
Between March 1984 and December 2000, eighty-nine consecutive patients received 
allogeneic stem cell transplantation for CML in first chronic phase. Donors were HLA A,
B, DRB, DQB-identical siblings. The median age of the recipients (48 males and 41 
females) and donors (54 males and 35 females) was 40 years (range, 16-61) and 40 years 
(range, 13-71), respectively. Age distribution was similar between the patients who were 
transplanted with and without the intensified conditioning. All recipients and donors or 
their guardians gave their informed consent. The Ethics Committee of the University 
Medical Center St Radboud approved all protocols and consent forms.
Chemotherapy before allo-grafting
Before SCT all 89 patients were treated with hydroxyurea. In nine patients interferon 
alpha was added. In these patients interferon was stopped three months before 
allografting. From the nine patients pre-treated with interferon alpha 6  patients received 
the intensified conditioning regimen and three patients received the standard conditioning.
Conditioning, GVHD prophylaxis and supportive care
Nineteen patients received a standard conditioning consisting of cyclophosphamide 60 
mg/kg body weight (b.w.) intravenously (i.v.) on each of two consecutive days (day - 6  
and -5 ) followed by fractionated total body irradiation (TBI) in two equal fractions on day 
-2  and -1 to a total dose of 9 Gy (13 patients) or 12 Gy ( 6  patients). In 70 patients the 
conditioning regimen was intensified with the addition of demethoxydaunorubicine 
(idarubicine) to a total dose of 42 mg/m body surface given by continuous i.v. infusion on 
days -12 and -11 followed by cyclophosphamide 60 mg/kg b.w. i.v. on days - 6  and -5  
and TBI to a total dose of 9 Gy on day -2  and -1. The donor stem cells were infused 24 
hours after completion of TBI. Donor marrow was partially depleted of T lymphocytes by
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density gradient centrifugation followed by counterflow centrifugation as previously 
described . 22,23 The median number of T cells in the marrow grafts was 0.7 (range, 0.4-1.9) 
x 106 CD3+ cells/kg b.w. All patients received prophylactic antibiotics according to 
institutional guidelines. Immunoprophylaxis after transplant consisted of cyclosporine A 
(CsA) 3 mg/kg/d by continuous i.v. infusion from days -1 to +14, followed by 2 mg/kg/d 
as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally at 
a dose of 6  mg/kg/d until 8  to10 weeks after BMT. In the absence of GVHD cyclosporine 
A was gradually tapered and discontinued at 12 weeks post-grafting. All patients were 
managed in single rooms with filtered air under positive pressure during their hospital 
stay.
GVHD
The clinical manifestations of acute GVHD were classified from grade 1 to 4 according to
24the criteria described by Glucksberg, et al. Chronic GVHD was graded as none, limited
25or extensive as described by Shulman et al.
Red blood cell phenotyping and cytogenetic analysis for the assessment of Chimerism
Chimerism in all 89 patients was investigated prospectively by cytogenetic analysis of 
blood and bone marrow and/or by red blood cell phenotyping (RCP). Cytogenetic analysis 
of unstimulated bone marrow cells (myelo-monocytic and erythrocytic progenitor cells) 
and PHA-stimulated T cells was performed routinely before BMT, 6  and 12 months after 
BMT and annually thereafter as described previously .26 ,27 The median number of bone
marrow metaphases analyzed was 31 (range, 14-34) and the median number of
28metaphases of lymphocytes was 32 (range, 8-32), allowing a sensitivity level of 10-12%. 
When the recipient and donor were of different sex, heterosome determination of 400 
interphases fluorescent in-situ hybridization: (FISH) allowed additional differentiation 
between donor and host cells. RCP was performed using a flow cytometric and/or
29 31fluorescent microscopic microsphere method as described previously. -
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Chimerism in granulocytes and PBMCs subsets using real-time PCR on single 
nucleotide polymorphisms
Eleven patients in this study were randomized between either a standard conditioning 
regimen or the intensified idarubicine containing conditioning. Five patients received the 
standard conditioning and in 6  patients the conditioning was intensified by the addition of 
idarubicine. In 10 out of 11 patients the dynamics of chimerism were sequentially 
analyzed in purified subsets of white blood cells at 1, 3, 6 , 12 months after SCT and 
annually thereafter using a newly developed real-time PCR for the detection of single 
nucleotide polymorphic alleles (SNP) and/or the SMCY gene (SMCY).
Granulocytes were separated from mononuclear cells by Ficoll-Hypaque density gradient 
centrifugation. Mononuclear cells were purified using a magnetic cell separation technique 
(MiniMacs, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
manufacturer's instructions. Mononuclear subsets were defined as follows: CD3+/CD4+ 
(Th lymphocytes), CD3+/CD8+ (Tc lymphocytes), CD45+/CD19+ (B lymphocytes), 
CD45+/CD14+ (monocytes), CD45+/CD15+ (granulocytes) and CD3-/CD56+ (NK cells). 
After direct labeling with anti CD4, anti CD8 , anti CD19 and anti CD14, Microbeads 
(Miltenyi Biotec), subsets were magnetically isolated on MiniMacs columns. Subsets with 
a purity of 93-97% were obtained. Magnetic sorted subsets were re-incubated with 
fluorescent antibodies specific for each cell population and resorted on the flow cytometer 
to obtain a purity of more than 98% in each subset. Granulocytes were isolated after lysing 
the red blood cells and after incubating with anti CD45-FITC and anti CD15-PE using 
flow-cytometric sorting (Coulter-Elite, Miami Fl, USA). CD56-PE positive NK cells were 
sorted excluding CD3-FITC positive staining cells.
Chimerism of granulocytes and PBMC subsets was determined using real-time PCR for
32the detection of single nucleotide polymorphic alleles and the SMCY gene. Briefly, 
patients and donors were screened with 7 single nucleotide polymorphism (SNP) specific 
PCR primer sets for both polymorphic alleles to identify discriminating SNPs. SMCY 
male specific PCR was included to determine chimerism in sex-mismatched patient/donor 
couples. Furthermore, it was determined whether the discriminating SNP was contained in 
a mono- or bialleleic form. DNA input of the samples was normalized to the albumin 
gene. This normalized value was used for relative quantification of discriminating SNP
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using the comparative cycle threshold method (ABI PRISM 7700 Sequence Detection 
System User Bulleting #2, PE Applied Biosystems). Determination of the percentage of 
patient (or donor) content was performed by reference to two calibration samples, i.e. 
recipient (or donor) DNA sampled prior to SCT and DNA from a Ebstein Barr Virus- 
transformed cell line containing the respective SNP.
Definitions
Relapse in this study was defined as hematological relapse and/or cytogenetic relapse 
and/or molecular relapse. Hematological relapse was defined as the reappearance of 
clinical features and laboratory findings characteristic for CML. Cytogenetic relapse was 
the recurrence of metaphases with the Philadelphia chromosome or recurrence of the 
t(9;22) detected with FISH techniques. Molecular relapse was defined as a positive PCR at 
two or more consecutive points with a tenfold increase of the Bcr/Abl fusion transcript
33measured by real-time PCR. Leukemia-free survival was defined as survival in first 
hematological, cytogenetic and if available molecular remission. Current leukemia-free 
survival is defined as remission in second hematological, cytogenetic and molecular 
remission, respectively, and remaining in that remission until the end of follow-up. For 
these patients follow-up was calculated from SCT onwards.
Follow-up
Follow-up was until death or December 1, 2001. Survival and relapse were followed to the 
time of last contact with the patient. The median survival of the 58 patients alive at end of 
follow-up was 100 months (range, 10-187).
Statistics
Fisher’s exact test and Chi square test were used for comparison of two proportions. The 
probability of relapse, leukemia-free survival, current leukemia-free survival and survival 
were calculated using the Kaplan-Meier product limit method. Differences in probabilities 
were calculated using the Wilcoxon’s log rank test. Differences in number of the 
sequentially evaluated autologous CD4+ and CD8 + cells between the patients conditioned 
with and without idarubicine, respectively, were tested using ANOVA univariate analysis.
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Results
Engraftment
Three out of 89 patients (3%) had a primary (n = 1) or secondary (n = 2) take failure. All 
three patients received idarubicine in the conditioning. These patients were retransplanted 
with an unmanipulated graft after conditioning with total lymphoid irradiation given in 
two fractions of 2 Gy on each of 3 consecutive days to a total dose of 12 Gy. One of these 
patients died of fungal infection before he was evaluable for engraftment. Another patient 
died of severe grade 4 acute GVHD three months after retransplantation. One patient 
engrafted and remained in molecular remission 110 months after the first SCT and 108 
months after retransplantation. Eighty-six patients had full engraftment without any 
secondary take failure.
GVHD
The characteristics of acute and chronic GVHD are summarized in table 1. Eighty-three 
out of 89 patients were evaluable for acute GVHD. Forty-seven out of 67 patients (70%) 
conditioned with the intensified regimen developed acute GVHD. From the 16 patients 
conditioned with the standard regimen 6  (37%) developed acute GVHD. The incidence of 
acute GVHD was significantly higher in the patients conditioned with idarubicine (P  = 
0.015, chi square). The number of patients with > grade 2 acute GVHD was comparable 
between the two conditioning regimens used (P  = 0.15), although the patients conditioned 
with anthracyclines tended to have more acute GVHD > grade 2. Severe acute GVHD 
(grade 3 and 4) occurred in only one of 67 patients (1%) conditioned with the intensified 
regimen and in 1 of 16 patients who were given the standard regimen (P  > 0.05). Twenty- 
eight out of 58 evaluable patients (48%) conditioned with idarubicine developed chronic 
GVHD. The incidence of chronic GVHD in the patients conditioned without 
anthracyclines was 5 out of 15 patients (33%) (P  = 0.3). Extensive chronic GVHD 
occurred more frequently in patients conditioned with the intensified regimen (P  = 0.16). 
However, the incidence of extensive chronic GVHD was very low in both groups (12% 
and 0%, respectively). Twenty-eight patients received therapeutic DLI after hematological 
and/or cytogenetic relapse. Eight out of 28 patients developed > grade 2 acute GVHD after
182
Immunosuppressive activity ofidarubicine in the conditioning before SCT
DLI. Six patients had chronic limited GVHD and 2 patients developed extensive chronic 
GVHD after DLI.
Table 1 Incidence of GVHD in evaluable patients conditioned with or without the addition of 
idarubicine
No. (%) of patients
Conditioned with idarubicine Conditioned without idarubicine
Acute GVHD
COIIN N = 16
Grade 0 20 (30) 10 (63)
Grade 1 33 (49) 5 (31)
Grade 2 13 (20) 0 (0)
Grade 3 0 (0) 0 (0)
Grade 4 1 (1) 1 (6)
Chronic GVHD N = 58 N=16
None 30 (52) 10 (67)
Limited 21 (36) 5 (33)
Extensive 7 (12) 0 (0)
Mortality
Thirty-one of 89 patients (35%) died after SCT. Principal causes of death were relapse (n 
= 10), GVHD-related causes (n = 6 ), infection (n = 6 ), acute respiratory distress syndrome 
(n = 2 ), veno-occlusive disease (n = 2 ), secondary malignancy (n = 2 ), failure of 
engraftment (n = 1), miscellaneous (n = 2). Nine out of 19 patients (47%) conditioned with 
the standard regimen have died. Overall mortality in the patients conditioned with 
idarubicine was 22 out of 70 (29%). Non relapse mortality was 32% in the patients 
conditioned with the standard conditioning regimen and 2 1 % in the patients conditioned 
with idarubicine. The day-100 mortality after SCT was lower in the patients conditioned
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with anthracyclines although this difference was not significant (21% versus 6 %, P  = 
0.06).
Relapse
Thirty-three out of 89 patients (37%) relapsed after SCT. The 5-year probability of relapse 
for all CML patients was 46% (95% CI, 37-55%). The 5-year probability of relapse for the 
patients conditioned with and without idarubicine, respectively, is shown in table 2. The 
patients conditioned with the intensified conditioning regimen had a significantly (P = 
0 .0 0 2 ) lower probability of relapse compared with the patients conditioned with the 
standard conditioning (Figure 1a). Before the introduction of donor lymphocyte infusions, 
two patients received chemotherapy for relapse and died subsequently. Two patients were 
retransplanted with an unmanipulated stem cell graft after conditioning with 16 mg/kg 
bodyweight busulphan alone. One of these patients died from subsequent relapse 17 
months after retransplantation. The other patient died from sepsis 2 years after second 
SCT. Twenty-eight patients received lymphocytes from the original donor as described 
before . 15,34 The median number of CD3+ lymphocytes infused in these patients was 0.7 
(range, 0.1-2.8) x 108/kg body weight. Twenty out of 28 patients (71%) responded to DLI 
and reached a second hematological, cytogenetic and molecular remission. They are 
without any sign of relapse in current leukemia-free-survival at end of follow-up. One 
patient did not respond to repetitive DLI and was retransplanted with an unmanipulated 
graft after re-conditioning with busulphan alone. After this SCT he received pre-emptive 
DLI and he remained in complete molecular remission 135 months after first SCT.
Leukemia-free survival
The 5-year probability of LFS for all CML patients was 42% (95% CI 34-50%). The 5- 
year probability of LFS for the patients conditioned with the intensified conditioning was 
significantly better compared with the probability of LFS obtained in the patients 
conditioned with the standard conditioning regimen (P  = 0.006) (table 2). The 
probabilities of LFS for the two different conditioning regimens are depicted in Figure 1b.
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Survival
Fifty-eight of 89 patients (65%) were alive at a median of 100 months (range, 10-187) 
after SCT. In the patients conditioned without idarubicine 10 out of 19 patients were alive 
at a median of 90 months (range, 23-187) after SCT. In the patients conditioned with the 
intensified regimen 48 out of 70 patients (69%) were alive at 11-185 months (median 77) 
after SCT. The 5-year probability of survival for all CML patients was 71% (95% CI 64­
78%). The 5-year probability of survival for the patients conditioned with the intensified 
regimen was not different from the 5-year probability of survival in the patients 
conditioned without idarubicine (P  = 0.14) (table 2 ).
Current leukemia-free survival
Patients who responded with a second complete hematological, cytogenetic and molecular 
remission after therapeutic donor leukocyte infusion (N=20) or after retransplantation 
(N=1) were considered as “current” leukemia-free. The 5-year probability of current LFS 
for all CML patients was 67% (95% CI 58-76%). The 5-year probability of current LFS 
was equal for the patients conditioned with and without idarubicine, respectively, (P  = 
0.17) (table 2). The probabilities of current LFS for the two different conditioning 
regimens are shown in Figure 1c.
Table 2 Five-year probability of relapse, leukemia-free survival, survival and current leukemia-free 
survival and P  values for patients conditioned with and without the addition of idarubicine
5-year probability Per cent probability (95% Confidence Interval) P-value*
Standard conditioning Intensified conditioning
Relapse 69 (45-9S) 40 (26-54) P = 0.002
Survival 68 (47-89) 72 (61-8S) P = 0.14
Leukemia-free-survival 24 (4-44) 47 (S1-6S) P = 0.006
Current leukemia-free-survival 62 (41-8S) 69 (57-81) P = 0.17
*P value of differences in treatment outcome of patients conditioned with idarubicine versus no idarubicine 
using two-tailed Log Rank test.
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Hematopoietic chimerism
Hematopoietic chimerism was assessed at regular intervals after SCT and DLI using red 
blood cell phenotyping and/or cytogenetic analysis. Concordant with the results in a 
smaller group of relapsed CML patients34 there was a good correlation between the 
increasing number of autologous red blood cells (as part of the CML-clone), the re­
appearance of Philadelphia chromosome positive metaphases, FISH-positivity for the 
Philadelphia translocation and the quantitative amount of Bcr/Abl fusion transcripts 
measured by quantitative real-time PCR. Using RCP and cytogenetics there was no 
difference observed in the number of patients with mixed chimerism at 6  and 1 2  months 
after SCT who were conditioned with or without idarubicine.
Chimerism subset analysis in 11 patients using Single Nucleotide Polymorphisms
Eleven patients were randomized between the standard conditioning regimen and the 
intensified conditioning with the addition of idarubicine. The median follow-up of the 10 
patients alive in this group was 47 months (range, 14-54) after SCT. Six (3/6 patients 
conditioned with idarubicine and 3/5 patients conditioned without idarubicine) out of 11 
patients in this group relapsed from CML.
Five out of six patients responded to therapeutic DLI with a second complete remission. 
One patient who relapsed in accelerated phase/blast crises did not respond to DLI and died 
of progressive disease.
In 11 patients (six patients conditioned with idarubicine and 5 patients conditioned 
without idarubicine) chimerism was monitored sequentially in purified subsets of PBMCs 
and granulocytes using a real-time quantitative PCR technique on SNP/SMCY. 
Chimerism was simultaneously analyzed by RCP in these patients. Using these techniques 
all donor/recipient couples could be discriminated. Eight out of 11 randomized patients 
had both, a discriminating recipient and donor marker. Two patients carried only a 
recipient specific allele and in 1 patient only a donor marker was found.
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m onths
Figure 1a. Probability of relapse in 89 
CML-CP1 patients conditioned with and 
without (standard conditioning) 
idarubicine. Marks in the relapse curves 
denote leukemia-free survivors.
m onths
Figure 1b. Probability of leukemia-free 
survival in 89 CML-CP1 patients 
conditioned with and without (standard 
conditioning) the addition of idarubicine. 
Marks in the curves indicate leukemia-free 
survivors
months
Figure 1c. Probability of current leukemia­
free survival (leukemia-free survival in first 
or second complete remission) in 89 CML- 
CP1 patients conditioned with the 
standard regimen and conditioned with the 
intensified (idarubicine) regimen. Marks in 
the curves denote current leukemia-free 
survivors.
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Chimerism in red blood cells
Four out of 11 patients had a recipient and donor marker, in 1 patient only recipient cells 
were detectable, 5 patients had only a discriminating donor marker and in one patient no 
discrimination could be made between patient and donor. In four patients with a 
discriminating recipient red cell marker all red blood cells were of donor origin at a 
median of 3.5 months after SCT. One patient (UPN 459) never reached complete red cell 
donor chimerism because of relapsing CML early after SCT and in 1 patient (UPN 470) 
autologous red blood cells had completely disappeared at 6  months but reappeared at 9 
months after SCT representing relapsing CML. In the five patients with a discriminating 
recipient RCP marker there was a good correlation (r = 0.87) between the number of 
recipient cells after SCT/DLI and the amount of normalized BCR-ABL ratio in blood and 
bone marrow .34 In Figure 2a these data are shown for a representative patient (UPN 480). 
Chimerism in granulocytes and monocytes
In the ten patients with a discriminating recipient marker all granulocytes and monocytes 
were donor derived at a median of 1 month (range, 1-3 months) after SCT. In the six 
patients who relapsed, the recipient granulocytes and monocytes started to increase at time 
of relapse suggesting they are part of the malignant CML clone. These recipient cells 
started to decrease after responding to therapeutic DLI and became undetectable at time of 
second complete remission until end of follow-up. Figure 2b shows the percentages of 
autologous granulocytes and monocytes after SCT in UPN 480.
NK cells
Recipient NK cells defined as CD3-/CD56+ cells had completely disappeared at a median 
of 6  months (range, 3-12) in the 10 patients with a discriminating recipient marker. These 
cells did not increase during relapse of CML except in one patient (UPN 480). In this 
patient CD3-/CD56+ recipient cells increased simultaneously with the red cells, 
monocytes and granulocytes during relapse of CML (Figure 2c).
B lymphocytes
During density gradient and counterflow centrifugation not only the T cells but also B 
lymphocytes are depleted from the stem cell graft. This B cell-depletion results in a 
delayed B cell reconstitution after SCT. In the first six months after SCT the number of B 
cells isolated by MACS and flow-cytometric techniques were too small to obtain
188
Immunosuppressive activity ofidarubicine in the conditioning before SCT
sufficient amounts of DNA for a reliable quantification by real-time PCR. Therefore, after 
the fifth randomized patient we stopped the isolation of CD45+/CD19+ cells from the 
peripheral blood.
Figure 2a. Sequential detection of 
recipient red blood cells combined 
with quantitative real-time PCR 
data on the BCR-ABL fusion 
transcript in blood and bone 
marrow measured from SCT 
onwards in UPN 480. The vertical 
arrow indicates donor leukocyte 
infusion.
Figure 2b. Sequential detection of 
recipient granulocytes and 
monocytes in the peripheral blood 
after SCT in UPN 480 using 
quantitative real-time PCR on 
single nucleotide polymorphisms in 
patient and donor. The vertical 
arrow indicates donor leukocyte 
infusion.
Figure 2c. Sequential detection of 
recipient peripheral blood CD4+ 
and CD8+ T-lymphocytes in UPN 
480 measured from SCT onwards 
by real-time quantitative PCR on 
single nucleotide polymorphisms. 
The vertical arrow indicates donor 
leukocyte infusion.
Days post SCT
Days post SCT
189
Chapter 8
T lymphocytes
One month after SCT the median percentages of CD3+/CD4+ and CD3+/CD8+ 
lymphocytes were 10 (range, 0.1-28%) and 20 (range, 0.2-22%), respectively, in the 5 
patients conditioned with the intensified conditioning regimen. The median percentages of 
CD3+/CD4+ and CD3+/CD8+ lymphocytes in the patients who received the standard 
conditioning were higher with a median of 95% (range, 8-100%) and a median of 30% (3­
100%), respectively, (Figure 3a, 3b). At 3 months after SCT the same pattern was 
observed; a median of 0.1% (range, 0.1-4%) (CD3+/CD8+) and a median of 0.4% (range 
0.1-4%) (CD3+/CD8+), respectively, in the patients conditioned with idarubicine and a 
median of 15% (range, 0.1-52%) (CD3+/CD4+) and 16% (range 0.2-55%) (CD3+/CD8+), 
respectively in the patients conditioned with the standard regimen. (Figure 3a, 3b). In 
univariate analysis the addition of anthracyclines contributed significantly to a lower 
number CD3+/CD4+ and CD3+/CD8+ cells at 1 and 3 months after SCT (P  = 0.02).
Six months after SCT no significant differences in the percentages of recipient T cells 
existed anymore in the patients conditioned with and without idarubicine.
In the patients conditioned with idarubicine complete donor T cell chimerism was 
observed at a median of 3 months (range, 1-12) after SCT. In the standard conditioned 
patients mixed T cell chimerism persisted longer and complete donor chimerism 
developed at a median of 12 months (range, 3-24) after SCT. In the six patients who 
relapsed with CML the percentage CD3+/CD4+ and CD3+/CD8+ recipient cells showed a 
continuous decreasing pattern independently from the increasing number of myeloid cells 
and red blood cells as part of the CML clone. In figure 2a, b, and c these observations are 
shown for UPN 480. In relapsed patients who had not been treated with idarubicine in the 
conditioning and who had still a relatively high number of autologous lymphocytes left in 
the blood at time of relapse and DLI (Figure 3a, 3b), the infusion of fresh donor 
lymphocytes resulted in a sharp decrease of autologous T cells.
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Figure 3a. Sequential detection of 
CD3+/CD4+ lymphocytes using real time 
PCR on single nucleotide 
polymorphisms in 5 CML-CP1 patients 
conditioned with the standard regimen 
(dark bars) and 5 CML-CP1 patients 
conditioned with the intensified 
(idarubicine) regimen (white bars). The 
arrows in UPN 459 and UPN 480
CL 3  
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Figure 3b. Sequential detection of 
CD3+/CD8+ lymphocytes using real time 
PCR on single nucleotide 
polymorphisms in 5 CML-CP1 patients 
conditioned with the standard regimen 
(dark bars) and 5 CML-CP1 patients 
conditioned with the intensified 
(idarubicine) regimen (white bars). The 
arrows in UPN 459 and UPN 480
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Discussion
The main obstacles after transplantation with stem cell grafts depleted of T lymphocytes 
are the higher rates of graft failure and increased relapse rate a result of decreased allo-
reactivity directed against autologous T lymphocytes and a decreased graft-versus-
8 10leukemia effect, respectively. , SCT with grafts partially depleted of T lymphocytes by 
counterflow centrifugation with a fixed number of T cells added to the stem cell graft 
results in a low incidence of graft failure in patients transplanted for standard risk acute
and chronic leukemia. Initially, relapse rates were high, however, the introduction of an
21anthracycline-intensified conditioning regimen reduced relapse significantly. This 
intensified conditioning regimen has no negative effect on transplant-related-mortality
although significantly more acute GVHD and a trend towards more chronic GVHD was
21observed in these patients.
In the current study we evaluated the significance of this intensified conditioning regimen 
in a larger population of patients with Philadelphia chromosome positive CML in first 
chronic phase. Concordant with the earlier observations, intensification of the 
conditioning resulted in a significantly lower incidence of relapse and increased LFS. 
Graft failure and acute transplant-related-mortality were low. The amount of identified 
relapses in the patients conditioned with and without anthracyclines, respectively, 
increased after the introduction of highly sensitive molecular techniques that detect 
minimal residual disease in earlier phase after SCT. Although relapse rates were high in 
this study, the majority of relapsed patients (71%) entered a second complete remission 
after therapeutic donor leukocyte infusions resulting in a 5-year probability of current LFS 
of 67%. Early detection of relapse by RCP and/or by real-time PCR for the detection of 
the BCR-ABL fusion protein may have contributed to the high number of induced
15 35secondary remissions. , The conditioning received before SCT did not influence 
response to DLI. The patients in this study treated with the intensified conditioning 
developed significantly more acute GVHD compared to the patients who received the 
standard conditioning. There was a trend for more chronic GVHD in the patients
conditioned with the intensified regimen. These observations are congruent with the data
21obtained in the study on 181 standard risk patients. From these results we may conclude
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that in CML patients the favorable responses to therapeutic DLI in the patients who 
received the standard conditioning largely compensate for the advantages of an intensified 
conditioning regimen. Higher probability of GVHD may be a significant complication 
inducing late transplant-related mortality and morbidity in patients conditioned with the 
intensified regimen and in standard conditioned patients treated with DLI for relapsed 
CML. Theoretically, pre-emptive DLI in CML patients who did not suffer from significant 
GVHD after SCT and who were conditioned with the standard regimen may be a safe and 
powerful tool to prevent relapse without the risk of severe GVHD. We already 
demonstrated the power of this strategy in patients who were treated with an intensified
17conditioning regimen prior SCT and who did not develop significant GVHD. Combining 
T cell depletion with post transplantation DLI may result in survival rates that are similar 
or even better compared to patients transplanted with non T cell-depleted grafts. The
lower incidence and the lower severity of GVHD associated with less late complications
18 20may increase survival rates and may improve quality of life in these patients. , The 
introduction of anthracyclines decreased the probability of relapse in patients transplanted
for CML as well as in patients transplanted for ALL and AML. Furthermore, the
21intensification of the conditioning contributed to increased LFS. In patients who relapsed 
from ALL and AML the success rate of therapeutic DLI is low and can not compensate
15,35for the higher relapse rates in patients conditioned with the standard regimen. , For this 
category of patients we advise an intensified conditioning regimen, followed by partially T
17cell-depleted SCT, combined with pre-emptive DLI if no significant GVHD is observed. 
We considered several potential different mechanisms underlying the increased incidence 
and severity of GVHD and the lower relapse rates in patients treated with an intensified 
conditioning. For instance, anthracyclines may eliminate more immunocompetent 
autologous T lymphocytes tipping the immunological balance towards the relatively low 
number of donor T cells given within the graft, leading to more GVHD and graft-versus-
17host-associated graft-versus-leukemia effect. Another important factor affecting GVHD 
and relapse may be the direct toxicity of anthracyclines on tissues like gastro-intestinal 
mucosa, liver and skin resulting in an increased release of cytokines from these tissues 
with additional activation of donor T lymphocytes.36 Finally, anthracyclines may 
contribute to an increased eradication of residual leukemic cells resulting in decreased
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relapse rates after SCT. In order to investigate this effect of idarubicine on donor and 
patient T cells we randomized 11 patients to be treated with or without anthracyclines in 
the conditioning regimen. Chimerism in lymphoid and myeloid subsets was investigated 
by a recently developed real-time quantitative PCR for the detection and quantification 
single nucleotide polymorphic alleles. This technique with a high discriminative capacity 
between donors and patients allows sensitive quantitative monitoring of hemopoietic 
chimerism that may reflect reactivity of donor derived immunocompetent cells against
32cells of recipient origin including the leukemic cells. In patients conditioned with the 
standard regimen recipient CD4+ and CD8+ lymphocytes were significantly higher in 
number in the first months after SCT and thereafter were longer demonstrable compared 
to the patients conditioned with the intensified regimen. The profound immunosuppressive 
activity of anthracyclines induces a rapid disappearance of autologous T lymphocytes that 
may reduce the possibility of induction of tolerance in the donor lymphocytes towards 
recipient hematopoietic cells of benign and malignant origin and thereby reducing the 
possibility of relapse in the intensified conditioned patients. These observations confirm 
the hypothesis of the increased immunosuppressive activity by anthracyclines on the 
autologous T lymphocytes after conditioning with an intensified regimen.
A continuously increasing number donor T lymphocytes or 100% donor T cell chimerism 
in all relapsing CML patients additionally demonstrates the induction and existence of 
tolerance contributing to the relapse of the original disease. These observations are
37 38concordant with results from previous studies. ’ . However, relapsing CML in the 
background of mixed T cell chimerism has also been described39,40 underlining the 
complex mechanisms that may be involved in the development of tolerance and 
subsequent relapse.41,42 Donor lymphocyte infusions in a pre-emptive or therapeutic 
setting can break this tolerance and may prevent relapse or induce a secondary graft- 
versus-leukemia effect which results in a (second) complete remission of the disease. This 
phenomenon is clearly demonstrated after therapeutic DLI and before the onset of clinical 
GVHD in two patients (UPN 459, UPN 480) resulting in a rapid disappearance of 
recipient derived T cells (fig. 3a, 3b). Together with the decreasing number of T 
lymphocytes the myeloid recipient subsets (belonging to the CML clone) disappeared and 
Bcr/Abl fusion protein in blood and bone marrow became undetectable (fig. 2a, 2b, 2c).
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Recent studies also attribute important anti-leukemic activity to activated NK cells.43-46 In 
this study we did not observe any difference in the percentages donor/recipient NK cells in 
the patients treated with and without an intensified conditioning regimen. At one month 
after SCT all NK cells were donor derived. A remarkable observation was made in UPN 
480. In this patient CD3-/CD56+ (NK) recipient cells increased simultaneously with the 
red cells, monocytes and granulocytes during relapse of the CML (fig. 2c). This 
unexpected finding may be explained by the expression of the CD56+ antigen on cells 
belonging to the CML clone. The CD56+ antigen may not be restricted exclusively to the 
NK-cells but may also be expressed on subsets of granulocytes belonging to the CML- 
clone.
We conclude that the addition of idarubicine to the conditioning regimen in patients with 
chronic myeloid leukemia transplanted with partially T cell-depleted grafts resulted in a 
significantly higher incidence of mild acute GVHD, significantly lower relapse rates and 
improved LFS. The increased disappearance of autologous T lymphocytes by the 
immunosuppressive effect of anthracyclines may play a crucial role in the prevention of 
tolerance after T cell-depleted SCT. In CML patients the higher relapse rates had no 
influence in overall survival due to the high responsiveness to therapeutic DLI. However, 
for those patients with hematological malignancies that do not respond very well to DLI 
these observations may be very important. With respect to this last category of patients the
17 21results of our previous studies , combined with this study warrant the use of an 
idarubicine intensified conditioning regimen preceding T cell-depleted allogeneic SCT if 
necessary followed by pre-emptive DLI. The real-time PCR technique on single 
nucleotide polymorphisms provides a fast, easy and reliable tool to investigate chimerism 
in any subset of nucleated blood cells.
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Chapter 9
Summary
Allogeneic stem cell transplantation has been accepted world wide as an effective post 
consolidation therapy in patients treated with poly-chemotherapy for acute leukemias and 
lymphoblastic lymphoma. In patients suffering from chronic myeloid leukemia, 
myelodysplastic syndrome, non Hodgkin’s lymphoma, chronic lymphoid leukemia and 
probably also multiple myeloma, allo-SCT is the only available curative option.
Chapter one of this thesis describes the general principles of allogeneic stem cell 
transplantation (SCT), graft-versus-host disease (GVHD), graft-versus-leukemia (GVL) 
effect, T cell depletion, the use of therapeutic and pre-emptive donor leukocyte infusions 
and the significance of chimerism studies representing the balance between donor and 
patient hemopoiesis.
A significant problem after SCT is the development of acute and chronic GVHD caused 
by immunocompetent allo-reactive donor derived T lymphocytes directed against 
noninvolved recipient tissues like skin liver, gut and lungs. Acute and chronic GVHD is 
the major cause of transplant related morbidity and mortality. Complete or partial removal 
of immunocompetent T cells from the graft (T cell depletion) is an effective method to 
prevent GVHD. However, together with the reduced GVHD the GVL effect is also 
reduced resulting in an increased probability of relapse from the original disease. 
Especially in CML, the discovery of the immunological capacity of freshly infused donor 
leukocytes to induce a strong graft-versus-leukemia effect in patients who had recurrent 
disease after transplantation was a major breakthrough in the treatment of relapsed 
leukemia. Immunotherapy with donor leukocytes used in a therapeutic or pre-emptive 
setting shed a new light on T cell-depleted SCT. The presence of residual autologous 
hemopoietic cells after SCT is called mixed chimerism. Major goal after SCT is the 
complete eradication of all autologous benign and malignant blood cells and the 
development of complete donor chimerism. Residual malignant cells may cause a relapse 
of the original disease. Residual benign patient cells that survive the conditioning may 
play an important role in the induction of tolerance between the donor immune system and 
malignant patient cells resulting in increased probabilities of relapse. The long term 
clinical significance of mixed chimerism after SCT remains controversial. Some studies
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described high relapse rates in patients with mixed chimerism after SCT while other 
studies could not demonstrate this correlation. Sequential quantitative monitoring of 
chimerism in the different subsets of white blood cells using sensitive molecular 
techniques like real time quantitative polymerase chain reaction (PCR) detection of single 
nucleotide polymorphisms (SNP) together with quantitative determination of minimal 
residual disease is essential to get more information about the dynamics between patient 
and donor represented by mixed chimerism. The decision to treat patients with additional 
immunotherapy and the timing of this therapy may also depend on the results obtained by 
sensitive evaluation of the chimeric status in these patients.
From 1981 onwards in Nijmegen all stem cell grafts have been partially depleted of T 
lymphocytes by density gradient and counterflow centrifugation in order to find a balance 
between GVHD and GVL. The addition of a relatively fixed number of T cells to the stem 
cell grafts reduced the incidence and severity of GVHD, however, relapse rates remained 
high compared with results of stem cell transplantation with unmanipulated grafts. On the 
other hand these results stimulated us to develop and apply new methods to increase the 
GVL effect without aggravating GVHD and improve outcome of T cell-depleted SCT.
In an attempt to reduce the probability of relapse after T cell-depleted allo SCT the 
conditioning regimen was intensified by adding anthracyclines to the conventional 
cyclophosphamide and total body irradiation (TBI) combination.
Chapter 2 describes 116 standard risk leukemia patients conditioned with an regimen 
intensified by the addition of anthracyclines. Outcome in these patients was 
retrospectively compared with 65 patients treated with the standard cyclophosphamide / 
TBI conditioning. Patients were transplanted with HLA-identical siblings and all stem cell 
grafts were depleted of T cells using density gradient and counterflow centrifugation. In 
multivariate analysis the addition of anthracyclines to the conditioning regimen correlated 
significantly with more acute GVHD > grade 2 and a trend existed towards more chronic 
GVHD. The risk for chronic GVHD increased with a higher number of T cells in the graft. 
The addition of anthracyclines resulted in significantly lower relapse rates and 
consequently increased probabilities of leukemia-free and overall survival. In multivariate 
analysis the addition of anthracyclines was the only factor contributing to a lower
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probability of relapse. The addition of anthracyclines correlated with a lower number of 
mixed chimeras in patients at 6 and 12 months after SCT. Mixed chimerism at 6 months 
after transplantation did not significantly correlate with a higher incidence of relapse in 
further follow-up, however, mixed chimerism at 12 months after SCT was significantly 
associated with higher relapse rate. In this study it was hypothesized that an additional 
immunosuppressive activity caused by anthracyclines may have resulted in an increased 
elimination of autologous T lymphocytes. This effect may have tipped the immunological 
balance to the relatively low number of donor T lymphocytes given within the graft, 
resulting in more GVHD, simultaneously increasing the GVHD associated GVL activity 
and consequently, favorable outcome in patients conditioned with anthracycline- 
intensified conditioning regimens.
Sequential monitoring of chimerism in blood and bone marrow for many years resulted in 
a remarkable number of patients with persisting mixed chimerism after partially T cell- 
depleted SCT. These patients are described in chapter 3. Purpose of this study was the 
long term follow-up of patients with mixed chimerism and definition of patterns of the 
chimerism in the various subsets of PBMCs, granulocytes and red blood cells using a PCR 
technique on short tandem repeats (STR) and red blood cell phenotyping (RCP). Using 
cytogenetic analysis and RCP 19 patients with long term persisting mixed chimerism 
(MC) were identified among 231 patients transplanted with partially T cell-depleted stem 
cell grafts from HLA-identical siblings. Persisting MC was defined as MC for more than 2 
years in patients without any evidence of relapse. Median leukemia-free survival in these 
patients was 150 (range, 50-218) months. The majority of patients with persisting MC had 
lymphoid malignancies, they were conditioned with a less intensive conditioning regimen 
and had little or no GVHD after transplantation. The different dynamic patterns of mixed 
chimerism were demonstrated either by a very slowly transient mixed chimerism, an 
almost completely autologous repopulation or a relatively stable mixed chimerism in 
different subgroups, respectively. Using a PCR-STR technique on CD3+/CD4+ (T4 
lymphocytes), CD3+/CD8+ (T8 lymphocytes), CD45+/CD19+ (B lymphocytes), 
CD45+/CD14+ (monocytes), CD45+/CD15+ (granulocytes) and CD3-/CD56+ (NK cells) 
marked individual differences in the hemopoietic cells involved in the mixed chimerism
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were observed. These intra-individual differences in the subsets of white blood cells 
correlated well with RCP and cytogenetic data with exception of the NK cells. Mixed 
chimerism did not correlate with relapse in further follow-up despite the less intensive 
conditioning regimens and the low incidence of GVHD in the majority of these patients. 
The relationship between the incidence of mixed chimerism and the type of leukemia 
disappeared after the introduction of anthracyclines to the conditioning regimen.
In patients with Philadelphia chromosome-positive CML, the reciprocal translocation 
between chromosome 9 (regulatory domains of the BCR-gene) and chromosome 22 
(tyrosine kinase domains of the ABL gene) results in the generation of a fusion gene that 
leads to the expression of chimeric Bcr/Abl messenger RNA and the production of a 
functional Bcr/Abl fusion protein. The chimeric Bcr/Abl messenger RNA is an attractive 
target for monitoring minimal residual disease by reverse transcriptase (RT)-PCR assays. 
Before a reliable and sensitive quantitative PCR for the detection of the Bcr/Abl fusion 
transcript became available, we were already able to determine residual disease or early 
relapse from CML in a very sensitive way using RCP. This technique was based on the 
observation that increasing numbers of patient red blood cells after transplantation almost 
always belonged to the original CML clone. Recently we developed a real-time 
quantitative RT-PCR for the detection of the Bcr/Abl fusion transcript in CML patients 
which now has replaced RCP.
Chapter 4 describes fifteen consecutive patients with Philadelphia chromosome (Ph)- 
positive chronic myeloid leukemia who relapsed from partially T cell-depleted SCT and 
who were successfully treated with donor leukocyte infusions (DLI). Chimerism was 
analyzed using red blood cell phenotyping (RCP), and the results were compared with 
cytogenetic analysis and outcome of qualitative and quantitative PCR for breakpoint 
molecules. In all patients, an increase of autologous red cells and/or a decrease in donor 
red cells indicated relapse. A GVL response represented by an increase of donor red cells 
and/or a decrease of autologous red cells was observed at a median of 12 (range, 4-20) 
weeks after DLI. At 6 and 12 months after DLI, complete donor chimerism was found in 
11 and 15 patients, respectively, and all patients were in cytogenetic remission. A high 
percentage of autologous red cells at the time of DLI predicted pancytopenia. During
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relapse and after DLI, the percentage of autologous red cells correlated strongly with the 
reappearance and disappearance of Ph-positive metaphases. The same observations were 
made for the correlation between the percentage of autologous red cells and 
positivity/negativity in PCR for Bcr-Abl breakpoint molecules. A normalized Bcr/Abl 
dose of greater than 10-3 in real-time quantitative PCR correlated well with relapse and the 
presence of autologous blood cells. From this study, it was concluded that, in patients 
transplanted for CML, RCP was a sensitive method for the detection of the onset of CML 
relapse. RCP offered the opportunity to treat patients in an early phase during relapse with 
adoptive immunotherapy (DLI) which has contributed to the success of DLI in our hands. 
RCP could also be used to evaluate accurately the response of the patient to DLI, and to 
predict the development of aplasia after DLI.
Not in all patients who relapse from hematological malignancies a GVL effect could be 
obtained by infusion of lymphocytes from the original donor.
In chapter 5 the factors which were associated with remission after DLI were analyzed in 
26 patients who relapsed after T cell-depleted SCT. Remission was achieved in 11 of 15 
patients (73%) treated for relapsed CML and in one of 11 patients (9%) treated for 
relapsed AML, ALL or RAEB-t. Patients who had < 40% of T lymphocytes from donor 
origin at time of DLI attained significantly less complete remissions compared with 
patients who had more > 40% donor lymphocytes at DLI. Another significant factor 
correlating with the attainment of complete remission was the interval between SCT and 
DLI. Two of 13 patients (15%) with an interval of < 18 months between SCT and first 
DLI entered remission compared with 10 of 13 patients (77%) with an interval of > 18 
months. Multivariate analysis demonstrated that indication for transplantation (CML 
versus AML/ALL and RAEB-t) and the percentage T lymphocytes from donor origin (< 
40 versus > 40) were significantly correlated with remission. The occurrence of GVHD 
post DLI was also highly associated with achievement of remission. Best results were 
obtained in patients treated for relapsed CML who had more than 40% of T lymphocytes 
from donor origin. These data also demonstrate the need for sensitive quantitative 
detection techniques to investigate chimerism and residual disease, respectively.
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The positive experience with therapeutic DLI in a large number of patients combined with 
experimental data published in animal studies about delayed add back of donor T 
lymphocytes and spleen cells was the motive behind the design of a prospective trial in 
which high risk patients were treated with pre-emptive DLI in order to reduce relapse rates 
after T cell depleted SCT.
In Chapter 6 a prospective study is described analyzing the influence of pre-emptive DLI 
on relapse, disease-free survival, survival and chimerism in 82 patients who were at high 
risk for relapse and who did not suffer from significant acute nor chronic GVHD after 
partially T cell-depleted SCT with stem cell grafts from HLA-identical siblings. 
Indications for transplantations were AML, ALL, CML, RAEB, RAEB-t and MM. 
Patients without significant acute (>grade 1) and/or chronic GVHD who had stopped all 
immunosuppressive therapy were scheduled to be treated with DLI (35 patients) and 31 
actually received DLI. Patients who developed acute GVHD > grade 1 and/or chronic 
GVHD were not scheduled to receive DLI and served as a comparison group (47 patients). 
The median interval between SCT and DLI was 22 weeks. GVHD in the first six patients 
who received 0.7 x 10 CD3+ cells/kg body weight (b.w.) was more frequent and more 
severe than had been anticipated. Consequently, it was decided to reduce the CD3+ 
content of the mononuclear cells infused to 0.1 x 10 /kg b.w. The next 25 patients who 
received the lower dose CD3+ cells in the DLI developed only mild GVHD, which did not 
contribute to severe morbidity or mortality. Patients in the DLI group needed more time to 
establish complete donor chimerism confirmed by a higher number of mixed chimeras at 6 
months after SCT. The projected 3-year probability of disease-free survival was 77% for 
the 35 patients intended to be treated with DLI which was significantly higher compared 
with 45% for the patients in the control group. The increased disease-free survival was 
caused by significantly lower relapse rates in the DLI group (18% versus 44%). This was 
the first study that demonstrated that pre-emptive DLI in patients who had no significant 
GVHD after partially T cell-depleted SCT and who were not on immunosuppressive 
therapy is feasible and resulted in low relapse rates in patients who were at high risk for 
relapse.
207
Chapter 9
Follow-up of chimerism after allo-SCT is an essential method in monitoring the dynamics 
of the patient and donor hemopoietic system. Accurate quantitative analysis of chimerism 
kinetics would permit early differentiation between absence of engraftment and a delay in 
engraftment as well as early detection of patients with high risk of relapse or those liable 
to respond to therapeutic DLI after relapse. Moreover, new therapeutic approaches such as 
pre-emptive DLI in patients after T-cell depleted SCT and DLI after non myeloablative 
stem cell transplantation of unmanipulated grafts are dependent on accurate monitoring of 
early chimerism patterns to set up these additional therapeutic interventions. Chimerism 
studies using conventional techniques like cytogenetics, FISH, RCP, RFLPs, VNTRs and 
STRs all have their limitations. The techniques are either not sensitive enough, or they can 
only be applied if donor and patient are of different sex, or they supply information about 
one cell type only, or quantification is difficult as a consequence of PCR competition 
biases.
Chapter 7 describes a completely new technique to investigate chimerism after SCT using 
a real-time PCR method with single nucleotide polymorphisms (SNP) as discriminating 
markers. Allele specific PCR of seven SNP resulted in specific markers for donor or 
recipient in 97% of HLA-identical sibling pairs. Both, recipient and donor derived 
hemopoietic cells can be simultaneously analyzed in 67% sibling pairs. With the addition 
of three additional SNP-PCR which are currently being developed the discriminative 
capacity may be increased to approximately 99%. Serial dilution of SNP-positive DNA 
into either SNP-negative DNA or water revealed a detection limit of 0.1-0.01% depending 
on the amount of input DNA and start Ct of the used SNP-PCR. Real-time SNP-PCR 
appears to be a valuable diagnostic tool for monitoring engraftment after SCT and it may 
help to identify those patients with a high risk of relapse who are candidate for 
immunomodulation therapeutic strategies such as pre-emptive and therapeutic DLI, whose 
effects also require monitoring by reliable and sensitive quantitative analysis of 
chimerism.
In the previous studies several potential different mechanisms were considered underlying 
the increased incidence and severity of GVHD, decreased number of patients with mixed 
chimerism and the lower relapse rates in patients treated with a conditioning regimen
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intensified by the addition of anthracyclines. For instance, anthracyclines may contribute 
to an increased eradication of the tumor burden and may also eliminate more 
immunocompetent autologous T lymphocytes tipping the immunological balance towards 
the relatively low number of donor T cells given within the graft, leading to more GVHD, 
earlier complete donor chimerism, and an increased GVL effect.
In chapter 8 a large cohort of patients transplanted with partially T cell-depleted grafts for 
CML in first chronic phase between 1984 and 2000 was evaluated. Nineteen patients 
received a standard conditioning with cyclophosphamide and TBI and in 70 patients the 
conditioning regimen was intensified by the addition of idarubicine. Concordant with the 
observations in a smaller cohort of CML patients, the introduction of idarubicine resulted 
in more acute GVHD, did not influence transplant related morbidity and mortality, and 
resulted in significantly lower relapse rates and increased leukemia-free survival. Current 
leukemia-free survival defined as survival in first or second (after DLI) complete 
remission was identical for both conditioning regimens as result of the successful 
treatment with therapeutic DLI in relapsed patients. Eleven patients were randomized 
prospectively between the standard and the intensified conditioning. In 10 out of 11 
patients chimerism was monitored frequently in highly purified subsets of PBMCs and 
granulocytes using real-time quantitative PCR for the detection of recipient/donor-specific 
single nucleotide polymorphic alleles and/or the male-specific SMCY gene. Patients 
conditioned with idarubicine had significantly lower percentages of recipient T cells at 1 
and 3 months after SCT and developed earlier (median, 3 versus 12 months) complete 
donor chimerism in the T lymphoid (CD3+/CD4+ and CD3+/CD8+ ) subsets compared to 
the patients conditioned with the standard regimen. The addition of idarubicine in the 
conditioning had no influence on the time to reach complete donor chimerism in the 
investigated non-T lymphoid subsets of peripheral blood cells.
The addition of idarubicine to the conditioning regimen in the setting of allogeneic 
partially T cell-depleted SCT resulted in a rapid clearance of autologous T lymphocytes. 
The tipping of the donor-patient immunological balance towards the donor immune 
system may explain the increased probability of acute GVHD and GVL, and prevention of 
tolerance, respectively, resulting in increased disease-free survival with preservation of 
quality of life after T cell-depleted SCT.
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General Conclusions
Cure of hematological malignancies by allogeneic stem cell transplantation is 
predominantly complicated by immunocompetent donor-derived T lymphocytes 
recognizing differences in major and/or minor histocompatibility antigens resulting in 
graft-versus-host disease and consequently, increased transplant related mortality. One of 
the most effective steps to prevent GVHD is depletion of the stem cell grafts from T 
lymphocytes. However, the reduction of allo-reactive donor T cells in the stem cell graft is 
inextricably bound up with reduction of the GVL effect resulting in higher relapse rates 
from the original disease. The introduction of pre-emptive and adoptive 
immunotherapeutic strategies before and after transplantation opens new perspectives for 
T cell depletion.
An intensified conditioning regimen resulted in reduced relapse rates and increased 
leukemia-free survival after partially T cell-depleted SCT. Transplant related morbidity 
and mortality did not increase despite the higher intensity of the preparative regimen. 
Using chimerism studies we demonstrated the immunosuppressive effects on autologous T 
lymphocytes induced by anthracyclines which may be one of the explanations for the 
lower relapse rates. Treatment of relapsed hematological malignancies by DLI, especially 
in CML increased current leukemia-free and overall survival. Pre-emptive DLI in patients 
at high risk for relapse after SCT turned out to be feasible and resulted in reduced relapse 
rates. These promising results were an incentive to start a large randomized prospective 
multicenter trial in the Netherlands. The development and application of more specific and 
sensitive techniques to investigate chimerism like the PCR-SNP technique provides more 
insight into the dynamics of hemopoietic cells after allogeneic stem cell transplantation.
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Allogene stamceltransplantatie (SCT) neemt een belangrijke plaats in als 
consolidatietherapie bij patiënten die door middel van combinatie-chemotherapie in 
remissie zijn gebracht van een acute myeloide leukemie (AML), acute lymfatische 
leukemie (ALL), lymfoblastair non Hodgkin lymfoom (NHL) of myelodysplastisch 
syndroom (MDS). Voor patiënten lijdend aan kwaadaardige hematologische ziekten als 
chronische myeloide leukemie (CML), chronische lymfatische leukemie (CLL), laaggradig 
NHL en wellicht ook multiple myeloma (MM) is allogene SCT momenteel de enige 
behandeling met kans op definitieve genezing.
Hoofdstuk 1 van dit proefschrift beschrijft de principes van een SCT. Er wordt dieper 
ingegaan op het verschijnsel graft-versus-host ziekte (GVHD) en graft-versus-leukemia 
reactie (GVL). T-cel depletie als techniek om GVHD te voorkomen wordt uitgelegd en 
ook de principes van profylactische en therapeutische donorlymfocyten infusies (DLI) ter 
preventie en behandeling van een recidief van de hematologische maligniteit worden 
besproken. Dit hoofdstuk gaat tenslotte in op de betekenis van chimerisme studies voor de 
prognose van patiënten na SCT.
Een van de belangrijkste complicatie na SCT is de acute en later ook de chronische 
GVHD. Dit fenomeen wordt veroorzaakt door allo-reactieve T-lymfocyten afkomstig van 
de stamceldonor die gezonde weefsels van de patiënt als huid, darmen, lever en longen als 
vreemd herkennen en een immuunreactie tegen deze weefsels in gang zetten. Het beeld 
kan gepaard gaan met ontstekingsreacties in de huid tot en met blaarvorming toe en in de 
chronische fase overgaand in een zeer droge of zelfs pantserhuid, ernstige diarree waarbij 
liters vocht per dag kunnen worden verloren, leverontsteking met irreversibele schade aan 
de kleine galwegen en een ontstekingsreactie in de longen uiteindelijk leidend tot 
verbindweefseling van de gehele long. Acute en chronische GVHD zijn de belangrijkste 
oorzaken van morbiditeit en mortaliteit na SCT. De kans op GVHD kan belangrijk 
verminderd worden door een groot deel van de T-lymfocyten uit het toe te dienen 
stamceltransplantaat te verwijderen (T-cel depletie). Nadeel van T-cel depletie is dat naast 
GVHD ook het GVL effect wordt onderdrukt waardoor de kans op een recidief van de 
oorspronkelijke ziekte toeneemt. De ontdekking dat bij patiënten met een recidief
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leukemie (dit geldt met name voor CML patiënten) een infusie met lymfocyten van de 
oorspronkelijke donor opnieuw of alsnog een GVL reactie in gang kan zetten betekende 
een grote doorbraak in de behandeling van deze groep patiënten waarvoor normaliter geen 
therapeutische opties meer voorhanden waren. Immunotherapie met DLI in therapeutische 
maar ook in de profylactische setting heeft in de laatste jaren het principe van de T-cel 
depletie in een nieuw perspectief geplaatst. Minder GVHD gerelateerde sterfte en ziekte 
door het toepassen van T-cel depletie in combinatie met immuuntherapie door middel van 
DLI zou theoretisch moeten leiden tot betere resultaten dan wanneer patiënten behandeld 
worden met ongedepleteerde stamceltransplantaten. Het na de transplantatie tegelijkertijd 
naast elkaar voorkomen van zowel bloedcellen van patiënt-origine als nieuwe van de 
donor afkomstige bloedcellen wordt gemengd of mixed chimerisme genoemd. Het 
uiteindelijke doel van een SCT is echter het volledig uitroeien van alle van de patiënt 
afkomstige goedaardige en kwaadaardige bloedcellen en het bereiken van volledige van de 
donor afkomstige bloedaanmaak. Dit laatste wordt aangeduid met compleet donor 
chimerisme. Achtergebleven van de patiënt afkomstige kwaadaardige cellen zijn immers 
in staat om opnieuw uit te groeien tot uiteindelijk een recidief van de ziekte maar ook de 
aanwezigheid van gezonde bloedvormende cellen die de conditionering hebben overleefd 
kan een negatief effect hebben op het beloop na transplantatie. De na de transplantatie nog 
aanwezige autologe niet kwaadaardige bloedcellen lijken een rol te spelen in het ontstaan 
van tolerantie van de donorcellen jegens patiëntcellen waardoor er een verminderd GVL 
effect plaats vindt met een grotere kans op terugkeer van de oorspronkelijke ziekte. De 
betekenis van blijvend gemengd chimerisme na transplantatie is nog steeds niet volledig 
duidelijk en blijft een punt van discussie. In sommige studies wordt gemengd chimerisme 
in verband gebracht met een verhoogd recidief risico terwijl andere studies dit verband 
niet kunnen aantonen. Om een goed antwoord op deze vraag te kunnen geven en tevens 
inzicht te krijgen in de dynamiek van het chimerisme na SCT is het essentieel het 
chimerisme tegelijkertijd en verspreid over een langere periode in de diverse soorten witte 
bloedcellen afzonderlijk te kunnen bepalen met behulp van gevoelige en betrouwbare 
technieken zoals de real-time polymerase ketting reactie (PCR) van single nucleotide 
polymorfismes (SNP). Parallel hieraan is het ook essentieel minimaal residuale ziekte door 
middel van dezelfde PCR technieken vroegtijdig te kunnen detecteren. De beslissing om
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patiënten na transplantatie te behandelen met aanvullende immunotherapie en de timing 
van deze behandeling wordt mede gebaseerd op resultaten van het chimerisme onderzoek. 
Dit laatste onderschrijft nogmaals het belang van een betrouwbare, gevoelige en efficiënt 
uit te voeren techniek ter bepaling van het chimerisme na SCT.
In Nijmegen zijn vanaf de start van het transplantatieprogramma in 1981 alle 
stamceltransplantaten partieel T-cel gedepleteerd middels de counterflow centrifugatie 
techniek. Door middel van een gereduceerd maar wel vaststaand aantal T-cellen in het 
transplantaat werd getracht een goede balans tussen GVHD en GVL te bewerkstelligen. 
Belangrijkste probleem bleef echter de verhoogde kans op terugkeer van de 
oorspronkelijke ziekte. Tegelijkertijd vormde dit ook een uitdaging om met behulp van 
nieuwe inzichten en strategieën te proberen de resultaten van T-cel depletie te verbeteren.
In een poging de kans op recidief van de ziekte na T-cel gedepleteerde SCT te 
verminderen werd de gebruikelijke conditionering bestaande uit cyclofosfamide en totale 
lichaamsbestraling (TBI) geïntensiveerd door het toevoegen van anthracyclines.
In hoofdstuk 2 worden 116 patiënten beschreven die door middel van een met 
anthracyclines geïntensiveerd conditioneringsregime werden behandeld. Deze groep 
patiënten werd vervolgens retrospectief vergeleken met 65 patiënten die op “standaard” 
wijze (cyclofosfamide en TBI) waren geconditioneerd. Donors waren HLA-identieke 
broers of zussen en alle stamceltransplantaten werden door middel van dichtheids gradient 
en counterflow centrifugatie T-cel gedepleteerd. Multivariate analyse toonde een 
significante correlatie tussen het gebruik van anthracyclines in de conditionering en het 
ontstaan van acute GVHD > graad 2. Ook bestond een trend in de richting van meer 
chronische GVHD na het toevoegen van anthracyclines aan de conditionering. 
Tegelijkertijd nam ook de kans op chronische GVHD toe bij hogere aantallen T-cellen in 
het stamceltransplantaat. Toevoegen van anthracyclines resulteerde in een significant 
lagere recidiefkans en als gevolg hiervan een betere ziektevrije en totale overleving. In de 
multivariate analyse kwam het gebruik van anthracyclines als enige factor naar voren die 
significant bij droeg aan het verminderen van de recidiefkans. Zowel na 6 als na 12 
maanden na transplantatie was het aantal patiënten met mixed chimerisme significant 
lager in de groep behandeld met anthracyclines. De aanwezigheid van mixed chimerisme
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tot en met 6 maanden na SCT had geen invloed op de recidiefkans, dit in tegenstelling tot 
mixed chimerisme aanwezig na 12 maanden na transplantatie waarbij de recidiefkans wel 
duidelijk verhoogd was.
Een van de mogelijke verklaringen voor het gunstige effect veroorzaakt door 
anthracyclines is een sterkere afweer onderdrukkende werking zich uitend in een 
toegenomen verwijdering van eigen T-lymfocyten. Het immunologisch accent na 
transplantatie komt hierdoor meer te liggen bij de donor T-lymfocyten afkomstig uit het 
transplantaat dan bij de nog aanwezige van de patiënt afkomstige T-cellen met als 
resultaat meer GVHD en graft-versus-host gerelateerde GVL reactie.
Door bij elke patiënt waarbij de bloedcellen van die van de donor zijn te onderscheiden 
met behulp van een discriminerende patiënt en/of donor merker frequent na transplantatie 
chimerisme onderzoek uit te voeren werd in de Nijmeegse populatie een opvallend aantal 
patiënten gevonden die langdurig en stabiel gemengd chimerisme vertoonden. Deze 
patiënten worden beschreven in hoofdstuk 3. Doel van deze studie was het in de tijd 
volgen van patiënten die na de SCT blijvend gemengd chimera blijven of dit geleidelijk- 
aan worden. Specifiek is onderzocht welke cellijnen betrokken waren in het gemengd 
chimerisme (MC) waarbij gebruik werd gemaakt van een PCR techniek op short tandem 
repeats (STR) in combinatie met rode bloedceltypering (Red Cell Phenotyping; RCP) als 
technieken om donor en patiënt zo gevoelig mogelijk van elkaar te kunnen onderscheiden. 
In een populatie van 231 patiënten getransplanteerd met partieel T-cel gedepleteerd 
beenmerg werden gebruikmakend van cytogenetica en RCP 19 patiënten gevonden die 
langdurig MC vertoonden. Langdurig of persisterend MC werd gedefinieerd als het na 
transplantatie langer dan 2 jaar tegelijkertijd aanwezig zijn van zowel patiënten als donor 
bloedcellen in beenmerg en/of bloed bij een patiënt zonder tekenen van een recidief van 
de oorspronkelijke ziekte. De mediane ziektevrije overleving na transplantatie van deze 
groep patiënten was 150 (interval, 50-218) maanden. Mixed chimerisme werd vooral 
aangetroffen in patiënten getransplanteerd voor lymfatische maligniteiten die waren 
voorbehandeld met een minder intensief conditioneringregime en geen of weinig GVHD 
hadden doorgemaakt na de transplantatie. De dynamiek van het MC in deze patiënten liet 
zich vertalen in een aantal patronen. Een groep patiënten had een zeer langzaam
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voorbijgaand MC dat uiteindelijk na lange tijd toch resulteerde in compleet donor 
chimerisme, een tweede groep patiënten toonde een relatief stabiel blijvend gemengd 
chimerisme en een derde groep werd na de transplantatie gekenmerkt werd door een grote 
mate van autologe hergroei in het beenmerg. Gebruikmakend van de PCR-STR techniek 
werden in de CD3+/CD4+ (T4-lymfocyten), CD3+/CD8+ (T8-lymfocyten), 
CD45+/CD19+ (B-lymfocyten), CD45+/CD14+ (monocyten), CD45+/CD15+ 
(granulocyten) and CD3-/CD56+ (NK cellen) celpopulaties grote individuele verschillen 
gevonden betreffende de diverse subgroepen betrokken in het aanwezige MC. De duidelijk 
aanwezige intra-individuele verschillen binnen de verschillende witte bloedcelpopulaties 
correleerden goed met de resultaten verkregen via RCP en cytogenetica. Uitzondering 
vormden de NK cellen waar geen correlatie kon worden aangetoond. Langdurig gemengd 
chimerisme leidde niet tot een hogere recidiefkans in de verdere follow-up ondanks dat de 
meerderheid van deze patiënten met minder intensieve conditioneringregimes waren 
voorbehandeld en relatief weinig GVHD doormaakten na de SCT. De relatie tussen het 
voorkomen van MC en het hebben van een kwaadaardige ziekte van lymfatische origine 
verdween na het toevoegen van extra anthracyclines aan de “standaard” conditionering.
In patiënten met een Philadelphia chromosoom positieve CML resulteert de wederzijdse 
translocatie tussen chromosoom 9 (regulerend domein van het Bcr-gen) en chromosoom 
22 (tyrosine kinase domein van het Abl-gen) in een fusie-gen dat uiteindelijk aanleiding 
geeft tot de expressie van chimeer messenger RNA en de productie van een nieuw 
functioneel Bcr/Abl fusie eiwit. Gebruik makend van reverse transcriptase (RT)-PCR 
technieken om het chimere Bcr/Abl messenger RNA gevoelig aan te tonen is deze 
techniek bij uitstek geschikt om minimaal residuele ziekte aan te tonen.
Voordat er een betrouwbare en gevoelige PCR beschikbaar was om het Bcr/Abl 
fusietranscript aan te tonen werd in Nijmegen gebruik gemaakt van RCP om al in een 
vroeg stadium een recidief CML aan te kunnen tonen. Deze techniek ontleent zijn 
betekenis aan het feit dat na een allo-SCT voor CML, een stijgend aantal autologe rode 
bloedcellen vrijwel altijd tegelijkertijd gepaard ging met een recidief van de 
oorspronkelijke ziekte. Een stijging na voorafgaande daling of na een tevoren volledig 
verdwijnen van de autologe rode bloedcel aanmaak duidt veelal op hergroei van
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functionele erythrocyten vanuit de kwaadaardige kloon die de conditionering heeft 
overleefd. Deze van de patiënt afkomstige rode bloedcellen zijn gevoelig kwantitatief aan 
te tonen middels RCP. Recentelijk is deze lang gebruikte methode vervangen door een 
kwantitatieve real-time PCR op het Bcr/Abl fusietranscript die in het Nijmeegse 
hematologisch laboratorium is ontwikkeld en waarmee de ziekte gevoelig rechtstreeks kan 
worden aangetoond.
In hoofdstuk 4 worden 15 patiënten beschreven met een recidief Philadelphia 
chromosoom positieve CML na T-cel gedepleteerde allo-SCT die vervolgens succesvol 
werden behandeld met lymfocyten van de oorspronkelijke donor. Chimerisme in deze 
patiënten werd vanaf transplantatie gevolgd middels RCP en de uitkomsten van deze 
onderzoeken zijn vergeleken met cytogenetische data en de resultaten van kwalitatief PCR 
onderzoek op het Bcr/Abl fusie transcript. In alle patiënten werd een hematologisch en/of 
cytogenetisch recidief voorafgegaan door een procentuele stijging van het aantal autologe 
rode bloedcellen en/of daling van het aantal van de donor afkomstige rode bloedcellen. Na 
immuuntherapie met DLI werd er een GVL reactie waargenomen na mediaan 12 (interval, 
4-20) weken. Deze reactie werd gekarakteriseerd door het hernieuwd stijgen van het 
percentage donor rode bloedcellen en dalen van het percentage autologe erythrocyten in 
het bloed van de patiënt. Op 6 en 12 maanden na DLI werden respectievelijk 11 en 15 
patiënten compleet donor chimera en bleken alle patiënten hematologisch en cytogenetisch 
in remissie. Een hoog percentage autologe rode bloedcellen aanwezig op het moment van 
DLI had een sterk voorspellende waarde met betrekking tot het ontstaan van een 
pancytopenie na het op gang komen van een GVL respons. Ook bestond tijdens het 
ontstaan van het recidief en tijdens de GVL reactie na DLI een sterke correlatie tussen het 
percentage autologe rode bloedcellen en het aantal Philadelphia chromosoom positieve 
cellen (metafasen) gevonden middels cytogenetisch onderzoek. Tegelijkertijd bestond een 
significant verband tussen het percentage autologe rode bloedcellen en het positief dan wel 
negatief zijn van het Bcr/Abl signaal in de PCR reactie. Real-time kwantitatieve PCR op 
het Bcr/Abl fusietranscript liet zien dat een genormaliseerde Bcr/Abl dosis van groter dan 
10- goed correleerde met de aanwezigheid van autologe rode bloedcellen en een 
cytogenetisch en/of hematologisch recidief CML. In deze studie bleek RCP een goede 
techniek om een vroeg recidief CML gevoelig aan te kunnen tonen. Gebruik makend van
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RCP bleek het mogelijk om patiënten al in een vroege fase van het recidief te behandelen 
middels DLI hetgeen een belangrijke bijdrage heeft geleverd aan het succes van deze 
vorm van immunotherapie. RCP bleek tegelijkertijd een goede techniek om op gevoelige 
wijze de reactie van de patiënt op DLI nauwkeurig te monitoren en tevens had RCP een 
goede voorspellende waarde met betrekking tot het ontstaan van beenmerg aplasie na DLI.
Niet alle patiënten met een recidief kwaadaardige bloedziekte na SCT reageren op DLI 
met een GVL reactie en een nieuwe complete remissie van de oorspronkelijke ziekte.
In hoofdstuk 5 werd bij 26 patiënten met een recidief hematologische maligniteit na T-cel 
gedepleteerde SCT nagegaan welke factoren van belang waren bij het al dan niet reageren 
van de patiënt op een infusie met lymfocyten van de oorspronkelijke donor. Een complete 
remissie na DLI werd bij 11 van de 15 patiënten (73%) met een recidief CML en slechts 
bij 1 van de 11 patiënten (9%) met een recidief AML, ALL of RAEB-t bereikt. Patiënten 
met minder dan 40% donor T-lymfocyten op het moment van DLI bereikten significant 
minder vaak een complete remissie dan patiënten met meer dan 40% donor T-lymfocyten 
in het bloed ten tijde van de lymfocyteninfusie. Een andere belangrijke factor van invloed 
op het bereiken van een complete remissie na DLI was het interval tussen de transplantatie 
en het moment van DLI. Twee van de 13 patiënten (15%) met een interval < 18 maanden 
tussen SCT en DLI bereikten een complete remissie in tegenstelling tot 10 van de 13 
patiënten (77%) met een interval van meer dan 18 maanden tussen transplantatie en DLI. 
Multivariate analyse toonde dat de indicatie voor transplantatie (CML versus AML, ALL 
en RAEB-t) en het percentage T-lymfocyten van donor origine aanwezig op het moment 
van DLI significant het bereiken van een complete remissie voorspelden. De beste 
resultaten werden bereikt in een patiënt met een recidief CML waarbij op het moment van 
DLI meer dan 40% van de T-lymfocyten afkomstig waren van de oorspronkelijke donor. 
Deze data onderstrepen nog eens de noodzaak en het belang van gevoelige en betrouwbare 
technieken om zowel chimerisme als residuele ziekte kwantitatief te kunnen bepalen.
De gunstige effecten van DLI na recidief van de ziekte en de inmiddels bij een groot 
aantal patiënten opgedane ervaring met lymfocyteninfusies in combinatie met gegevens uit 
de literatuur over het gebruik van DLI in de profylactische setting in diermodellen heeft
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onder andere geleid tot een prospectief onderzoek in Nijmegen waarin hoog risico 
patiënten werden behandeld met profylactische DLI. Doel van dit onderzoek was de kans 
op een recidief van de ziekte na T-cel gedepleteerde allo-SCT te verlagen.
In hoofdstuk 6 wordt een prospectieve studie beschreven waarin werd nagegaan wat het 
effect was van het gebruik van profylactische DLI op de recidiefkans, ziektevrije 
overleving, overleving in het algemeen en chimerisme bij 82 patiënten na T-cel 
gedepleteerde allo-SCT met beenmerg van HLA-identieke broers of zussen. Alle patiënten 
hadden een verhoogd risico op een recidief van de oorspronkelijke ziekte en maakten na 
de transplantatie geen significante acute en/of chronische GVHD door. Indicaties voor 
transplantatie waren AML, ALL, CML, RAEB, RAEB-t en MM. Patiënten zonder 
doorgemaakte klinisch belangrijke acute GVHD (>graad 1) en zonder tekenen van 
chronische GVHD na minimaal 2 maanden stoppen van alle immunosuppressieve 
medicatie waren kandidaat voor behandeling met profylactische DLI. In totaal kwamen 35 
patiënten hiervoor in aanmerking waarvan 31 patiënten ook daadwerkelijk DLI ontvingen. 
Patiënten met meer dan graad 1 acute GVHD en/of chronische GVHD (47 patiënten) 
dienden als vergelijkende groep. Het mediane interval tussen SCT en profylactische DLI 
was 22 weken. De eerste 6 patiënten ontvingen een dosis van 0,7 x 10 CD3+ T-cellen/kg 
lichaamsgewicht. Ondanks het feit dat deze patiënten weinig of geen GVHD hadden 
doorgemaakt na de SCT ontstond er in deze groep meer en ernstiger GVHD dan verwacht. 
De ervaring bij deze eerste groep behandelde patiënten heeft ertoe geleid het aantal te 
infunderen T-cellen verlaagd werd naar 0,1 x 10 /kg. De volgende 25 patiënten die de 
lagere dosis DLI ontvingen ontwikkelden slechts geringe GVHD zonder dat hierdoor de 
morbiditeit of mortaliteit negatief beïnvloed werd. Patiënten die op basis van weinig 
GVHD na transplantatie in aanmerking kwamen voor profylactische DLI ontwikkelden 
trager compleet donor chimerisme. Het aantal gemengde chimeren 6 en 12 maanden na 
transplantatie was in deze groep dan ook hoger dan in de groep met patiënten die wel 
significante GVHD ontwikkelden. De kans op ziektevrije overleving geprojecteerd op 3 
jaar na transplantatie was 77% voor de patiënten die in aanmerking kwamen voor DLI 
(intention to treat). Deze overleving was significant beter dan de geprojecteerde 3- 
jaarsoverleving van 45% in de vergelijkingsgroep. De betere ziektevrije overleving werd 
veroorzaakt door significant minder recidieven (18% versus 44%) in de patiëntengroep die
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kandidaat waren voor profylactische DLI. Deze studie was de eerste studie die liet zien dat 
het gebruik van profylactische DLI na T-cel gedepleteerde SCT bij patiënten zonder 
significante GVHD, ook na afbouwen van alle immunosuppressiva, daadwerkelijk 
toepasbaar bleek. Profylactische DLI resulteerde in lage recidiefkansen in een groep 
patiënten met normaliter een hoge kans op terugkeer van de ziekte. De GVHD die na DLI 
ontstond bleek goed hanteerbaar en resulteerde niet in toegenomen morbiditeit c.q. verlies 
van kwaliteit van leven.
Een frequente en nauwkeurige monitoring van het chimerisme is essentieel om goed 
inzicht te kunnen krijgen in de dynamiek van de donor-en patiënt hematopoëse na SCT. 
Gevoelige en betrouwbare kwantitatieve analyse van de kinetiek in het chimerisme na 
transplantatie geeft informatie over het uitblijven van repopulatie dan wel vertraagde 
repopulatie in het beenmerg, draagt bij aan het vroeg herkennen van een recidief van de 
ziekte en informeert over die patiënten waarvan een gunstige respons na DLI verwacht 
kan worden. Ook de reactie op de DLI zelf valt indirect te monitoren d.m.v. chimerisme 
onderzoek. Nieuwe ontwikkelingen zoals het gebruik van profylactische DLI na T-cel 
gedepleteerde stamceltransplantatie en DLI na niet myelo-ablatieve stamceltransplantatie 
maken gebruik van chimerisme onderzoek bij de toepassing van deze 
behandelingsvormen. Methoden om chimerisme te bepalen als FISH, RCP, RFLP, VNTR, 
en STR hebben allemaal hun beperkingen. De sensitiviteit van de technieken is te laag, of 
ze kunnen alleen gebruikt worden bij sekse verschillen tussen donor en patiënt, of ze 
geven slechts informatie over één specifiek celtype, of de kwantificering is moeilijk ten 
gevolge van competitie in de PCR reactie.
In hoofdstuk 7 wordt een volledig nieuwe techniek beschreven om chimerisme na SCT te 
onderzoeken. Het betreft een methode waarbij gebruik gemaakt wordt van real-time 
kwantitatieve PCR van single nucleotide polymorfismen in het humane genoom. Deze 
polymorfismen kunnen gebruikt worden om patiënt en donor van elkaar te onderscheiden 
in elk celtype dat DNA bevat. Met behulp van een allel specifieke PCR voor 7 
verschillende polymorfismen lukte het om 97% van alle donor-acceptor koppels van 
elkaar te kunnen onderscheiden. Zevenenzestig procent van de ontvangers had zowel een 
discriminerend donor- als acceptor polymorfisme dat gebruikt kon worden als chimerisme
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kenmerk waarbij het extra toevoegen van nog drie nieuwe SNP theoretisch het 
discriminerend vermogen zal kunnen vergroten tot 99%. Verdunningsreeksen van SNP 
positief DNA in SNP negatief DNA dan wel water resulteerde in een gevoeligheid van
0.1-0.01% afhankelijk van de hoeveelheid DNA aanwezig bij aanvang van de PCR en de 
drempelwaarde voor het aantal PCR cycli die gebruikt wordt in de SNP-PCR. Real-time 
SNP-PCR blijkt een prima methode om repopulatie na SCT te volgen en tegelijkertijd 
patiënten te identificeren met een verhoogd risico op recidief van de ziekte die in potentie 
kandidaat zijn voor aanvullende immuuntherapie met bijvoorbeeld DLI. Ook de respons 
op aanvullende immuuntherapie na de transplantatie valt goed te monitoren met deze 
betrouwbare en gevoelige PCR-SNP techniek.
De vorige hoofdstukken beschrijven verschillende mechanismen die ten grondslag zouden 
kunnen liggen aan het frequenter en in ernstiger mate voorkomen van GVHD, het minder 
vaak voorkomen van mixed chimerisme en de geringere kans op recidief van de 
oorspronkelijke ziekte na voorbehandeling met een anthracycline geïntensiveerd 
conditioneringregime. Het gebruik van anthracyclines zou in potentie een extra tumor 
reducerend effect kunnen veroorzaken maar tegelijkertijd zou het ook zo kunnen zijn dat 
deze middelen meer autologe T-lymfocyten uitschakelen waardoor op het moment van 
transplantatie zelf de immunologische balans makkelijker door kan slaan naar het relatief 
lage aantal donor T-lymfocyten afkomstig uit het transplantaat met als gevolg meer 
GVHD, het sneller bereiken van compleet donor chimerisme en een sterker GVL effect.
In hoofdstuk 8 wordt een grote groep patiënten beschreven die tussen 1984 en 2000 een 
T-cel gedepleteerde allogene SCT ondergingen vanwege CML in eerste chronische fase. 
De conditionering bestond bij 19 patiënten uit het zogenaamde “standaard” regime 
(cyclofosfamide en TBI) en 70 patiënten uit een met anthracyclines geïntensiveerd 
conditioneringregime (anthracycline, cyclofosfamide en TBI). Overeenkomstig de 
resultaten in een kleiner cohort CML patiënten ontstond meer acute GVHD, werd de 
transplantatie gerelateerde morbiditeit en mortaliteit niet beïnvloed, was het aantal 
recidi even lager en werd een langere ziektevrije overleving waargenomen bij patiënten 
behandeld met anthracyclines in het conditioneringsregime. De “huidige” ziektevrije 
overleving gedefinieerd als overleving in eerste of tweede (na DLI) complete remissie was 
echter niet verschillend voor beide groepen. Dit laatste werd veroorzaakt door de gunstige
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reactie op therapeutische DLI bij patiënten met een recidief CML. E lf patiënten uit dit 
cohort werden prospectief gerandomiseerd tussen de “standaard” conditionering en een 
met idarubicine geïntensiveerd schema. In 10 van de 11 patiënten werden in opgezuiverde 
sub-populaties van de mononucleaire cellen en granulocyten frequent chimerisme 
bepalingen verricht met behulp van real-time kwantitatieve PCR voor een donor/patiënt 
specifieke SNP en/of het specifiek mannelijke SMCY-gen. Vergeleken met de 
“standaard”geconditioneerde patiënten werd er bij de patiënten geconditioneerd met 
idarubicine in de voorbehandeling op 1 en 3 maanden na transplantatie een significant 
lager aantal T-cellen van autologe origine waargenomen. Ook ontwikkelden deze 
patiënten sneller (mediaan, 3 versus 12 maanden) een compleet donor chimerisme in de 
T4 (CD3+/CD4+) en T8 (CD3+/CD8+) lymfocyten subpopulaties. Het toevoegen van 
anthracyclines aan de conditionering had geen invloed op de snelheid waarmee een 
compleet donor chimerisme werd bereikt in de niet lymfatische subpopulaties van het 
perifere bloed.
Het gebruik van anthracyclines in de conditionering voorafgaand aan T-cel gedepleteerde 
SCT veroorzaakt een sneller verdwijnen van autologe T-lymfocyten na transplantatie. Het 
sneller doorslaan van de immunologische balans naar de kant van het donor 
afweersysteem lijkt in ieder geval één van de redenen waardoor na intensieve 
conditionering meer GVHD en GVL optreedt. Dit leidt tot minder tolerantie en resulteert 
uiteindelijk in minder recidieven en een langduriger ziektevrije overleving zonder verlies 
van kwaliteit van leven.
Algemene Conclusie
Genezing van kwaadaardige hematologische ziekten door middel van allogene 
stamceltransplantatie wordt voornamelijk beperkt door de aanwezigheid van immuun 
reactieve T-cellen afkomstig van de donor die in staat zijn verschillen in major en minor 
histocompatibiliteit-antigenen te herkennen en die aanleiding kunnen geven tot ernstige 
graft-versus-host ziekte. Deze ziekte is de belangrijkste oorzaak van complicaties en 
mortaliteit na stamceltransplantatie. De meest effectieve manier om GVHD te voorkomen 
is het verwijderen van T-cellen uit het stamceltransplantaat (T-cel depletie). Het
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immunologisch verzwakken van het transplantaat heeft echter ook nadelen omdat het 
verwijderen van deze immuuncompetente cellen tegelijkertijd onlosmakelijk verbonden is 
met het verzwakken van het graft-versus-leukemia effect met hierdoor een grotere kans op 
een recidief van de oorspronkelijke ziekte. De mogelijkheden die in toenemende mate 
ontstaan om vóór, tijdens en ná stamceltransplantatie de behandeling te beïnvloeden met 
preventieve immuun-therapeutische maatregelen plaatsen de T-cel verwijdering in een 
geheel nieuw perspectief.
Intensiveren van het conditioneringsregime met anthracyclines voorafgaand aan T-cel 
gedepleteerde allogene stamceltransplantatie leidde tot significante reductie van het aantal 
recidieven en hieruit voortvloeiend verbetering van de totale ziektevrije overleving. 
Transplantatie gerelateerde morbiditeit en mortaliteit werden hierdoor niet negatief 
beïnvloed. Gebruik makend van chimerisme studies kon het immuun onderdrukkende 
effect van anthracyclines op de autologe T-lymfocyten worden aangetoond als een van de 
verklaringen voor de geringere recidiefkans na transplantatie. Behandeling van 
gerecidiveerde hematologische maligniteiten na transplantatie door middel van leukocyten 
van de oorspronkelijke donor resulteerde in een hogere ziektevrije en totale overleving. 
Profylactisch gebruik van deze vorm van immuuntherapie lijkt ook veilig toepasbaar en 
leidde tot een verminderde kans op een recidief van de oorspronkelijke ziekte. Deze 
veelbelovende resultaten vormden de basis voor een groot nationaal onderzoek in 
Nederland waarin deze bevindingen momenteel op gerandomiseerde wijze worden 
onderzocht. De ontwikkeling en het gebruik van meer specifieke en gevoeliger technieken 
zoals de PCR-SNP techniek waarbij chimerisme na transplantatie ook kwantitatief 
vastgelegd kan worden en makkelijk te volgen is in de tijd geven meer inzicht in de 
dynamiek van het hematopoëtische systeem in het hele traject na allogene 
stamceltransplantatie.
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jullie enthousiasme vormden de basis voor het chimerisme onderzoek nieuwe stijl en heeft 
bijgedragen aan hetgeen we nu weten over de betekenis van het chimerisme na 
stamceltransplantatie. De mensen van de ABTI. Lang hebben we gevaren op de rode 
bloedcel typering die ons klinisch handelen na de transplantatie voor een groot deel 
bepaalde. We meten nu direct de ziekte maar de fraaie correlatie tussen de directe en 
indirecte methode laat zien wel belang deze techniek lang gediend heeft. Veel patiënten 
hebben er mede hun genezing aan te danken. Prof. dr. B. de Pauw, beste Ben, veel dank 
voor het in mij gestelde vertrouwen, jij hebt me naar de ABTI toegehaald en me daar ook 
de ruimte gegeven het onderzoek af te ronden. We kunnen nu op volle kracht weer nieuwe 
zaken ter hand nemen. Collegae doorstromers, het verrichten van promotieonderzoek 
gedurende de opleiding tot hematoloog of tijdens het werk als junior staflid is geen 
sinecure. Organiseren, delegeren, schipperen, frustratietolerantie, collegialiteit en een 
lange adem zijn hierbij sleutelwoorden. Toch kijk ik hier niet met een vervelend gevoel op 
terug, iets om moed uit te putten. Ook jullie bedankt. De nog niet genoemde stafleden van 
de hematologie wil ik bedanken voor hun steun, het vertrouwen en de scholing die ik van 
hen heb mogen genieten. Verpleging kliniek en polikliniek, jullie professionele zorg en 
toewijding is onmisbaar in de keten, een solide schakel zoals is gebleken. Patiënten, 
eigenlijk zou ik hen als eerste moeten bedanken. Hun optimisme, strijdlust en 
relativeringsvermogen hebben ook mij leren te relativeren. Steeds bereid om voor allerlei 
onderzoeken opnieuw bloed af te staan en hier zelfs speciaal voor naar Nijmegen te komen 
dwingt groot respect af.
Pap en Mam ook jullie wil ik danken voor de onvoorwaardelijke steun en immer 
aanwezige interesse voor mijn doen en laten. Pap, een deel van de liefde voor het mooie
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vak dat jij zo lang beoefend hebt, en ik nu, heb ik zeker van jou meegekregen. Ik ben blij 
en bevoorrecht dat jullie mijn promotie in goede gezondheid mee mogen maken.
Als laatste maar niet als minste het thuisfront. Lieve Lianne, jouw organisatietalent is 
ongeëvenaard, je zorg voor de kinderen groots, je  interesse voor mij en mijn werk steeds 
aanwezig. Een beter fundament kan ons gezin niet wensen. Lieve Charlotte, Anne-Jetske 
en Jan-Willem, papa is supertrots op jullie.
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Curriculum vitae
Curriculum vitae
De schrijver van dit proefschrift werd geboren te Nijmegen op 20 maart 1959. Na verhuisd 
te zijn naar Weert werd de lagere school (Anne Frank School) en de middelbare school 
(Philips van Horne Scholengemeenschap) aldaar doorlopen. Het Atheneum B diploma 
werd behaald in 1978. In verband met uitloting voor de medicijnenstudie werd datzelfde 
jaar gestart met de studie psychologie aan de Katholieke Universiteit Nijmegen. In 1981 
werd het kandidaatsexamen psychologie behaald. Na eindelijk te zijn ingeloot voor de 
studie geneeskunde kon hiermee in 1981 worden aangevangen. Het doctoraalexamen werd 
behaald in 1986 en het artsexamen in mei 1988. Sindsdien was hij werkzaam in het St 
Joseph ziekenhuis te Eindhoven (later Veldhoven). Allereerst op onderzoeksbasis 
(vrijwillig) en vanaf februari 1989 in opleiding tot internist (opleider dr. P.G.G. Gerlag). 
Vanaf februari 1992 kreeg de opleiding een vervolg in het Academisch Ziekenhuis 
Nijmegen (Opleider prof. dr. A. van ‘t Laar en prof. dr. J.W.M. van der Meer). In februari 
1995 volgde de registratie als internist. Sinds februari 1995 is hij verbonden aan de 
afdeling hematologie van het UMC St Radboud, allereerst in opleiding tot hematoloog, 
later (vanaf 1999) als junior staflid. Vanaf 1997 werd de opleiding gecombineerd met het 
onderzoek waarvan de resultaten in dit proefschrift zijn terug te vinden. De registratie als 
hematoloog vond plaats in 1999. Sinds september 2000 is hij als hematoloog en senior 
staflid werkzaam op de afdeling Hematologie en de afdeling Bloedtransfusie en 
Transplantatie Immunologie (ABTI) van het UMC St Radboud te Nijmegen.
De schrijver is getrouwd met Lianne Jacobs en is de trotse vader van Charlotte, Anne- 
Jetske en Jan-Willem.
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ALL acute lymphoid leukemia
AML acute myeloid leukemia
CLL chronic lymphoid leukemia
CD cluster of differentiation
CML chronic myeloid leukemia
CP chronic phase
CsA cyclosporine A
Cy cyclophosphamide
CYT cytogenetics
DLI donor leukocyte infusion
EBV-LPDs Epstein Barr virus associated B cell lymphoproliferative disorders
FISH fluorescent in situ hybridization
FITC fluorescein isothiocyanate
GVHD graft-versus-host disease
GVL graft-versus-leukemia
HLA human leukocyte antigen
IL-2 interleukine 2
Ida idarubicine
LFS leukemia-free survival
MDS myelodysplastic syndrome
MM multiple myeloma
mHag minor histocompatibility antigens
MHC major histocompatibility complex
MLC mixed lymphocyte culture
MTX methotrexate
NHL non-Hodgkin’s lymphoma
NK natural killer
PCR polymerase chain reaction
PBMCs peripheral blood mononuclear cells
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PBSCT peripheral blood stem cell transplantation
PE phycoerythrin
PHA phytohemaglutinin
Ph Philadelphia
RAEB refractory anemia with excess of blasts
RAEB-t refractory anemia with excess of blasts in transformation
RBCs red blood cells
RCP red blood cell phenotyping
RFLP restriction fragment length polymorphism
RT reverse transcriptase
SAA severe aplastic anemia
SCT stem cell transplantation
SNP single nucleotide polymorphisms
STR short tandem repeats
TBI total body irradiation
UPN unique patient number
VNTR variable number of tandem repeats
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